{
  "file_name": "CUAD_v1/full_contract_pdf\\Part_I\\Distributor\\ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement.pdf",
  "annotations": [
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Document Name_0",
      "question": "Highlight the parts (if any) of this contract related to \"Document Name\" that should be reviewed by a lawyer. Details: The name of the contract",
      "answer_text": "DISTRIBUTORSHIP AGREEMENT",
      "page_number": 0,
      "words": [
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        }
      ],
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Parties_5",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Zogenix and Distributor may be referred to individually as a \"Party\" and collectively as the \"Parties\".",
      "page_number": 5,
      "words": [
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "ZOGENIX, INC.",
      "page_number": 0,
      "words": [
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        }
      ],
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Distributor",
      "page_number": 0,
      "words": [
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        }
      ],
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Zogenix",
      "page_number": 0,
      "words": [
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        }
      ],
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Parties_0",
      "question": "Highlight the parts (if any) of this contract related to \"Parties\" that should be reviewed by a lawyer. Details: The two or more parties who signed the contract",
      "answer_text": "Nippon Shinyaku Company, Ltd.",
      "page_number": 0,
      "words": [
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        }
      ],
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Agreement Date_5",
      "question": "Highlight the parts (if any) of this contract related to \"Agreement Date\" that should be reviewed by a lawyer. Details: The date of the contract",
      "answer_text": "March 18, 2019",
      "page_number": 5,
      "words": [
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Effective Date_5",
      "question": "Highlight the parts (if any) of this contract related to \"Effective Date\" that should be reviewed by a lawyer. Details: The date when the contract is effective ",
      "answer_text": "March 18, 2019",
      "page_number": 5,
      "words": [
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Expiration Date_7",
      "question": "Highlight the parts (if any) of this contract related to \"Expiration Date\" that should be reviewed by a lawyer. Details: On what date will the contract's initial term expire?",
      "answer_text": "This Agreement shall commence on the Effective Date and shall remain in effect until September 1, 2045, unless earlier terminated by either Party pursuant to this Article 12 (the \"Term\").",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Governing Law_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement and all questions regarding its existence, validity, interpretation, breach or performance and any dispute or claim arising out of or in connection with it (whether contractual or non-contractual in nature such as claims in tort, from breach of statute or regulation or otherwise) shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles to the extent those principles would require applying another jurisdiction's laws.",
      "page_number": 6,
      "words": [
        {
          "text": "1.2 \"Alliance Manager' has the meaning set forth in Section 3.3.",
          "bbox": [
            448.0,
            685.0,
            1836.0,
            736.0
          ],
          "confidence": 0.9859306216239929
        },
        {
          "text": "1.3 \"Annual Report' has the meaning set forth in Section 6.5(c)",
          "bbox": [
            446.0,
            809.0,
            1823.0,
            861.0
          ],
          "confidence": 0.9771308302879333
        },
        {
          "text": "1.4 \"Applicable Laws\" means the applicable provisions of any and all national, supranational, regional, state and local",
          "bbox": [
            448.0,
            936.0,
            3027.0,
            985.0
          ],
          "confidence": 0.985500156879425
        },
        {
          "text": "laws, treaties, statutes, rules, regulations, administrative codes, industry codes, guidance, ordinances, judgments, decrees,.",
          "bbox": [
            277.0,
            1001.0,
            3025.0,
            1053.0
          ],
          "confidence": 0.9961791634559631
        },
        {
          "text": "directives, injunctions, orders or permits (including Regulatory Approvals) of or from any court, arbitrator, Regulatory Authority or",
          "bbox": [
            279.0,
            1067.0,
            3027.0,
            1118.0
          ],
          "confidence": 0.9920154213905334
        },
        {
          "text": "governmental agency or authority having jurisdiction over or related to the subject item, including the FCPA, export control,",
          "bbox": [
            277.0,
            1133.0,
            3025.0,
            1188.0
          ],
          "confidence": 0.9949026703834534
        },
        {
          "text": "embargo, trade sanction and data privacy laws, regulations, rules and licenses, and other laws and regulations pertaining to",
          "bbox": [
            277.0,
            1201.0,
            3025.0,
            1254.0
          ],
          "confidence": 0.993232011795044
        },
        {
          "text": "domestic or international corruption, commercial bribery, fraud, embezzlement or money laundering.",
          "bbox": [
            275.0,
            1259.0,
            2365.0,
            1325.0
          ],
          "confidence": 0.9901788830757141
        },
        {
          "text": "1.5 \"Business Day\"' means a day other than a Saturday, Sunday, any public holiday, or any bank holiday in the United",
          "bbox": [
            444.0,
            1389.0,
            3027.0,
            1440.0
          ],
          "confidence": 0.9882254004478455
        },
        {
          "text": "States or Japan.",
          "bbox": [
            279.0,
            1458.0,
            613.0,
            1508.0
          ],
          "confidence": 0.9998754262924194
        },
        {
          "text": "1.6 \"Change of Control' means any (a) direct or indirect acquisition of assets of a Party (i) equal to fifty percent (50%)",
          "bbox": [
            448.0,
            1581.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9898536801338196
        },
        {
          "text": "or more of the fair market value of a Party's consolidated assets, or (ii) to which fifty percent (50%) or more of a Party's net",
          "bbox": [
            281.0,
            1650.0,
            3029.0,
            1694.0
          ],
          "confidence": 0.9935340881347656
        },
        {
          "text": "revenues or net income on a consolidated basis are attributable, or (iii) representing substantially all of the properties or assets",
          "bbox": [
            277.0,
            1718.0,
            3027.0,
            1762.0
          ],
          "confidence": 0.9949082136154175
        },
        {
          "text": "related to a Party's obligations under this Agreement, (b) direct or indirect acquisition by a Person, or group of Persons acting in.",
          "bbox": [
            275.0,
            1780.0,
            3027.0,
            1831.0
          ],
          "confidence": 0.9926859736442566
        },
        {
          "text": "concert, of fifty percent (50%) or more of the voting equity interests of a Party, (c) tender offer or exchange offer that if",
          "bbox": [
            277.0,
            1846.0,
            3031.0,
            1899.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "consummated would result in any Person, or group of Persons acting in concert, beneficially owning fifty percent (50%) or more of.",
          "bbox": [
            277.0,
            1915.0,
            3032.0,
            1964.0
          ],
          "confidence": 0.9912351369857788
        },
        {
          "text": "the voting equity interests of a Party, (d) merger, consolidation, other business combination or similar transaction involving a Party,.",
          "bbox": [
            277.0,
            1979.0,
            3025.0,
            2032.0
          ],
          "confidence": 0.9915239810943604
        },
        {
          "text": "pursuant to which any Person would own fifty percent (50%) or more of the consolidated assets, net revenues or net income of a",
          "bbox": [
            275.0,
            2045.0,
            3029.0,
            2098.0
          ],
          "confidence": 0.9893941283226013
        },
        {
          "text": "Party, taken as a whole, or which results in the holders of the voting equity interests of a Party immediately prior to such merger.",
          "bbox": [
            277.0,
            2109.0,
            3023.0,
            2167.0
          ],
          "confidence": 0.9963723421096802
        },
        {
          "text": "consolidation, business combination or similar transaction ceasing to hold fifty percent (50%) or more of the combined voting",
          "bbox": [
            277.0,
            2178.0,
            3027.0,
            2231.0
          ],
          "confidence": 0.997050404548645
        },
        {
          "text": "power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, business combination or.",
          "bbox": [
            277.0,
            2246.0,
            3031.0,
            2297.0
          ],
          "confidence": 0.9887821078300476
        },
        {
          "text": "similar transaction, (e) liquidation or dissolution (or the adoption of a plan of liquidation or dissolution) of a Party, or (f) declaration",
          "bbox": [
            281.0,
            2317.0,
            3025.0,
            2361.0
          ],
          "confidence": 0.9977426528930664
        },
        {
          "text": "or payment of an extraordinary dividend (whether in cash or other property) by a Party, where the amount of the dividend or the in.",
          "bbox": [
            277.0,
            2379.0,
            3029.0,
            2434.0
          ],
          "confidence": 0.9966531991958618
        },
        {
          "text": "specie property which is the subject of the dividend would otherwise come within the application of any of clauses (a)-(e) above,.",
          "bbox": [
            277.0,
            2443.0,
            3027.0,
            2500.0
          ],
          "confidence": 0.9955662488937378
        },
        {
          "text": "in all cases where such transaction is to be entered into with any Person other than the other Party.",
          "bbox": [
            275.0,
            2509.0,
            2336.0,
            2564.0
          ],
          "confidence": 0.994972288608551
        },
        {
          "text": "1.7 \"CMC' means chemistry, manufacturing and controls.",
          "bbox": [
            446.0,
            2633.0,
            1649.0,
            2686.0
          ],
          "confidence": 0.9895760416984558
        },
        {
          "text": "1.8 \"Commercialization\"' means all activities directed to marketing, promoting, advertising, exhibiting, distributing",
          "bbox": [
            444.0,
            2756.0,
            3025.0,
            2810.0
          ],
          "confidence": 0.9943382143974304
        },
        {
          "text": "(including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise",
          "bbox": [
            285.0,
            2829.0,
            3025.0,
            2873.0
          ],
          "confidence": 0.9882383942604065
        },
        {
          "text": "commercially exploiting the Product in the Field in the Territory.",
          "bbox": [
            275.0,
            2887.0,
            1606.0,
            2946.0
          ],
          "confidence": 0.9925694465637207
        },
        {
          "text": "1.9 \"Commercialization Plan' has the meaning set forth in Section 5.1(b)",
          "bbox": [
            448.0,
            3013.0,
            2046.0,
            3061.0
          ],
          "confidence": 0.9942542314529419
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3223.0,
            1668.0,
            3262.0
          ],
          "confidence": 0.9846658706665039
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ],
          "confidence": 0.9990366697311401
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9950901865959167
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 6,
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Governing Law_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Governing Law\" that should be reviewed by a lawyer. Details: Which state/country's law governs the interpretation of the contract?",
      "answer_text": "This Agreement and all questions regarding its existence, validity, interpretation, breach or performance and any dispute or claim arising out of or in connection with it (whether contractual or non-contractual in nature such as claims in tort, from breach of statute or regulation or otherwise) shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles to the extent those principles would require applying another jurisdiction's laws.",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Non-Compete_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector? ",
      "answer_text": "During the Term, without the prior written approval of Zogenix, Distributor shall not, and shall cause its Affiliates not to, either directly or indirectly, file for Regulatory Approval of, promote, market, offer for sale, sell, import or distribute in the Territory any product containing fenfluramine or any salt, enantiomer, or polymorph of fenfluramine, or any product for [***].",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Non-Compete_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Non-Compete\" that should be reviewed by a lawyer. Details: Is there a restriction on the ability of a party to compete with the counterparty or operate in a certain geography or business or technology sector? ",
      "answer_text": "During the Term, without the prior written approval of Zogenix, Distributor shall not, and shall cause its Affiliates not to, either directly or indirectly, file for Regulatory Approval of, promote, market, offer for sale, sell, import or distribute in the Territory any product containing fenfluramine or any salt, enantiomer, or polymorph of fenfluramine, or any product for [***].",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Zogenix shall supply (or have supplied) to Distributor, in accordance with the terms set forth on Exhibit 2.3, and Distributor shall purchase exclusively from Zogenix, Distributor's and its Affiliates' and Sub- distributors' Unlabeled Drug Product requirements of the Product for sale by Distributor or its Affiliates or Sub-distributors in the Territory in the Field, subject to and under the provisions of Section 5.2 and the Supply Agreement.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Zogenix shall supply (or have supplied) to Distributor, in accordance with the terms set forth on Exhibit 2.3, and Distributor shall purchase exclusively from Zogenix, Distributor's and its Affiliates' and Sub- distributors' Unlabeled Drug Product requirements of the Product for sale by Distributor or its Affiliates or Sub-distributors in the Territory in the Field, subject to and under the provisions of Section 5.2 and the Supply Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "During the Term, Zogenix shall retain and have the sole and exclusive right to supply or have supplied all of Distributors' and its Affiliates' and Sub-distributors' requirements of the Product for sale in the Field in the Territory.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "During the Term, Zogenix shall retain and have the sole and exclusive right to supply or have supplied all of Distributors' and its Affiliates' and Sub-distributors' requirements of the Product for sale in the Field in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Without limiting the foregoing, Distributor will have the exclusive right and responsibility in the Field in the Territory for the following:\n\n(i) designing the Commercialization strategy and tactics for the Product, subject to JSC approval of the Commercialization Plan;\n\n(ii) undertaking all promotional activities for the Product;",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Without limiting the foregoing, Distributor will have the exclusive right and responsibility in the Field in the Territory for the following:\n\n(i) designing the Commercialization strategy and tactics for the Product, subject to JSC approval of the Commercialization Plan;\n\n(ii) undertaking all promotional activities for the Product;",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "(iii) establishing and implementing post-marketing surveillance studies for the Product in the Territory as required or recommended by a Regulatory Authority;\n\n(iv) receiving, accepting and filling orders for the Product from customers;\n\n(v) warehousing and distributing the Product to customers;\n\n(vi) controlling invoicing, order processing and collection of accounts receivable for sales of the Product;\n\n(vii) recording sales of the Product in the Territory in its books of account for sales; and\n\n(viii) providing results of sales of the Product in the Territory for purposes of periodic safety reports and exposure estimates.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "(iii) establishing and implementing post-marketing surveillance studies for the Product in the Territory as required or recommended by a Regulatory Authority;\n\n(iv) receiving, accepting and filling orders for the Product from customers;\n\n(v) warehousing and distributing the Product to customers;\n\n(vi) controlling invoicing, order processing and collection of accounts receivable for sales of the Product;\n\n(vii) recording sales of the Product in the Territory in its books of account for sales; and\n\n(viii) providing results of sales of the Product in the Territory for purposes of periodic safety reports and exposure estimates.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby appoints Distributor, and Distributor accepts appointment, as the exclusive distributor (even as to Zogenix) of the Product in the Field in the Territory during the Term, and grants to Distributor the exclusive rights to maintain Regulatory Approval of (while Distributor is the MAH Party), package, promote, market, offer for sale, sell, import and distribute the Product in the Field in the Territory during the Term",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby appoints Distributor, and Distributor accepts appointment, as the exclusive distributor (even as to Zogenix) of the Product in the Field in the Territory during the Term, and grants to Distributor the exclusive rights to maintain Regulatory Approval of (while Distributor is the MAH Party), package, promote, market, offer for sale, sell, import and distribute the Product in the Field in the Territory during the Term",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Distributor shall have the exclusive right to market, promote, sell, offer for sale, import, package and otherwise Commercialize the Product in the Field in the Territory, at its sole cost and expense, in accordance with Applicable Laws and the Commercialization Plan and subject to the terms and conditions of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Exclusivity_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Exclusivity\" that should be reviewed by a lawyer. Details: Is there an exclusive dealing  commitment with the counterparty? This includes a commitment to procure all “requirements” from one party of certain technology, goods, or services or a prohibition on licensing or selling technology, goods or services to third parties, or a prohibition on  collaborating or working with other parties), whether during the contract or  after the contract ends (or both).",
      "answer_text": "Distributor shall have the exclusive right to market, promote, sell, offer for sale, import, package and otherwise Commercialize the Product in the Field in the Territory, at its sole cost and expense, in accordance with Applicable Laws and the Commercialization Plan and subject to the terms and conditions of this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Termination For Convenience_5",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?",
      "answer_text": "At any time following the expiration of the Distribution Term (as defined in Section 1.17), the Distributor may terminate this Agreement at will upon [***] prior written notice to Zogenix.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Termination For Convenience_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?",
      "answer_text": "\"Distribution Term\" means the period commencing on the first Regulatory Approval of the Product in the Territory and continuing until [***], or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Termination For Convenience_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Termination For Convenience\" that should be reviewed by a lawyer. Details: Can a party terminate this  contract without cause (solely by giving a notice and allowing a waiting  period to expire)?",
      "answer_text": "\"Distribution Term\" means the period commencing on the first Regulatory Approval of the Product in the Territory and continuing until [***], or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Change Of Control_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "This Agreement may be terminated by either Party upon [***] written notice to the other Party in the event that the other Party undergoes a Change of Control; provided, however, that such termination notice shall only be effective if delivered within [***] after the later of the occurrence of such Change of Control or the date the Party undergoing the Change of Control delivers written notice thereof to the other Party.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Change Of Control_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "This Agreement may be terminated by either Party upon [***] written notice to the other Party in the event that the other Party undergoes a Change of Control; provided, however, that such termination notice shall only be effective if delivered within [***] after the later of the occurrence of such Change of Control or the date the Party undergoing the Change of Control delivers written notice thereof to the other Party.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Change Of Control_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Except as expressly provided in this Section 14.3, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party's consent:\n\n(a) in connection with the transfer or sale of all or substantially all of the business of the assigning Party to a Third Party, whether by merger, sale of stock, sale of assets or otherwise; provided that in the event of a transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), unless otherwise agreed with the acquiring party in writing, intellectual property of the acquiring party shall not be included in the intellectual property to which the other Party has access under this Agreement; or\n\n(b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non‑assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Change Of Control_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Change Of Control\" that should be reviewed by a lawyer. Details: Does one party have the right to terminate or is consent or notice required of the counterparty if such party undergoes a change of control, such as a merger, stock sale, transfer of all or substantially all of its assets or business, or assignment by operation of law?",
      "answer_text": "Except as expressly provided in this Section 14.3, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party's consent:\n\n(a) in connection with the transfer or sale of all or substantially all of the business of the assigning Party to a Third Party, whether by merger, sale of stock, sale of assets or otherwise; provided that in the event of a transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), unless otherwise agreed with the acquiring party in writing, intellectual property of the acquiring party shall not be included in the intellectual property to which the other Party has access under this Agreement; or\n\n(b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non‑assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Anti-Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "For the avoidance of doubt, in the event that either Party assigns this Agreement pursuant to this Section 14.3(a), the other Party shall have the right to terminate this Agreement pursuant to Section 12.2(i).",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Anti-Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "For the avoidance of doubt, in the event that either Party assigns this Agreement pursuant to this Section 14.3(a), the other Party shall have the right to terminate this Agreement pursuant to Section 12.2(i).",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Anti-Assignment_5",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Any assignment not in accordance with this Section 14.3 will be null and void.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Anti-Assignment_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as expressly provided in this Section 14.3, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party's consent:\n\n(a) in connection with the transfer or sale of all or substantially all of the business of the assigning Party to a Third Party, whether by merger, sale of stock, sale of assets or otherwise; provided that in the event of a transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), unless otherwise agreed with the acquiring party in writing, intellectual property of the acquiring party shall not be included in the intellectual property to which the other Party has access under this Agreement; or\n\n(b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non‑assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Anti-Assignment_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Anti-Assignment\" that should be reviewed by a lawyer. Details: Is consent or notice required of a party if the contract is assigned to a third party?",
      "answer_text": "Except as expressly provided in this Section 14.3, neither this Agreement nor any rights or obligations hereunder may be assigned or otherwise transferred by either Party without the prior written consent of the other Party, which consent shall not be unreasonably withheld; provided, however, that either Party may assign this Agreement and its rights and obligations hereunder without the other Party's consent:\n\n(a) in connection with the transfer or sale of all or substantially all of the business of the assigning Party to a Third Party, whether by merger, sale of stock, sale of assets or otherwise; provided that in the event of a transaction (whether this Agreement is actually assigned or is assumed by the acquiring party by operation of law (e.g., in the context of a reverse triangular merger)), unless otherwise agreed with the acquiring party in writing, intellectual property of the acquiring party shall not be included in the intellectual property to which the other Party has access under this Agreement; or\n\n(b) to an Affiliate, provided that the assigning Party shall remain liable and responsible to the non‑assigning Party hereto for the performance and observance of all such duties and obligations by such Affiliate.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Revenue/Profit Sharing_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "During the Distribution Term, and in addition to the consideration provided pursuant to Sections 6.1, 6.2, 6.3, and 6.4, for all Product supplied by Zogenix to Distributor under purchase orders submitted pursuant to the Supply Agreement in a particular Fiscal Year, Distributor shall pay to Zogenix a transfer price per unit of Product supplied (the \"Transfer Price\") equal to the sum of (i) [***] of the Fully-Burdened Manufacturing Cost per unit of Product for such Fiscal Year, (ii) [***] of aggregate annual Net Sales for such Fiscal Year, and (iii) the applicable markup percent of the applicable aggregate Net Price for such Fiscal Year, which markup percent is determined based on the incremental amount of Product ordered in such Fiscal Year as set forth below, as may be adjusted pursuant to Section 6.5(b):\n\nAmount of Product Supplied per Fiscal Year Net Price Markup\n\nFor the portion of Product supplied less than or equal to the equivalent of [***] in Net Sales in such Fiscal Year [***]\n\nFor the portion of Product supplied in excess of the equivalent of [***] in Net Sales and less than or equal to the equivalent of [***] in Net Sales in such Fiscal Year [***]\n\nFor the portion of Product supplied in excess of the equivalent of [***] in Net Sales and less than or equal to the equivalent of [***] in Net Sales in such Fiscal Year [***]\n\nFor the portion of Product supplied in excess of the equivalent of [***] in Net Sales in such Fiscal Year [***]",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Revenue/Profit Sharing_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "During the Distribution Term, and in addition to the consideration provided pursuant to Sections 6.1, 6.2, 6.3, and 6.4, for all Product supplied by Zogenix to Distributor under purchase orders submitted pursuant to the Supply Agreement in a particular Fiscal Year, Distributor shall pay to Zogenix a transfer price per unit of Product supplied (the \"Transfer Price\") equal to the sum of (i) [***] of the Fully-Burdened Manufacturing Cost per unit of Product for such Fiscal Year, (ii) [***] of aggregate annual Net Sales for such Fiscal Year, and (iii) the applicable markup percent of the applicable aggregate Net Price for such Fiscal Year, which markup percent is determined based on the incremental amount of Product ordered in such Fiscal Year as set forth below, as may be adjusted pursuant to Section 6.5(b):\n\nAmount of Product Supplied per Fiscal Year Net Price Markup\n\nFor the portion of Product supplied less than or equal to the equivalent of [***] in Net Sales in such Fiscal Year [***]\n\nFor the portion of Product supplied in excess of the equivalent of [***] in Net Sales and less than or equal to the equivalent of [***] in Net Sales in such Fiscal Year [***]\n\nFor the portion of Product supplied in excess of the equivalent of [***] in Net Sales and less than or equal to the equivalent of [***] in Net Sales in such Fiscal Year [***]\n\nFor the portion of Product supplied in excess of the equivalent of [***] in Net Sales in such Fiscal Year [***]",
      "page_number": 6,
      "words": [
        {
          "text": "1.2 \"Alliance Manager' has the meaning set forth in Section 3.3.",
          "bbox": [
            448.0,
            685.0,
            1836.0,
            736.0
          ],
          "confidence": 0.9859306216239929
        },
        {
          "text": "1.3 \"Annual Report' has the meaning set forth in Section 6.5(c)",
          "bbox": [
            446.0,
            809.0,
            1823.0,
            861.0
          ],
          "confidence": 0.9771308302879333
        },
        {
          "text": "1.4 \"Applicable Laws\" means the applicable provisions of any and all national, supranational, regional, state and local",
          "bbox": [
            448.0,
            936.0,
            3027.0,
            985.0
          ],
          "confidence": 0.985500156879425
        },
        {
          "text": "laws, treaties, statutes, rules, regulations, administrative codes, industry codes, guidance, ordinances, judgments, decrees,.",
          "bbox": [
            277.0,
            1001.0,
            3025.0,
            1053.0
          ],
          "confidence": 0.9961791634559631
        },
        {
          "text": "directives, injunctions, orders or permits (including Regulatory Approvals) of or from any court, arbitrator, Regulatory Authority or",
          "bbox": [
            279.0,
            1067.0,
            3027.0,
            1118.0
          ],
          "confidence": 0.9920154213905334
        },
        {
          "text": "governmental agency or authority having jurisdiction over or related to the subject item, including the FCPA, export control,",
          "bbox": [
            277.0,
            1133.0,
            3025.0,
            1188.0
          ],
          "confidence": 0.9949026703834534
        },
        {
          "text": "embargo, trade sanction and data privacy laws, regulations, rules and licenses, and other laws and regulations pertaining to",
          "bbox": [
            277.0,
            1201.0,
            3025.0,
            1254.0
          ],
          "confidence": 0.993232011795044
        },
        {
          "text": "domestic or international corruption, commercial bribery, fraud, embezzlement or money laundering.",
          "bbox": [
            275.0,
            1259.0,
            2365.0,
            1325.0
          ],
          "confidence": 0.9901788830757141
        },
        {
          "text": "1.5 \"Business Day\"' means a day other than a Saturday, Sunday, any public holiday, or any bank holiday in the United",
          "bbox": [
            444.0,
            1389.0,
            3027.0,
            1440.0
          ],
          "confidence": 0.9882254004478455
        },
        {
          "text": "States or Japan.",
          "bbox": [
            279.0,
            1458.0,
            613.0,
            1508.0
          ],
          "confidence": 0.9998754262924194
        },
        {
          "text": "1.6 \"Change of Control' means any (a) direct or indirect acquisition of assets of a Party (i) equal to fifty percent (50%)",
          "bbox": [
            448.0,
            1581.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9898536801338196
        },
        {
          "text": "or more of the fair market value of a Party's consolidated assets, or (ii) to which fifty percent (50%) or more of a Party's net",
          "bbox": [
            281.0,
            1650.0,
            3029.0,
            1694.0
          ],
          "confidence": 0.9935340881347656
        },
        {
          "text": "revenues or net income on a consolidated basis are attributable, or (iii) representing substantially all of the properties or assets",
          "bbox": [
            277.0,
            1718.0,
            3027.0,
            1762.0
          ],
          "confidence": 0.9949082136154175
        },
        {
          "text": "related to a Party's obligations under this Agreement, (b) direct or indirect acquisition by a Person, or group of Persons acting in.",
          "bbox": [
            275.0,
            1780.0,
            3027.0,
            1831.0
          ],
          "confidence": 0.9926859736442566
        },
        {
          "text": "concert, of fifty percent (50%) or more of the voting equity interests of a Party, (c) tender offer or exchange offer that if",
          "bbox": [
            277.0,
            1846.0,
            3031.0,
            1899.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "consummated would result in any Person, or group of Persons acting in concert, beneficially owning fifty percent (50%) or more of.",
          "bbox": [
            277.0,
            1915.0,
            3032.0,
            1964.0
          ],
          "confidence": 0.9912351369857788
        },
        {
          "text": "the voting equity interests of a Party, (d) merger, consolidation, other business combination or similar transaction involving a Party,.",
          "bbox": [
            277.0,
            1979.0,
            3025.0,
            2032.0
          ],
          "confidence": 0.9915239810943604
        },
        {
          "text": "pursuant to which any Person would own fifty percent (50%) or more of the consolidated assets, net revenues or net income of a",
          "bbox": [
            275.0,
            2045.0,
            3029.0,
            2098.0
          ],
          "confidence": 0.9893941283226013
        },
        {
          "text": "Party, taken as a whole, or which results in the holders of the voting equity interests of a Party immediately prior to such merger.",
          "bbox": [
            277.0,
            2109.0,
            3023.0,
            2167.0
          ],
          "confidence": 0.9963723421096802
        },
        {
          "text": "consolidation, business combination or similar transaction ceasing to hold fifty percent (50%) or more of the combined voting",
          "bbox": [
            277.0,
            2178.0,
            3027.0,
            2231.0
          ],
          "confidence": 0.997050404548645
        },
        {
          "text": "power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, business combination or.",
          "bbox": [
            277.0,
            2246.0,
            3031.0,
            2297.0
          ],
          "confidence": 0.9887821078300476
        },
        {
          "text": "similar transaction, (e) liquidation or dissolution (or the adoption of a plan of liquidation or dissolution) of a Party, or (f) declaration",
          "bbox": [
            281.0,
            2317.0,
            3025.0,
            2361.0
          ],
          "confidence": 0.9977426528930664
        },
        {
          "text": "or payment of an extraordinary dividend (whether in cash or other property) by a Party, where the amount of the dividend or the in.",
          "bbox": [
            277.0,
            2379.0,
            3029.0,
            2434.0
          ],
          "confidence": 0.9966531991958618
        },
        {
          "text": "specie property which is the subject of the dividend would otherwise come within the application of any of clauses (a)-(e) above,.",
          "bbox": [
            277.0,
            2443.0,
            3027.0,
            2500.0
          ],
          "confidence": 0.9955662488937378
        },
        {
          "text": "in all cases where such transaction is to be entered into with any Person other than the other Party.",
          "bbox": [
            275.0,
            2509.0,
            2336.0,
            2564.0
          ],
          "confidence": 0.994972288608551
        },
        {
          "text": "1.7 \"CMC' means chemistry, manufacturing and controls.",
          "bbox": [
            446.0,
            2633.0,
            1649.0,
            2686.0
          ],
          "confidence": 0.9895760416984558
        },
        {
          "text": "1.8 \"Commercialization\"' means all activities directed to marketing, promoting, advertising, exhibiting, distributing",
          "bbox": [
            444.0,
            2756.0,
            3025.0,
            2810.0
          ],
          "confidence": 0.9943382143974304
        },
        {
          "text": "(including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise",
          "bbox": [
            285.0,
            2829.0,
            3025.0,
            2873.0
          ],
          "confidence": 0.9882383942604065
        },
        {
          "text": "commercially exploiting the Product in the Field in the Territory.",
          "bbox": [
            275.0,
            2887.0,
            1606.0,
            2946.0
          ],
          "confidence": 0.9925694465637207
        },
        {
          "text": "1.9 \"Commercialization Plan' has the meaning set forth in Section 5.1(b)",
          "bbox": [
            448.0,
            3013.0,
            2046.0,
            3061.0
          ],
          "confidence": 0.9942542314529419
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3223.0,
            1668.0,
            3262.0
          ],
          "confidence": 0.9846658706665039
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ],
          "confidence": 0.9990366697311401
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9950901865959167
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 6,
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Revenue/Profit Sharing_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "Following the expiration of the Distribution Term and during the remaining Term of this Agreement, for all Product supplied by Zogenix to Distributor under purchase orders submitted pursuant to the Supply Agreement in a particular Fiscal Year, Distributor shall pay to Zogenix the Transfer Price per unit of Product supplied shall be equal to the sum of (i) [***] of the Fully-Burdened Manufacturing Cost per unit of Product for such Fiscal Year, and (ii) [***] of aggregate annual Net Sales for such Fiscal Year.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Revenue/Profit Sharing_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Revenue/Profit Sharing\" that should be reviewed by a lawyer. Details: Is one party required to share revenue or profit with the counterparty for any technology, goods, or services?",
      "answer_text": "Following the expiration of the Distribution Term and during the remaining Term of this Agreement, for all Product supplied by Zogenix to Distributor under purchase orders submitted pursuant to the Supply Agreement in a particular Fiscal Year, Distributor shall pay to Zogenix the Transfer Price per unit of Product supplied shall be equal to the sum of (i) [***] of the Fully-Burdened Manufacturing Cost per unit of Product for such Fiscal Year, and (ii) [***] of aggregate annual Net Sales for such Fiscal Year.",
      "page_number": 6,
      "words": [
        {
          "text": "1.2 \"Alliance Manager' has the meaning set forth in Section 3.3.",
          "bbox": [
            448.0,
            685.0,
            1836.0,
            736.0
          ],
          "confidence": 0.9859306216239929
        },
        {
          "text": "1.3 \"Annual Report' has the meaning set forth in Section 6.5(c)",
          "bbox": [
            446.0,
            809.0,
            1823.0,
            861.0
          ],
          "confidence": 0.9771308302879333
        },
        {
          "text": "1.4 \"Applicable Laws\" means the applicable provisions of any and all national, supranational, regional, state and local",
          "bbox": [
            448.0,
            936.0,
            3027.0,
            985.0
          ],
          "confidence": 0.985500156879425
        },
        {
          "text": "laws, treaties, statutes, rules, regulations, administrative codes, industry codes, guidance, ordinances, judgments, decrees,.",
          "bbox": [
            277.0,
            1001.0,
            3025.0,
            1053.0
          ],
          "confidence": 0.9961791634559631
        },
        {
          "text": "directives, injunctions, orders or permits (including Regulatory Approvals) of or from any court, arbitrator, Regulatory Authority or",
          "bbox": [
            279.0,
            1067.0,
            3027.0,
            1118.0
          ],
          "confidence": 0.9920154213905334
        },
        {
          "text": "governmental agency or authority having jurisdiction over or related to the subject item, including the FCPA, export control,",
          "bbox": [
            277.0,
            1133.0,
            3025.0,
            1188.0
          ],
          "confidence": 0.9949026703834534
        },
        {
          "text": "embargo, trade sanction and data privacy laws, regulations, rules and licenses, and other laws and regulations pertaining to",
          "bbox": [
            277.0,
            1201.0,
            3025.0,
            1254.0
          ],
          "confidence": 0.993232011795044
        },
        {
          "text": "domestic or international corruption, commercial bribery, fraud, embezzlement or money laundering.",
          "bbox": [
            275.0,
            1259.0,
            2365.0,
            1325.0
          ],
          "confidence": 0.9901788830757141
        },
        {
          "text": "1.5 \"Business Day\"' means a day other than a Saturday, Sunday, any public holiday, or any bank holiday in the United",
          "bbox": [
            444.0,
            1389.0,
            3027.0,
            1440.0
          ],
          "confidence": 0.9882254004478455
        },
        {
          "text": "States or Japan.",
          "bbox": [
            279.0,
            1458.0,
            613.0,
            1508.0
          ],
          "confidence": 0.9998754262924194
        },
        {
          "text": "1.6 \"Change of Control' means any (a) direct or indirect acquisition of assets of a Party (i) equal to fifty percent (50%)",
          "bbox": [
            448.0,
            1581.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9898536801338196
        },
        {
          "text": "or more of the fair market value of a Party's consolidated assets, or (ii) to which fifty percent (50%) or more of a Party's net",
          "bbox": [
            281.0,
            1650.0,
            3029.0,
            1694.0
          ],
          "confidence": 0.9935340881347656
        },
        {
          "text": "revenues or net income on a consolidated basis are attributable, or (iii) representing substantially all of the properties or assets",
          "bbox": [
            277.0,
            1718.0,
            3027.0,
            1762.0
          ],
          "confidence": 0.9949082136154175
        },
        {
          "text": "related to a Party's obligations under this Agreement, (b) direct or indirect acquisition by a Person, or group of Persons acting in.",
          "bbox": [
            275.0,
            1780.0,
            3027.0,
            1831.0
          ],
          "confidence": 0.9926859736442566
        },
        {
          "text": "concert, of fifty percent (50%) or more of the voting equity interests of a Party, (c) tender offer or exchange offer that if",
          "bbox": [
            277.0,
            1846.0,
            3031.0,
            1899.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "consummated would result in any Person, or group of Persons acting in concert, beneficially owning fifty percent (50%) or more of.",
          "bbox": [
            277.0,
            1915.0,
            3032.0,
            1964.0
          ],
          "confidence": 0.9912351369857788
        },
        {
          "text": "the voting equity interests of a Party, (d) merger, consolidation, other business combination or similar transaction involving a Party,.",
          "bbox": [
            277.0,
            1979.0,
            3025.0,
            2032.0
          ],
          "confidence": 0.9915239810943604
        },
        {
          "text": "pursuant to which any Person would own fifty percent (50%) or more of the consolidated assets, net revenues or net income of a",
          "bbox": [
            275.0,
            2045.0,
            3029.0,
            2098.0
          ],
          "confidence": 0.9893941283226013
        },
        {
          "text": "Party, taken as a whole, or which results in the holders of the voting equity interests of a Party immediately prior to such merger.",
          "bbox": [
            277.0,
            2109.0,
            3023.0,
            2167.0
          ],
          "confidence": 0.9963723421096802
        },
        {
          "text": "consolidation, business combination or similar transaction ceasing to hold fifty percent (50%) or more of the combined voting",
          "bbox": [
            277.0,
            2178.0,
            3027.0,
            2231.0
          ],
          "confidence": 0.997050404548645
        },
        {
          "text": "power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, business combination or.",
          "bbox": [
            277.0,
            2246.0,
            3031.0,
            2297.0
          ],
          "confidence": 0.9887821078300476
        },
        {
          "text": "similar transaction, (e) liquidation or dissolution (or the adoption of a plan of liquidation or dissolution) of a Party, or (f) declaration",
          "bbox": [
            281.0,
            2317.0,
            3025.0,
            2361.0
          ],
          "confidence": 0.9977426528930664
        },
        {
          "text": "or payment of an extraordinary dividend (whether in cash or other property) by a Party, where the amount of the dividend or the in.",
          "bbox": [
            277.0,
            2379.0,
            3029.0,
            2434.0
          ],
          "confidence": 0.9966531991958618
        },
        {
          "text": "specie property which is the subject of the dividend would otherwise come within the application of any of clauses (a)-(e) above,.",
          "bbox": [
            277.0,
            2443.0,
            3027.0,
            2500.0
          ],
          "confidence": 0.9955662488937378
        },
        {
          "text": "in all cases where such transaction is to be entered into with any Person other than the other Party.",
          "bbox": [
            275.0,
            2509.0,
            2336.0,
            2564.0
          ],
          "confidence": 0.994972288608551
        },
        {
          "text": "1.7 \"CMC' means chemistry, manufacturing and controls.",
          "bbox": [
            446.0,
            2633.0,
            1649.0,
            2686.0
          ],
          "confidence": 0.9895760416984558
        },
        {
          "text": "1.8 \"Commercialization\"' means all activities directed to marketing, promoting, advertising, exhibiting, distributing",
          "bbox": [
            444.0,
            2756.0,
            3025.0,
            2810.0
          ],
          "confidence": 0.9943382143974304
        },
        {
          "text": "(including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise",
          "bbox": [
            285.0,
            2829.0,
            3025.0,
            2873.0
          ],
          "confidence": 0.9882383942604065
        },
        {
          "text": "commercially exploiting the Product in the Field in the Territory.",
          "bbox": [
            275.0,
            2887.0,
            1606.0,
            2946.0
          ],
          "confidence": 0.9925694465637207
        },
        {
          "text": "1.9 \"Commercialization Plan' has the meaning set forth in Section 5.1(b)",
          "bbox": [
            448.0,
            3013.0,
            2046.0,
            3061.0
          ],
          "confidence": 0.9942542314529419
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3223.0,
            1668.0,
            3262.0
          ],
          "confidence": 0.9846658706665039
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ],
          "confidence": 0.9990366697311401
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9950901865959167
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 6,
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Ip Ownership Assignment_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), at Zogenix's option, which shall be exercised by written notice to Distributor, to the extent permitted under Applicable Laws, Distributor shall assign or cause to be assigned to Zogenix or its designee (or to the extent not so assignable, Distributor shall take all reasonable actions to make available to Zogenix or its designee the benefits of), at Zogenix's cost, all Regulatory Filings and Regulatory Approvals for the Product in the Field in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Ip Ownership Assignment_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Ip Ownership Assignment\" that should be reviewed by a lawyer. Details: Does intellectual property created  by one party become the property of the counterparty, either per the terms of the contract or upon the occurrence of certain events?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), at Zogenix's option, which shall be exercised by written notice to Distributor, to the extent permitted under Applicable Laws, Distributor shall assign or cause to be assigned to Zogenix or its designee (or to the extent not so assignable, Distributor shall take all reasonable actions to make available to Zogenix or its designee the benefits of), at Zogenix's cost, all Regulatory Filings and Regulatory Approvals for the Product in the Field in the Territory.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Joint Ip Ownership_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Notwithstanding the foregoing, if Zogenix asks Distributor to solely conduct any additional Territory-specific Development activities which are urgently required by the MHLW for the MAA in the Territory, Distributor shall retain co-ownership with Zogenix of any Data generated solely by Distributor.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Joint Ip Ownership_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Notwithstanding the foregoing, if Zogenix asks Distributor to solely conduct any additional Territory-specific Development activities which are urgently required by the MHLW for the MAA in the Territory, Distributor shall retain co-ownership with Zogenix of any Data generated solely by Distributor.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Joint Ip Ownership_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "In the event that either Zogenix or Distributor intends to file a patent application containing a Joint Invention, such Party shall promptly notify the other Party of such intention and shall provide a draft of any such patent application to such other Party [***] before filing such patent application with any patent office and the Parties shall negotiate in good faith concerning the terms and conditions of a joint patent agreement.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Joint Ip Ownership_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "In the event that either Zogenix or Distributor intends to file a patent application containing a Joint Invention, such Party shall promptly notify the other Party of such intention and shall provide a draft of any such patent application to such other Party [***] before filing such patent application with any patent office and the Parties shall negotiate in good faith concerning the terms and conditions of a joint patent agreement.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Joint Ip Ownership_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Zogenix and Distributor shall each own an undivided right, title, and interest in and to any and all Inventions discovered, developed, identified, made, conceived or reduced to practice jointly by or on behalf of Zogenix under or in connection with this Agreement and by Distributor or its Affiliates or Sub-distributors or its other subcontractors in the Territory and under or in connection with this Agreement (\"Joint Invention\").",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Joint Ip Ownership_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Joint Ip Ownership\" that should be reviewed by a lawyer. Details: Is there any clause providing for joint or shared ownership of intellectual property between the parties to the contract?",
      "answer_text": "Zogenix and Distributor shall each own an undivided right, title, and interest in and to any and all Inventions discovered, developed, identified, made, conceived or reduced to practice jointly by or on behalf of Zogenix under or in connection with this Agreement and by Distributor or its Affiliates or Sub-distributors or its other subcontractors in the Territory and under or in connection with this Agreement (\"Joint Invention\").",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Such license shall also include Zogenix's agreement to use Commercially Reasonable Efforts to enable Distributor to establish manufacturing capability for the Product in or for the Territory at Distributor's cost.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Such license shall also include Zogenix's agreement to use Commercially Reasonable Efforts to enable Distributor to establish manufacturing capability for the Product in or for the Territory at Distributor's cost.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby grants to Distributor a non-exclusive, royalty-free, limited right under the Zogenix Trademarks solely to promote, market, sell, offer for sale, import, package and distribute the Product in Field in the Territory in accordance with the terms of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby grants to Distributor a non-exclusive, royalty-free, limited right under the Zogenix Trademarks solely to promote, market, sell, offer for sale, import, package and distribute the Product in Field in the Territory in accordance with the terms of this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby appoints Distributor, and Distributor accepts appointment, as the exclusive distributor (even as to Zogenix) of the Product in the Field in the Territory during the Term, and grants to Distributor the exclusive rights to maintain Regulatory Approval of (while Distributor is the MAH Party), package, promote, market, offer for sale, sell, import and distribute the Product in the Field in the Territory during the Term.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby appoints Distributor, and Distributor accepts appointment, as the exclusive distributor (even as to Zogenix) of the Product in the Field in the Territory during the Term, and grants to Distributor the exclusive rights to maintain Regulatory Approval of (while Distributor is the MAH Party), package, promote, market, offer for sale, sell, import and distribute the Product in the Field in the Territory during the Term.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "In the event that Zogenix is the holder of the Regulatory Approval for the Product in the Territory at the time of termination pursuant to Section 12.2(c) by Zogenix or Section 12.2(d) by Distributor or expiration pursuant to Section 12.1, such license agreement shall also include a grant by Zogenix to Distributor of the right to reference and use all Data and Regulatory Filings (including all Regulatory Approvals), such reference and use solely for maintaining Regulatory Approval and commercializing the Product in the Territory in the Field.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "In the event that Zogenix is the holder of the Regulatory Approval for the Product in the Territory at the time of termination pursuant to Section 12.2(c) by Zogenix or Section 12.2(d) by Distributor or expiration pursuant to Section 12.1, such license agreement shall also include a grant by Zogenix to Distributor of the right to reference and use all Data and Regulatory Filings (including all Regulatory Approvals), such reference and use solely for maintaining Regulatory Approval and commercializing the Product in the Territory in the Field.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 8,
      "words": [
        {
          "text": "having the administrative authority to regulate the marketing of human pharmaceutical products in the United States.",
          "bbox": [
            281.0,
            693.0,
            2684.0,
            736.0
          ],
          "confidence": 0.990659236907959
        },
        {
          "text": "1.22 \"Field' means the Indications of treatment for the Product in the Territory.",
          "bbox": [
            446.0,
            808.0,
            2117.0,
            863.0
          ],
          "confidence": 0.987780749797821
        },
        {
          "text": "1.23 \"First Commercial Sale' means the first bona fide, arm's-length sale of the Product in the Field in the Territory",
          "bbox": [
            444.0,
            926.0,
            3025.0,
            987.0
          ],
          "confidence": 0.9975684285163879
        },
        {
          "text": "following Regulatory Approval of the Product in the Field in the Territory.",
          "bbox": [
            277.0,
            998.0,
            1814.0,
            1054.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "1.24 \"Fiscal Quarter' means a period of three (3) consecutive months during a Fiscal Year beginning on and including",
          "bbox": [
            444.0,
            1122.0,
            3023.0,
            1175.0
          ],
          "confidence": 0.9934802651405334
        },
        {
          "text": "April 1st, July 1st or October 1st or January 1st.",
          "bbox": [
            279.0,
            1184.0,
            1256.0,
            1245.0
          ],
          "confidence": 0.9987046718597412
        },
        {
          "text": "1.25 \"Fiscal Year\"' means a year that starts from April 1st and ends on March 31st",
          "bbox": [
            446.0,
            1307.0,
            2193.0,
            1363.0
          ],
          "confidence": 0.9862964153289795
        },
        {
          "text": "1.26 \"Fully-Burdened Manufacturing Cost' means the costs incurred by Zogenix that are directly attributable to and",
          "bbox": [
            448.0,
            1436.0,
            3025.0,
            1486.0
          ],
          "confidence": 0.9970605373382568
        },
        {
          "text": "reasonably allocated to the manufacture and delivery of the Product to Distributor. Fully-Burdened Manufacturing Costs shall.",
          "bbox": [
            281.0,
            1506.0,
            3025.0,
            1550.0
          ],
          "confidence": 0.9949726462364197
        },
        {
          "text": "include the following: [***].",
          "bbox": [
            277.0,
            1568.0,
            861.0,
            1623.0
          ],
          "confidence": 0.9931353330612183
        },
        {
          "text": "1.27 \"Generic Product' means a pharmaceutical product that (a) [***]; (b) [***]; (c) [***]; and (d) [***]",
          "bbox": [
            446.0,
            1687.0,
            2739.0,
            1743.0
          ],
          "confidence": 0.9896778464317322
        },
        {
          "text": "1.28 \"IFRS\" means international financial reporting standards, as may be amended from time to time.",
          "bbox": [
            444.0,
            1809.0,
            2576.0,
            1869.0
          ],
          "confidence": 0.9888802766799927
        },
        {
          "text": "1.29 \"IND\" means any Investigational New Drug application, as defined in Title 21 of the Code of Federal Regulations, on",
          "bbox": [
            446.0,
            1935.0,
            3025.0,
            1990.0
          ],
          "confidence": 0.9851425886154175
        },
        {
          "text": "file with the FDA before the commencement of clinical trials of the Product in humans, or any comparable filing with any.",
          "bbox": [
            279.0,
            1999.0,
            3021.0,
            2056.0
          ],
          "confidence": 0.9824780821800232
        },
        {
          "text": "Regulatory Authority.",
          "bbox": [
            283.0,
            2076.0,
            718.0,
            2120.0
          ],
          "confidence": 0.976063072681427
        },
        {
          "text": "1.30 \"Indemnitee' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2193.0,
            1729.0,
            2242.0
          ],
          "confidence": 0.9852561950683594
        },
        {
          "text": "1.31 \"Indemnitor' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2315.0,
            1735.0,
            2365.0
          ],
          "confidence": 0.9949570894241333
        },
        {
          "text": "1.32 \"Indication\" means the treatment of Dravet syndrome, Lennox-Gastaut syndrome, [***] during the Distribution",
          "bbox": [
            446.0,
            2436.0,
            3025.0,
            2489.0
          ],
          "confidence": 0.9924944639205933
        },
        {
          "text": "Term.",
          "bbox": [
            269.0,
            2497.0,
            403.0,
            2559.0
          ],
          "confidence": 0.9989998936653137
        },
        {
          "text": "1.33 \"Indirect Losses\" means any damages or other losses involving, but only to the extent of, any loss of profits,",
          "bbox": [
            446.0,
            2626.0,
            3023.0,
            2679.0
          ],
          "confidence": 0.9974219799041748
        },
        {
          "text": "diminution in value, or incidental, indirect, consequential, special or punitive damages.",
          "bbox": [
            279.0,
            2692.0,
            2061.0,
            2748.0
          ],
          "confidence": 0.9855474233627319
        },
        {
          "text": "1.34 \"Information\"' means information, ideas, inventions, discoveries, concepts, formulas, practices, procedures,",
          "bbox": [
            444.0,
            2816.0,
            3025.0,
            2867.0
          ],
          "confidence": 0.9948017001152039
        },
        {
          "text": "processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, development, designs,.",
          "bbox": [
            279.0,
            2887.0,
            3023.0,
            2937.0
          ],
          "confidence": 0.9927463531494141
        },
        {
          "text": "drawings, computer programs, skill, experience, documents, apparatus, results, clinical and regulatory strategies, documentation,",
          "bbox": [
            281.0,
            2957.0,
            3027.0,
            3000.0
          ],
          "confidence": 0.9933117032051086
        },
        {
          "text": "information and submissions pertaining to, or made in association with, filings with any Regulatory Authority, data, including",
          "bbox": [
            275.0,
            3015.0,
            3025.0,
            3072.0
          ],
          "confidence": 0.9905213117599487
        },
        {
          "text": "pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and descriptions, patent and.",
          "bbox": [
            281.0,
            3088.0,
            3025.0,
            3132.0
          ],
          "confidence": 0.9974802732467651
        },
        {
          "text": "legal data,",
          "bbox": [
            279.0,
            3152.0,
            493.0,
            3203.0
          ],
          "confidence": 0.998089075088501
        },
        {
          "text": "4",
          "bbox": [
            1638.0,
            3359.0,
            1669.0,
            3401.0
          ],
          "confidence": 0.9971023201942444
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ],
          "confidence": 0.9980375170707703
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9954956769943237
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 8,
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby grants to Distributor an co-exclusive, royalty-free, limited right under the Product Trademarks solely to promote, market, sell, offer for sale, import, package and distribute the Product in Field in the Territory in accordance with the terms of this Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__License Grant_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"License Grant\" that should be reviewed by a lawyer. Details: Does the contract contain a license granted by one party to its counterparty?",
      "answer_text": "Subject to the terms and conditions of this Agreement, Zogenix hereby grants to Distributor an co-exclusive, royalty-free, limited right under the Product Trademarks solely to promote, market, sell, offer for sale, import, package and distribute the Product in Field in the Territory in accordance with the terms of this Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 8,
      "words": [
        {
          "text": "having the administrative authority to regulate the marketing of human pharmaceutical products in the United States.",
          "bbox": [
            281.0,
            693.0,
            2684.0,
            736.0
          ],
          "confidence": 0.990659236907959
        },
        {
          "text": "1.22 \"Field' means the Indications of treatment for the Product in the Territory.",
          "bbox": [
            446.0,
            808.0,
            2117.0,
            863.0
          ],
          "confidence": 0.987780749797821
        },
        {
          "text": "1.23 \"First Commercial Sale' means the first bona fide, arm's-length sale of the Product in the Field in the Territory",
          "bbox": [
            444.0,
            926.0,
            3025.0,
            987.0
          ],
          "confidence": 0.9975684285163879
        },
        {
          "text": "following Regulatory Approval of the Product in the Field in the Territory.",
          "bbox": [
            277.0,
            998.0,
            1814.0,
            1054.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "1.24 \"Fiscal Quarter' means a period of three (3) consecutive months during a Fiscal Year beginning on and including",
          "bbox": [
            444.0,
            1122.0,
            3023.0,
            1175.0
          ],
          "confidence": 0.9934802651405334
        },
        {
          "text": "April 1st, July 1st or October 1st or January 1st.",
          "bbox": [
            279.0,
            1184.0,
            1256.0,
            1245.0
          ],
          "confidence": 0.9987046718597412
        },
        {
          "text": "1.25 \"Fiscal Year\"' means a year that starts from April 1st and ends on March 31st",
          "bbox": [
            446.0,
            1307.0,
            2193.0,
            1363.0
          ],
          "confidence": 0.9862964153289795
        },
        {
          "text": "1.26 \"Fully-Burdened Manufacturing Cost' means the costs incurred by Zogenix that are directly attributable to and",
          "bbox": [
            448.0,
            1436.0,
            3025.0,
            1486.0
          ],
          "confidence": 0.9970605373382568
        },
        {
          "text": "reasonably allocated to the manufacture and delivery of the Product to Distributor. Fully-Burdened Manufacturing Costs shall.",
          "bbox": [
            281.0,
            1506.0,
            3025.0,
            1550.0
          ],
          "confidence": 0.9949726462364197
        },
        {
          "text": "include the following: [***].",
          "bbox": [
            277.0,
            1568.0,
            861.0,
            1623.0
          ],
          "confidence": 0.9931353330612183
        },
        {
          "text": "1.27 \"Generic Product' means a pharmaceutical product that (a) [***]; (b) [***]; (c) [***]; and (d) [***]",
          "bbox": [
            446.0,
            1687.0,
            2739.0,
            1743.0
          ],
          "confidence": 0.9896778464317322
        },
        {
          "text": "1.28 \"IFRS\" means international financial reporting standards, as may be amended from time to time.",
          "bbox": [
            444.0,
            1809.0,
            2576.0,
            1869.0
          ],
          "confidence": 0.9888802766799927
        },
        {
          "text": "1.29 \"IND\" means any Investigational New Drug application, as defined in Title 21 of the Code of Federal Regulations, on",
          "bbox": [
            446.0,
            1935.0,
            3025.0,
            1990.0
          ],
          "confidence": 0.9851425886154175
        },
        {
          "text": "file with the FDA before the commencement of clinical trials of the Product in humans, or any comparable filing with any.",
          "bbox": [
            279.0,
            1999.0,
            3021.0,
            2056.0
          ],
          "confidence": 0.9824780821800232
        },
        {
          "text": "Regulatory Authority.",
          "bbox": [
            283.0,
            2076.0,
            718.0,
            2120.0
          ],
          "confidence": 0.976063072681427
        },
        {
          "text": "1.30 \"Indemnitee' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2193.0,
            1729.0,
            2242.0
          ],
          "confidence": 0.9852561950683594
        },
        {
          "text": "1.31 \"Indemnitor' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2315.0,
            1735.0,
            2365.0
          ],
          "confidence": 0.9949570894241333
        },
        {
          "text": "1.32 \"Indication\" means the treatment of Dravet syndrome, Lennox-Gastaut syndrome, [***] during the Distribution",
          "bbox": [
            446.0,
            2436.0,
            3025.0,
            2489.0
          ],
          "confidence": 0.9924944639205933
        },
        {
          "text": "Term.",
          "bbox": [
            269.0,
            2497.0,
            403.0,
            2559.0
          ],
          "confidence": 0.9989998936653137
        },
        {
          "text": "1.33 \"Indirect Losses\" means any damages or other losses involving, but only to the extent of, any loss of profits,",
          "bbox": [
            446.0,
            2626.0,
            3023.0,
            2679.0
          ],
          "confidence": 0.9974219799041748
        },
        {
          "text": "diminution in value, or incidental, indirect, consequential, special or punitive damages.",
          "bbox": [
            279.0,
            2692.0,
            2061.0,
            2748.0
          ],
          "confidence": 0.9855474233627319
        },
        {
          "text": "1.34 \"Information\"' means information, ideas, inventions, discoveries, concepts, formulas, practices, procedures,",
          "bbox": [
            444.0,
            2816.0,
            3025.0,
            2867.0
          ],
          "confidence": 0.9948017001152039
        },
        {
          "text": "processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, development, designs,.",
          "bbox": [
            279.0,
            2887.0,
            3023.0,
            2937.0
          ],
          "confidence": 0.9927463531494141
        },
        {
          "text": "drawings, computer programs, skill, experience, documents, apparatus, results, clinical and regulatory strategies, documentation,",
          "bbox": [
            281.0,
            2957.0,
            3027.0,
            3000.0
          ],
          "confidence": 0.9933117032051086
        },
        {
          "text": "information and submissions pertaining to, or made in association with, filings with any Regulatory Authority, data, including",
          "bbox": [
            275.0,
            3015.0,
            3025.0,
            3072.0
          ],
          "confidence": 0.9905213117599487
        },
        {
          "text": "pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and descriptions, patent and.",
          "bbox": [
            281.0,
            3088.0,
            3025.0,
            3132.0
          ],
          "confidence": 0.9974802732467651
        },
        {
          "text": "legal data,",
          "bbox": [
            279.0,
            3152.0,
            493.0,
            3203.0
          ],
          "confidence": 0.998089075088501
        },
        {
          "text": "4",
          "bbox": [
            1638.0,
            3359.0,
            1669.0,
            3401.0
          ],
          "confidence": 0.9971023201942444
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ],
          "confidence": 0.9980375170707703
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9954956769943237
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 8,
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "\"Data\" means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data (including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "\"Data\" means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data (including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "Distributor shall own the entire right, title and interest in and to any and all Inventions discovered, developed, identified, made, conceived or reduced to practice solely by Distributor or its Affiliates or Sub-distributors or its other subcontractors in the Territory and under or in connection with this Agreement, including in the course of conducting regulatory activities or Commercialization of the Product in the Field in the Territory, whether or not patented or patentable, together with any and all intellectual property rights in any such Inventions, including Patents that claim or disclose any such Inventions (collectively, the \"Distributor Invention\").",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensor_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensor\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant by affiliates of the licensor or that includes intellectual property of affiliates of the licensor? ",
      "answer_text": "Distributor shall own the entire right, title and interest in and to any and all Inventions discovered, developed, identified, made, conceived or reduced to practice solely by Distributor or its Affiliates or Sub-distributors or its other subcontractors in the Territory and under or in connection with this Agreement, including in the course of conducting regulatory activities or Commercialization of the Product in the Field in the Territory, whether or not patented or patentable, together with any and all intellectual property rights in any such Inventions, including Patents that claim or disclose any such Inventions (collectively, the \"Distributor Invention\").",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensee_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensee_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 8,
      "words": [
        {
          "text": "having the administrative authority to regulate the marketing of human pharmaceutical products in the United States.",
          "bbox": [
            281.0,
            693.0,
            2684.0,
            736.0
          ],
          "confidence": 0.990659236907959
        },
        {
          "text": "1.22 \"Field' means the Indications of treatment for the Product in the Territory.",
          "bbox": [
            446.0,
            808.0,
            2117.0,
            863.0
          ],
          "confidence": 0.987780749797821
        },
        {
          "text": "1.23 \"First Commercial Sale' means the first bona fide, arm's-length sale of the Product in the Field in the Territory",
          "bbox": [
            444.0,
            926.0,
            3025.0,
            987.0
          ],
          "confidence": 0.9975684285163879
        },
        {
          "text": "following Regulatory Approval of the Product in the Field in the Territory.",
          "bbox": [
            277.0,
            998.0,
            1814.0,
            1054.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "1.24 \"Fiscal Quarter' means a period of three (3) consecutive months during a Fiscal Year beginning on and including",
          "bbox": [
            444.0,
            1122.0,
            3023.0,
            1175.0
          ],
          "confidence": 0.9934802651405334
        },
        {
          "text": "April 1st, July 1st or October 1st or January 1st.",
          "bbox": [
            279.0,
            1184.0,
            1256.0,
            1245.0
          ],
          "confidence": 0.9987046718597412
        },
        {
          "text": "1.25 \"Fiscal Year\"' means a year that starts from April 1st and ends on March 31st",
          "bbox": [
            446.0,
            1307.0,
            2193.0,
            1363.0
          ],
          "confidence": 0.9862964153289795
        },
        {
          "text": "1.26 \"Fully-Burdened Manufacturing Cost' means the costs incurred by Zogenix that are directly attributable to and",
          "bbox": [
            448.0,
            1436.0,
            3025.0,
            1486.0
          ],
          "confidence": 0.9970605373382568
        },
        {
          "text": "reasonably allocated to the manufacture and delivery of the Product to Distributor. Fully-Burdened Manufacturing Costs shall.",
          "bbox": [
            281.0,
            1506.0,
            3025.0,
            1550.0
          ],
          "confidence": 0.9949726462364197
        },
        {
          "text": "include the following: [***].",
          "bbox": [
            277.0,
            1568.0,
            861.0,
            1623.0
          ],
          "confidence": 0.9931353330612183
        },
        {
          "text": "1.27 \"Generic Product' means a pharmaceutical product that (a) [***]; (b) [***]; (c) [***]; and (d) [***]",
          "bbox": [
            446.0,
            1687.0,
            2739.0,
            1743.0
          ],
          "confidence": 0.9896778464317322
        },
        {
          "text": "1.28 \"IFRS\" means international financial reporting standards, as may be amended from time to time.",
          "bbox": [
            444.0,
            1809.0,
            2576.0,
            1869.0
          ],
          "confidence": 0.9888802766799927
        },
        {
          "text": "1.29 \"IND\" means any Investigational New Drug application, as defined in Title 21 of the Code of Federal Regulations, on",
          "bbox": [
            446.0,
            1935.0,
            3025.0,
            1990.0
          ],
          "confidence": 0.9851425886154175
        },
        {
          "text": "file with the FDA before the commencement of clinical trials of the Product in humans, or any comparable filing with any.",
          "bbox": [
            279.0,
            1999.0,
            3021.0,
            2056.0
          ],
          "confidence": 0.9824780821800232
        },
        {
          "text": "Regulatory Authority.",
          "bbox": [
            283.0,
            2076.0,
            718.0,
            2120.0
          ],
          "confidence": 0.976063072681427
        },
        {
          "text": "1.30 \"Indemnitee' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2193.0,
            1729.0,
            2242.0
          ],
          "confidence": 0.9852561950683594
        },
        {
          "text": "1.31 \"Indemnitor' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2315.0,
            1735.0,
            2365.0
          ],
          "confidence": 0.9949570894241333
        },
        {
          "text": "1.32 \"Indication\" means the treatment of Dravet syndrome, Lennox-Gastaut syndrome, [***] during the Distribution",
          "bbox": [
            446.0,
            2436.0,
            3025.0,
            2489.0
          ],
          "confidence": 0.9924944639205933
        },
        {
          "text": "Term.",
          "bbox": [
            269.0,
            2497.0,
            403.0,
            2559.0
          ],
          "confidence": 0.9989998936653137
        },
        {
          "text": "1.33 \"Indirect Losses\" means any damages or other losses involving, but only to the extent of, any loss of profits,",
          "bbox": [
            446.0,
            2626.0,
            3023.0,
            2679.0
          ],
          "confidence": 0.9974219799041748
        },
        {
          "text": "diminution in value, or incidental, indirect, consequential, special or punitive damages.",
          "bbox": [
            279.0,
            2692.0,
            2061.0,
            2748.0
          ],
          "confidence": 0.9855474233627319
        },
        {
          "text": "1.34 \"Information\"' means information, ideas, inventions, discoveries, concepts, formulas, practices, procedures,",
          "bbox": [
            444.0,
            2816.0,
            3025.0,
            2867.0
          ],
          "confidence": 0.9948017001152039
        },
        {
          "text": "processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, development, designs,.",
          "bbox": [
            279.0,
            2887.0,
            3023.0,
            2937.0
          ],
          "confidence": 0.9927463531494141
        },
        {
          "text": "drawings, computer programs, skill, experience, documents, apparatus, results, clinical and regulatory strategies, documentation,",
          "bbox": [
            281.0,
            2957.0,
            3027.0,
            3000.0
          ],
          "confidence": 0.9933117032051086
        },
        {
          "text": "information and submissions pertaining to, or made in association with, filings with any Regulatory Authority, data, including",
          "bbox": [
            275.0,
            3015.0,
            3025.0,
            3072.0
          ],
          "confidence": 0.9905213117599487
        },
        {
          "text": "pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and descriptions, patent and.",
          "bbox": [
            281.0,
            3088.0,
            3025.0,
            3132.0
          ],
          "confidence": 0.9974802732467651
        },
        {
          "text": "legal data,",
          "bbox": [
            279.0,
            3152.0,
            493.0,
            3203.0
          ],
          "confidence": 0.998089075088501
        },
        {
          "text": "4",
          "bbox": [
            1638.0,
            3359.0,
            1669.0,
            3401.0
          ],
          "confidence": 0.9971023201942444
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ],
          "confidence": 0.9980375170707703
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9954956769943237
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 8,
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensee_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Affiliate License-Licensee_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Affiliate License-Licensee\" that should be reviewed by a lawyer. Details: Does the contract contain a license grant to a licensee (incl. sublicensor) and the affiliates of such licensee/sublicensor?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Irrevocable Or Perpetual License_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain a  license grant that is irrevocable or perpetual?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Irrevocable Or Perpetual License_8_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain a  license grant that is irrevocable or perpetual?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, world-wide, royalty-free, fully paid-up, non-exclusive license with the right to grant sublicenses under such Distributor Inventions and any patents or patent applications claiming or disclosing such Distributor Inventions.",
      "page_number": 8,
      "words": [
        {
          "text": "having the administrative authority to regulate the marketing of human pharmaceutical products in the United States.",
          "bbox": [
            281.0,
            693.0,
            2684.0,
            736.0
          ],
          "confidence": 0.990659236907959
        },
        {
          "text": "1.22 \"Field' means the Indications of treatment for the Product in the Territory.",
          "bbox": [
            446.0,
            808.0,
            2117.0,
            863.0
          ],
          "confidence": 0.987780749797821
        },
        {
          "text": "1.23 \"First Commercial Sale' means the first bona fide, arm's-length sale of the Product in the Field in the Territory",
          "bbox": [
            444.0,
            926.0,
            3025.0,
            987.0
          ],
          "confidence": 0.9975684285163879
        },
        {
          "text": "following Regulatory Approval of the Product in the Field in the Territory.",
          "bbox": [
            277.0,
            998.0,
            1814.0,
            1054.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "1.24 \"Fiscal Quarter' means a period of three (3) consecutive months during a Fiscal Year beginning on and including",
          "bbox": [
            444.0,
            1122.0,
            3023.0,
            1175.0
          ],
          "confidence": 0.9934802651405334
        },
        {
          "text": "April 1st, July 1st or October 1st or January 1st.",
          "bbox": [
            279.0,
            1184.0,
            1256.0,
            1245.0
          ],
          "confidence": 0.9987046718597412
        },
        {
          "text": "1.25 \"Fiscal Year\"' means a year that starts from April 1st and ends on March 31st",
          "bbox": [
            446.0,
            1307.0,
            2193.0,
            1363.0
          ],
          "confidence": 0.9862964153289795
        },
        {
          "text": "1.26 \"Fully-Burdened Manufacturing Cost' means the costs incurred by Zogenix that are directly attributable to and",
          "bbox": [
            448.0,
            1436.0,
            3025.0,
            1486.0
          ],
          "confidence": 0.9970605373382568
        },
        {
          "text": "reasonably allocated to the manufacture and delivery of the Product to Distributor. Fully-Burdened Manufacturing Costs shall.",
          "bbox": [
            281.0,
            1506.0,
            3025.0,
            1550.0
          ],
          "confidence": 0.9949726462364197
        },
        {
          "text": "include the following: [***].",
          "bbox": [
            277.0,
            1568.0,
            861.0,
            1623.0
          ],
          "confidence": 0.9931353330612183
        },
        {
          "text": "1.27 \"Generic Product' means a pharmaceutical product that (a) [***]; (b) [***]; (c) [***]; and (d) [***]",
          "bbox": [
            446.0,
            1687.0,
            2739.0,
            1743.0
          ],
          "confidence": 0.9896778464317322
        },
        {
          "text": "1.28 \"IFRS\" means international financial reporting standards, as may be amended from time to time.",
          "bbox": [
            444.0,
            1809.0,
            2576.0,
            1869.0
          ],
          "confidence": 0.9888802766799927
        },
        {
          "text": "1.29 \"IND\" means any Investigational New Drug application, as defined in Title 21 of the Code of Federal Regulations, on",
          "bbox": [
            446.0,
            1935.0,
            3025.0,
            1990.0
          ],
          "confidence": 0.9851425886154175
        },
        {
          "text": "file with the FDA before the commencement of clinical trials of the Product in humans, or any comparable filing with any.",
          "bbox": [
            279.0,
            1999.0,
            3021.0,
            2056.0
          ],
          "confidence": 0.9824780821800232
        },
        {
          "text": "Regulatory Authority.",
          "bbox": [
            283.0,
            2076.0,
            718.0,
            2120.0
          ],
          "confidence": 0.976063072681427
        },
        {
          "text": "1.30 \"Indemnitee' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2193.0,
            1729.0,
            2242.0
          ],
          "confidence": 0.9852561950683594
        },
        {
          "text": "1.31 \"Indemnitor' has the meaning set forth in Section 11.3.",
          "bbox": [
            448.0,
            2315.0,
            1735.0,
            2365.0
          ],
          "confidence": 0.9949570894241333
        },
        {
          "text": "1.32 \"Indication\" means the treatment of Dravet syndrome, Lennox-Gastaut syndrome, [***] during the Distribution",
          "bbox": [
            446.0,
            2436.0,
            3025.0,
            2489.0
          ],
          "confidence": 0.9924944639205933
        },
        {
          "text": "Term.",
          "bbox": [
            269.0,
            2497.0,
            403.0,
            2559.0
          ],
          "confidence": 0.9989998936653137
        },
        {
          "text": "1.33 \"Indirect Losses\" means any damages or other losses involving, but only to the extent of, any loss of profits,",
          "bbox": [
            446.0,
            2626.0,
            3023.0,
            2679.0
          ],
          "confidence": 0.9974219799041748
        },
        {
          "text": "diminution in value, or incidental, indirect, consequential, special or punitive damages.",
          "bbox": [
            279.0,
            2692.0,
            2061.0,
            2748.0
          ],
          "confidence": 0.9855474233627319
        },
        {
          "text": "1.34 \"Information\"' means information, ideas, inventions, discoveries, concepts, formulas, practices, procedures,",
          "bbox": [
            444.0,
            2816.0,
            3025.0,
            2867.0
          ],
          "confidence": 0.9948017001152039
        },
        {
          "text": "processes, methods, knowledge, know-how, trade secrets, technology, inventories, machines, techniques, development, designs,.",
          "bbox": [
            279.0,
            2887.0,
            3023.0,
            2937.0
          ],
          "confidence": 0.9927463531494141
        },
        {
          "text": "drawings, computer programs, skill, experience, documents, apparatus, results, clinical and regulatory strategies, documentation,",
          "bbox": [
            281.0,
            2957.0,
            3027.0,
            3000.0
          ],
          "confidence": 0.9933117032051086
        },
        {
          "text": "information and submissions pertaining to, or made in association with, filings with any Regulatory Authority, data, including",
          "bbox": [
            275.0,
            3015.0,
            3025.0,
            3072.0
          ],
          "confidence": 0.9905213117599487
        },
        {
          "text": "pharmacological, toxicological and clinical data, analytical and quality control data, manufacturing data and descriptions, patent and.",
          "bbox": [
            281.0,
            3088.0,
            3025.0,
            3132.0
          ],
          "confidence": 0.9974802732467651
        },
        {
          "text": "legal data,",
          "bbox": [
            279.0,
            3152.0,
            493.0,
            3203.0
          ],
          "confidence": 0.998089075088501
        },
        {
          "text": "4",
          "bbox": [
            1638.0,
            3359.0,
            1669.0,
            3401.0
          ],
          "confidence": 0.9971023201942444
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ],
          "confidence": 0.9980375170707703
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9954956769943237
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 8,
          "bbox": [
            281.0,
            3560.0,
            685.0,
            3591.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Irrevocable Or Perpetual License_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain a  license grant that is irrevocable or perpetual?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Irrevocable Or Perpetual License_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Irrevocable Or Perpetual License\" that should be reviewed by a lawyer. Details: Does the contract contain a  license grant that is irrevocable or perpetual?",
      "answer_text": "Distributor hereby grants Zogenix an irrevocable, perpetual, royalty-free, fully paid-up, exclusive license with the right to grant sublicenses to use such Data solely generated and co-owned by Distributor outside of the Territory and a co-exclusive license in the Territory upon expiration or termination of the Agreement.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Sections 12.2(f), (g)(i), (h)(ii), (j)(ii), or (j)(iii), or by Distributor under Sections 12.2(d), (g), or (l), or terminated automatically under Section 12.2(k), Distributor shall continue, to the extent that Distributor continues to have Product inventory, to fulfill orders received from customers for Product in the Territory until up to [***] after the date on which Zogenix notifies Distributor in writing that Zogenix has secured an alternative distributor for the Product in the Territory, but in no event for more for than [***] after the effective date of termination.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Sections 12.2(f), (g)(i), (h)(ii), (j)(ii), or (j)(iii), or by Distributor under Sections 12.2(d), (g), or (l), or terminated automatically under Section 12.2(k), Distributor shall continue, to the extent that Distributor continues to have Product inventory, to fulfill orders received from customers for Product in the Territory until up to [***] after the date on which Zogenix notifies Distributor in writing that Zogenix has secured an alternative distributor for the Product in the Territory, but in no event for more for than [***] after the effective date of termination.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), Distributor shall use Commercially Reasonable Efforts to cooperate with Zogenix and/or its designee to effect a smooth and orderly transition in the registration and Commercialization of the Product in the Field in the Territory during the applicable notice period under Section 12.2 and following the effective date of termination.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), Distributor shall use Commercially Reasonable Efforts to cooperate with Zogenix and/or its designee to effect a smooth and orderly transition in the registration and Commercialization of the Product in the Field in the Territory during the applicable notice period under Section 12.2 and following the effective date of termination.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), at Zogenix's option, which shall be exercised by written notice to Distributor, to the extent permitted under Applicable Laws, Distributor shall assign or cause to be assigned to Zogenix or its designee (or to the extent not so assignable, Distributor shall take all reasonable actions to make available to Zogenix or its designee the benefits of), at Zogenix's cost, all Regulatory Filings and Regulatory Approvals for the Product in the Field in the Territory.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), at Zogenix's option, which shall be exercised by written notice to Distributor, to the extent permitted under Applicable Laws, Distributor shall assign or cause to be assigned to Zogenix or its designee (or to the extent not so assignable, Distributor shall take all reasonable actions to make available to Zogenix or its designee the benefits of), at Zogenix's cost, all Regulatory Filings and Regulatory Approvals for the Product in the Field in the Territory.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Within [***] after receipt of such cessation request, Distributor shall provide Zogenix an estimate of the quantity and shelf life of all Product remaining in Distributor's or its Affiliates' or Sub-distributors' inventory, and Zogenix shall have the right to purchase any such quantities of Product from Distributor at a price mutually agreed by the Parties.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Within [***] after receipt of such cessation request, Distributor shall provide Zogenix an estimate of the quantity and shelf life of all Product remaining in Distributor's or its Affiliates' or Sub-distributors' inventory, and Zogenix shall have the right to purchase any such quantities of Product from Distributor at a price mutually agreed by the Parties.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), at the written request of Zogenix, Distributor shall assign to Zogenix any Product-specific Third Party agreements, to the furthest extent possible, provided that such assignment is permitted under the Product-specific agreement or is otherwise agreed by the applicable Third Party.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "Unless this Agreement is terminated by Zogenix under Section 12.2(c), at the written request of Zogenix, Distributor shall assign to Zogenix any Product-specific Third Party agreements, to the furthest extent possible, provided that such assignment is permitted under the Product-specific agreement or is otherwise agreed by the applicable Third Party.",
      "page_number": 3,
      "words": [
        {
          "text": "Article 13. Dispute Resolution.",
          "bbox": [
            292.0,
            700.0,
            903.0,
            744.0
          ],
          "confidence": 0.9863702058792114
        },
        {
          "text": "13.1",
          "bbox": [
            285.0,
            771.0,
            379.0,
            820.0
          ],
          "confidence": 0.9999197721481323
        },
        {
          "text": "Objective",
          "bbox": [
            587.0,
            771.0,
            789.0,
            826.0
          ],
          "confidence": 0.999786913394928
        },
        {
          "text": "13.2",
          "bbox": [
            285.0,
            848.0,
            381.0,
            897.0
          ],
          "confidence": 0.9999430179595947
        },
        {
          "text": "Resolution by Executives",
          "bbox": [
            591.0,
            855.0,
            1104.0,
            899.0
          ],
          "confidence": 0.9999337196350098
        },
        {
          "text": "13.3",
          "bbox": [
            285.0,
            926.0,
            379.0,
            976.0
          ],
          "confidence": 0.9999669194221497
        },
        {
          "text": "Arbitration",
          "bbox": [
            593.0,
            930.0,
            812.0,
            974.0
          ],
          "confidence": 0.999957799911499
        },
        {
          "text": "Article 14. General Provisions.",
          "bbox": [
            288.0,
            1005.0,
            905.0,
            1051.0
          ],
          "confidence": 0.9819156527519226
        },
        {
          "text": "14.1",
          "bbox": [
            285.0,
            1080.0,
            377.0,
            1129.0
          ],
          "confidence": 0.9999156594276428
        },
        {
          "text": "Governing Law",
          "bbox": [
            587.0,
            1080.0,
            906.0,
            1135.0
          ],
          "confidence": 0.9998216032981873
        },
        {
          "text": "14.2",
          "bbox": [
            285.0,
            1157.0,
            379.0,
            1206.0
          ],
          "confidence": 0.9999524354934692
        },
        {
          "text": "Force Majeure",
          "bbox": [
            589.0,
            1160.0,
            895.0,
            1210.0
          ],
          "confidence": 0.9948508143424988
        },
        {
          "text": "14.3",
          "bbox": [
            285.0,
            1235.0,
            379.0,
            1283.0
          ],
          "confidence": 0.9999619722366333
        },
        {
          "text": "Assignment",
          "bbox": [
            589.0,
            1237.0,
            837.0,
            1288.0
          ],
          "confidence": 0.9998873472213745
        },
        {
          "text": "14.4",
          "bbox": [
            285.0,
            1312.0,
            382.0,
            1361.0
          ],
          "confidence": 0.9999409914016724
        },
        {
          "text": "Severability",
          "bbox": [
            589.0,
            1314.0,
            826.0,
            1365.0
          ],
          "confidence": 0.9629895091056824
        },
        {
          "text": "14.5",
          "bbox": [
            285.0,
            1389.0,
            379.0,
            1438.0
          ],
          "confidence": 0.9999606609344482
        },
        {
          "text": "Notices",
          "bbox": [
            581.0,
            1387.0,
            753.0,
            1442.0
          ],
          "confidence": 0.9998845458030701
        },
        {
          "text": "14.6",
          "bbox": [
            285.0,
            1467.0,
            381.0,
            1515.0
          ],
          "confidence": 0.9999539256095886
        },
        {
          "text": "Entire Agreement; Amendments.",
          "bbox": [
            591.0,
            1469.0,
            1258.0,
            1515.0
          ],
          "confidence": 0.9874879121780396
        },
        {
          "text": "14.7",
          "bbox": [
            285.0,
            1544.0,
            379.0,
            1593.0
          ],
          "confidence": 0.9740194082260132
        },
        {
          "text": "Headings",
          "bbox": [
            583.0,
            1540.0,
            784.0,
            1600.0
          ],
          "confidence": 0.9998876452445984
        },
        {
          "text": "14.8",
          "bbox": [
            285.0,
            1621.0,
            381.0,
            1670.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "Independent Contractors",
          "bbox": [
            591.0,
            1626.0,
            1098.0,
            1668.0
          ],
          "confidence": 0.9999529123306274
        },
        {
          "text": "14.9",
          "bbox": [
            286.0,
            1698.0,
            379.0,
            1747.0
          ],
          "confidence": 0.9999675750732422
        },
        {
          "text": "Waiver",
          "bbox": [
            585.0,
            1695.0,
            744.0,
            1751.0
          ],
          "confidence": 0.999850332736969
        },
        {
          "text": "14.1",
          "bbox": [
            285.0,
            1774.0,
            377.0,
            1824.0
          ],
          "confidence": 0.9999295473098755
        },
        {
          "text": "Cumulative Remedies",
          "bbox": [
            591.0,
            1776.0,
            1037.0,
            1822.0
          ],
          "confidence": 0.9752135872840881
        },
        {
          "text": "14.11",
          "bbox": [
            286.0,
            1853.0,
            399.0,
            1900.0
          ],
          "confidence": 0.9998602867126465
        },
        {
          "text": "Waiver of Rule of Construction",
          "bbox": [
            593.0,
            1858.0,
            1227.0,
            1895.0
          ],
          "confidence": 0.995116651058197
        },
        {
          "text": "14.12",
          "bbox": [
            286.0,
            1930.0,
            404.0,
            1977.0
          ],
          "confidence": 0.9999540448188782
        },
        {
          "text": "Interpretation",
          "bbox": [
            585.0,
            1929.0,
            867.0,
            1983.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "14.13",
          "bbox": [
            286.0,
            2006.0,
            402.0,
            2054.0
          ],
          "confidence": 0.999951183795929
        },
        {
          "text": "No Third Party Beneficiaries.",
          "bbox": [
            589.0,
            2012.0,
            1185.0,
            2056.0
          ],
          "confidence": 0.9892049431800842
        },
        {
          "text": "14.14",
          "bbox": [
            286.0,
            2085.0,
            404.0,
            2133.0
          ],
          "confidence": 0.9999547004699707
        },
        {
          "text": "English Language",
          "bbox": [
            589.0,
            2085.0,
            956.0,
            2142.0
          ],
          "confidence": 0.9997346997261047
        },
        {
          "text": "14.15",
          "bbox": [
            286.0,
            2162.0,
            404.0,
            2209.0
          ],
          "confidence": 0.9999393224716187
        },
        {
          "text": "Counterparts",
          "bbox": [
            587.0,
            2163.0,
            858.0,
            2213.0
          ],
          "confidence": 0.9999754428863525
        },
        {
          "text": "14.16",
          "bbox": [
            286.0,
            2238.0,
            404.0,
            2286.0
          ],
          "confidence": 0.9999632835388184
        },
        {
          "text": "Further Actions",
          "bbox": [
            589.0,
            2238.0,
            912.0,
            2286.0
          ],
          "confidence": 0.988930881023407
        },
        {
          "text": "i1",
          "bbox": [
            1635.0,
            2706.0,
            1673.0,
            2756.0
          ],
          "confidence": 0.62410569190979
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2911.0,
            687.0,
            2942.0
          ],
          "confidence": 0.9991046786308289
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9972134232521057
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 3,
          "bbox": [
            279.0,
            2911.0,
            687.0,
            2942.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_0_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that Zogenix terminates this Agreement pursuant to Section 12.2(c) or Distributor terminates this Agreement pursuant to Section 12.2(d), or after the expiration of this Agreement in accordance with Section 12.1, Zogenix shall negotiate in good faith with Distributor a license agreement for Distributor to make, use and sell the Product in the Field in the Territory under the Zogenix Technology, Zogenix Trademarks and the Product Trademarks.",
      "page_number": 0,
      "words": [
        {
          "text": "Exhibit 10.2",
          "bbox": [
            2753.0,
            292.0,
            3025.0,
            331.0
          ],
          "confidence": 0.9771935939788818
        },
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ],
          "confidence": 0.9806544780731201
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ],
          "confidence": 0.9781444668769836
        },
        {
          "text": "Zogenix Inc..",
          "bbox": [
            1479.0,
            981.0,
            1825.0,
            1038.0
          ],
          "confidence": 0.9501119256019592
        },
        {
          "text": "and",
          "bbox": [
            1602.0,
            1266.0,
            1710.0,
            1327.0
          ],
          "confidence": 0.998648464679718
        },
        {
          "text": "Nippon Shinyaku Company Ltd.",
          "bbox": [
            1198.0,
            1564.0,
            2104.0,
            1621.0
          ],
          "confidence": 0.9882414937019348
        },
        {
          "text": "Distributorship Agreement",
          "bbox": [
            1276.0,
            1824.0,
            2035.0,
            1877.0
          ],
          "confidence": 0.9921382665634155
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ],
          "confidence": 0.9979470372200012
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9907844066619873
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "BECAUSE IT IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF",
          "page": 0,
          "bbox": [
            319.0,
            490.0,
            2991.0,
            526.0
          ]
        },
        {
          "text": "PUBLICLY DISCLOSED.",
          "page": 0,
          "bbox": [
            1363.0,
            554.0,
            1941.0,
            596.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 0,
          "bbox": [
            281.0,
            2659.0,
            685.0,
            2690.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Post-Termination Services_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Post-Termination Services\" that should be reviewed by a lawyer. Details: Is a party subject to obligations after the termination or expiration of a contract, including any post-termination transition, payment, transfer of IP, wind-down, last-buy, or similar commitments?",
      "answer_text": "In the event that Zogenix terminates this Agreement pursuant to Section 12.2(c) or Distributor terminates this Agreement pursuant to Section 12.2(d), or after the expiration of this Agreement in accordance with Section 12.1, Zogenix shall negotiate in good faith with Distributor a license agreement for Distributor to make, use and sell the Product in the Field in the Territory under the Zogenix Technology, Zogenix Trademarks and the Product Trademarks.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_16",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Such audit may be made no more than once each Fiscal Year (unless an audit reveals a violation under this Agreement, in which case an additional audit may be conducted within such Fiscal Year);",
      "page_number": 16,
      "words": [
        {
          "text": "meetings each calendar year prior to First Commercial Sale shall be in-person unless the Parties otherwise agree. The location of",
          "bbox": [
            277.0,
            687.0,
            3032.0,
            738.0
          ],
          "confidence": 0.9942839741706848
        },
        {
          "text": "in-person JSC meetings will alternate between Zogenix's offices and Distributor's offices, unless the Parties otherwise agree. At",
          "bbox": [
            277.0,
            755.0,
            3029.0,
            806.0
          ],
          "confidence": 0.9960679411888123
        },
        {
          "text": "least [***] prior to each JSC meeting, each Party shall provide written notice to the other Party of agenda items proposed by such",
          "bbox": [
            275.0,
            819.0,
            3027.0,
            877.0
          ],
          "confidence": 0.9887458086013794
        },
        {
          "text": "Party for discussion or decision at such meeting, together with appropriate information related thereto. Reasonably detailed written",
          "bbox": [
            277.0,
            888.0,
            3027.0,
            939.0
          ],
          "confidence": 0.9934518933296204
        },
        {
          "text": "minutes will be kept of all JSC meetings and will reflect material decisions made at such meetings. Meeting minutes will be",
          "bbox": [
            279.0,
            959.0,
            3023.0,
            1003.0
          ],
          "confidence": 0.989173412322998
        },
        {
          "text": "prepared by each Party on an alternating basis and sent to each member of the JSC for review and approval within [***] after a",
          "bbox": [
            275.0,
            1018.0,
            3027.0,
            1078.0
          ],
          "confidence": 0.983302891254425
        },
        {
          "text": "meeting. Minutes will be deemed approved unless a member of the JSC objects to the accuracy of such minutes within [***] of",
          "bbox": [
            277.0,
            1085.0,
            3031.0,
            1138.0
          ],
          "confidence": 0.9945055842399597
        },
        {
          "text": "receipt.",
          "bbox": [
            274.0,
            1157.0,
            435.0,
            1208.0
          ],
          "confidence": 0.9895222187042236
        },
        {
          "text": "(d) Decisions. The JSC may make decisions with respect to any subject matter that is within the JSC's",
          "bbox": [
            614.0,
            1274.0,
            3031.0,
            1330.0
          ],
          "confidence": 0.9856390357017517
        },
        {
          "text": "responsibilities. Subject to this Section 3.1(d), all decisions of the JSC shall be made by unanimous vote, with Zogenix and",
          "bbox": [
            277.0,
            1345.0,
            3029.0,
            1394.0
          ],
          "confidence": 0.9942149519920349
        },
        {
          "text": "Distributor each having, collectively, among its respective members, one (1) vote in all such decisions. If the JSC cannot reach",
          "bbox": [
            277.0,
            1413.0,
            3029.0,
            1462.0
          ],
          "confidence": 0.9897257089614868
        },
        {
          "text": "consensus with regard to any matter to be decided by the JSC within [***] after such matter has been brought to the JSC's",
          "bbox": [
            275.0,
            1476.0,
            3029.0,
            1530.0
          ],
          "confidence": 0.9943463206291199
        },
        {
          "text": "attention, then such matter shall be referred to the Chief Executive Officer of Zogenix and the Director, Member of the Board of",
          "bbox": [
            281.0,
            1548.0,
            3030.0,
            1592.0
          ],
          "confidence": 0.9953252077102661
        },
        {
          "text": "Distributor (the \"Executives') for resolution. If the Executives cannot resolve the issue within [***] after the matter has been",
          "bbox": [
            279.0,
            1610.0,
            3029.0,
            1659.0
          ],
          "confidence": 0.9907641410827637
        },
        {
          "text": "brought to their attention then:.",
          "bbox": [
            281.0,
            1681.0,
            903.0,
            1725.0
          ],
          "confidence": 0.9832639694213867
        },
        {
          "text": "(i) Subject to good faith consideration of the views of Distributor, Zogenix shall have the tie-breaking vote",
          "bbox": [
            783.0,
            1800.0,
            3023.0,
            1851.0
          ],
          "confidence": 0.9930132031440735
        },
        {
          "text": "on all matters to be decided by the JSC relating to [***]; provided, however, [***]; and.",
          "bbox": [
            279.0,
            1866.0,
            2151.0,
            1921.0
          ],
          "confidence": 0.9798537492752075
        },
        {
          "text": "(ii) Subject to good faith consideration of the views of Zogenix and to Section 3.1(d)(iii), Distributor shall",
          "bbox": [
            783.0,
            1988.0,
            3025.0,
            2041.0
          ],
          "confidence": 0.9936738610267639
        },
        {
          "text": "have the tie-breaking vote on all matters to be decided by the JSC relating to [***]; provided, however, [***]; and.",
          "bbox": [
            274.0,
            2052.0,
            2715.0,
            2111.0
          ],
          "confidence": 0.9888854622840881
        },
        {
          "text": "(iii) Subject to good faith consideration of the views of Zogenix and Section 12.2(g), Distributor shall have",
          "bbox": [
            785.0,
            2178.0,
            3027.0,
            2229.0
          ],
          "confidence": 0.9882254600524902
        },
        {
          "text": "the tie-breaking vote on the decision of [***1, unless otherwise mutually agreed between the Parties; and",
          "bbox": [
            279.0,
            2246.0,
            2481.0,
            2295.0
          ],
          "confidence": 0.9913249611854553
        },
        {
          "text": "(iv) Subject to good faith consideration of the views of Distributor, Zogenix shall have the tie-breaking vote",
          "bbox": [
            785.0,
            2370.0,
            3027.0,
            2419.0
          ],
          "confidence": 0.9876425862312317
        },
        {
          "text": "on all matters other than the decisions set forth in Section 3.1(d)(ii) and (iii) to be decided by the JSC that may affect",
          "bbox": [
            279.0,
            2434.0,
            3027.0,
            2485.0
          ],
          "confidence": 0.9976907968521118
        },
        {
          "text": "commercialization outside the Territory; provided, however, that Zogenix shall not have power to amend or waive compliance with",
          "bbox": [
            281.0,
            2505.0,
            3023.0,
            2549.0
          ],
          "confidence": 0.994779109954834
        },
        {
          "text": "this Agreement or the Commercialization Plan..",
          "bbox": [
            281.0,
            2569.0,
            1247.0,
            2613.0
          ],
          "confidence": 0.9788950085639954
        },
        {
          "text": "(e) Discontinuation of JSC Participation. The activities to be performed by the JSC relate solely to governance",
          "bbox": [
            618.0,
            2695.0,
            3027.0,
            2739.0
          ],
          "confidence": 0.9979451894760132
        },
        {
          "text": "under this Agreement, and are not intended to be or involve the delivery of services. The JSC will continue to exist until the Parties",
          "bbox": [
            283.0,
            2761.0,
            3027.0,
            2805.0
          ],
          "confidence": 0.9951134324073792
        },
        {
          "text": "mutually agreeing to disband the JSC. Once the Parties mutually agree to disband the JSC, the JSC shall have no further",
          "bbox": [
            279.0,
            2827.0,
            3027.0,
            2876.0
          ],
          "confidence": 0.9983352422714233
        },
        {
          "text": "obligations under this Agreement and, thereafter, each Party shall designate a contact person for the exchange of information under",
          "bbox": [
            279.0,
            2893.0,
            3027.0,
            2942.0
          ],
          "confidence": 0.9922906756401062
        },
        {
          "text": "this Agreement, and decisions of the JSC shall be",
          "bbox": [
            279.0,
            2957.0,
            1318.0,
            3008.0
          ],
          "confidence": 0.9967493414878845
        },
        {
          "text": "12",
          "bbox": [
            1622.0,
            3159.0,
            1686.0,
            3214.0
          ],
          "confidence": 0.9970016479492188
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3366.0,
            687.0,
            3397.0
          ],
          "confidence": 0.9989922642707825
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9947927594184875
        }
      ],
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 16,
          "bbox": [
            279.0,
            3366.0,
            687.0,
            3397.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_1_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Zogenix will have the right, upon reasonable prior written notice and during Distributor's regular business hours, to audit Distributor's and its Affiliates' books and records by an independent certified public accounting firm of recognized international standing, and Distributor shall ensure that Zogenix has the right to audit its Sub-distributors' and subcontractors' books and records, to investigation potential violations of any of the representations, warranties or covenants in this Section 10.2, the FCPA or other Applicable Laws or Distributor's compliance policies.",
      "page_number": 1,
      "words": [
        {
          "text": "Table of Contents.",
          "bbox": [
            1448.0,
            689.0,
            1858.0,
            735.0
          ],
          "confidence": 0.9616385698318481
        },
        {
          "text": "Article 1. Definitions",
          "bbox": [
            294.0,
            894.0,
            714.0,
            932.0
          ],
          "confidence": 0.9956732392311096
        },
        {
          "text": "Article 2. Grant of Rights",
          "bbox": [
            288.0,
            967.0,
            808.0,
            1014.0
          ],
          "confidence": 0.9959006905555725
        },
        {
          "text": "2.1",
          "bbox": [
            283.0,
            1042.0,
            355.0,
            1093.0
          ],
          "confidence": 0.9998816847801208
        },
        {
          "text": "Grant of Rights to Distributor.",
          "bbox": [
            593.0,
            1047.0,
            1189.0,
            1089.0
          ],
          "confidence": 0.9826526045799255
        },
        {
          "text": "2.2",
          "bbox": [
            283.0,
            1118.0,
            357.0,
            1170.0
          ],
          "confidence": 0.9998645782470703
        },
        {
          "text": "Sub-distribution by Distributor.",
          "bbox": [
            591.0,
            1122.0,
            1202.0,
            1168.0
          ],
          "confidence": 0.9827874302864075
        },
        {
          "text": "2.3",
          "bbox": [
            283.0,
            1195.0,
            355.0,
            1248.0
          ],
          "confidence": 0.9998989701271057
        },
        {
          "text": "Supply of Product for Distributorship",
          "bbox": [
            591.0,
            1201.0,
            1339.0,
            1250.0
          ],
          "confidence": 0.990572452545166
        },
        {
          "text": "2.4",
          "bbox": [
            283.0,
            1272.0,
            357.0,
            1323.0
          ],
          "confidence": 0.9998515248298645
        },
        {
          "text": "No Other Rights; Other Limitations",
          "bbox": [
            587.0,
            1275.0,
            1314.0,
            1321.0
          ],
          "confidence": 0.9979990720748901
        },
        {
          "text": "2.5",
          "bbox": [
            283.0,
            1349.0,
            355.0,
            1402.0
          ],
          "confidence": 0.9999158978462219
        },
        {
          "text": "Non-Compete Covenant",
          "bbox": [
            591.0,
            1356.0,
            1093.0,
            1400.0
          ],
          "confidence": 0.9998584985733032
        },
        {
          "text": "2.6",
          "bbox": [
            283.0,
            1425.0,
            359.0,
            1478.0
          ],
          "confidence": 0.9998889565467834
        },
        {
          "text": "No Activities Outside the Territory or Field",
          "bbox": [
            589.0,
            1433.0,
            1468.0,
            1476.0
          ],
          "confidence": 0.9878547191619873
        },
        {
          "text": "Article 3. Governance",
          "bbox": [
            290.0,
            1509.0,
            743.0,
            1550.0
          ],
          "confidence": 0.9977717399597168
        },
        {
          "text": "3.1",
          "bbox": [
            283.0,
            1581.0,
            353.0,
            1632.0
          ],
          "confidence": 0.9998733401298523
        },
        {
          "text": "Joint Steering Committee",
          "bbox": [
            591.0,
            1588.0,
            1104.0,
            1632.0
          ],
          "confidence": 0.9994843006134033
        },
        {
          "text": "3.2",
          "bbox": [
            283.0,
            1659.0,
            357.0,
            1709.0
          ],
          "confidence": 0.9998416900634766
        },
        {
          "text": "Expenses",
          "bbox": [
            591.0,
            1665.0,
            790.0,
            1710.0
          ],
          "confidence": 0.9998846650123596
        },
        {
          "text": "3.3",
          "bbox": [
            285.0,
            1738.0,
            355.0,
            1785.0
          ],
          "confidence": 0.9998757243156433
        },
        {
          "text": "Alliance Managers",
          "bbox": [
            591.0,
            1738.0,
            977.0,
            1789.0
          ],
          "confidence": 0.9998342990875244
        },
        {
          "text": "3.4",
          "bbox": [
            283.0,
            1813.0,
            357.0,
            1864.0
          ],
          "confidence": 0.9998750686645508
        },
        {
          "text": "Scope of Governance",
          "bbox": [
            593.0,
            1820.0,
            1035.0,
            1864.0
          ],
          "confidence": 0.9903308749198914
        },
        {
          "text": "Article 4. Development and Regulatory Activities",
          "bbox": [
            288.0,
            1891.0,
            1301.0,
            1942.0
          ],
          "confidence": 0.9987475275993347
        },
        {
          "text": "4.1",
          "bbox": [
            285.0,
            1966.0,
            355.0,
            2017.0
          ],
          "confidence": 0.9998335838317871
        },
        {
          "text": "Nonclinical and Clinical Studies and CMC Requirements",
          "bbox": [
            587.0,
            1970.0,
            1745.0,
            2016.0
          ],
          "confidence": 0.997993528842926
        },
        {
          "text": "4.2",
          "bbox": [
            285.0,
            2043.0,
            357.0,
            2094.0
          ],
          "confidence": 0.9997618794441223
        },
        {
          "text": "Regulatory Activities.",
          "bbox": [
            591.0,
            2048.0,
            1021.0,
            2098.0
          ],
          "confidence": 0.9745040535926819
        },
        {
          "text": "4.3",
          "bbox": [
            285.0,
            2122.0,
            355.0,
            2173.0
          ],
          "confidence": 0.999890148639679
        },
        {
          "text": "Distributor's Right to Use and Reference",
          "bbox": [
            589.0,
            2125.0,
            1436.0,
            2169.0
          ],
          "confidence": 0.9993627667427063
        },
        {
          "text": "4.4",
          "bbox": [
            283.0,
            2198.0,
            357.0,
            2249.0
          ],
          "confidence": 0.9997689127922058
        },
        {
          "text": "Zogenix's Right to Use and Reference",
          "bbox": [
            591.0,
            2200.0,
            1381.0,
            2251.0
          ],
          "confidence": 0.9918326139450073
        },
        {
          "text": "4.5",
          "bbox": [
            283.0,
            2275.0,
            357.0,
            2326.0
          ],
          "confidence": 0.9998205304145813
        },
        {
          "text": "Adverse Event Reporting",
          "bbox": [
            591.0,
            2275.0,
            1111.0,
            2330.0
          ],
          "confidence": 0.9992589354515076
        },
        {
          "text": "4.6",
          "bbox": [
            280.0,
            2349.0,
            360.0,
            2406.0
          ],
          "confidence": 0.9998282790184021
        },
        {
          "text": "Drug Safety and Pharmacovigilance System including Global Safety Database",
          "bbox": [
            591.0,
            2359.0,
            2190.0,
            2403.0
          ],
          "confidence": 0.9908342957496643
        },
        {
          "text": "4.7",
          "bbox": [
            285.0,
            2430.0,
            357.0,
            2482.0
          ],
          "confidence": 0.9998313784599304
        },
        {
          "text": "Regulatory Audit",
          "bbox": [
            587.0,
            2432.0,
            944.0,
            2485.0
          ],
          "confidence": 0.9999644160270691
        },
        {
          "text": "4.8",
          "bbox": [
            283.0,
            2507.0,
            357.0,
            2558.0
          ],
          "confidence": 0.9999110698699951
        },
        {
          "text": "Use of Subcontractors",
          "bbox": [
            591.0,
            2511.0,
            1051.0,
            2553.0
          ],
          "confidence": 0.9998341798782349
        },
        {
          "text": "4.9",
          "bbox": [
            283.0,
            2584.0,
            357.0,
            2635.0
          ],
          "confidence": 0.9998586773872375
        },
        {
          "text": "Recalls",
          "bbox": [
            587.0,
            2584.0,
            743.0,
            2635.0
          ],
          "confidence": 0.9998652338981628
        },
        {
          "text": "4.1",
          "bbox": [
            283.0,
            2661.0,
            355.0,
            2714.0
          ],
          "confidence": 0.9998404383659363
        },
        {
          "text": "Development Expenses",
          "bbox": [
            591.0,
            2668.0,
            1075.0,
            2712.0
          ],
          "confidence": 0.9998835325241089
        },
        {
          "text": "Article 5. Commercialization; Supply: Trademarks",
          "bbox": [
            288.0,
            2739.0,
            1309.0,
            2790.0
          ],
          "confidence": 0.9938747882843018
        },
        {
          "text": "5.1",
          "bbox": [
            285.0,
            2814.0,
            355.0,
            2867.0
          ],
          "confidence": 0.9998407959938049
        },
        {
          "text": "Commercialization of the Product.",
          "bbox": [
            589.0,
            2818.0,
            1289.0,
            2864.0
          ],
          "confidence": 0.9996488094329834
        },
        {
          "text": "5.2",
          "bbox": [
            283.0,
            2893.0,
            357.0,
            2944.0
          ],
          "confidence": 0.9998804926872253
        },
        {
          "text": "Supply",
          "bbox": [
            583.0,
            2888.0,
            731.0,
            2954.0
          ],
          "confidence": 0.9998927116394043
        },
        {
          "text": "5.3",
          "bbox": [
            285.0,
            2973.0,
            355.0,
            3021.0
          ],
          "confidence": 0.999910295009613
        },
        {
          "text": "Trademark Rights",
          "bbox": [
            587.0,
            2971.0,
            957.0,
            3024.0
          ],
          "confidence": 0.9999700784683228
        },
        {
          "text": "5.4",
          "bbox": [
            285.0,
            3048.0,
            357.0,
            3099.0
          ],
          "confidence": 0.9999281764030457
        },
        {
          "text": "Commercial Expenses",
          "bbox": [
            589.0,
            3048.0,
            1051.0,
            3101.0
          ],
          "confidence": 0.9998229146003723
        },
        {
          "text": "Article 6. Payments.",
          "bbox": [
            288.0,
            3126.0,
            700.0,
            3176.0
          ],
          "confidence": 0.9718054533004761
        },
        {
          "text": "6.1",
          "bbox": [
            285.0,
            3202.0,
            357.0,
            3253.0
          ],
          "confidence": 0.9997382164001465
        },
        {
          "text": "Upfront Payment",
          "bbox": [
            593.0,
            3207.0,
            952.0,
            3256.0
          ],
          "confidence": 0.9999457001686096
        },
        {
          "text": "6.2",
          "bbox": [
            285.0,
            3278.0,
            357.0,
            3331.0
          ],
          "confidence": 0.9998340606689453
        },
        {
          "text": "Funding to Support Development of The Product",
          "bbox": [
            591.0,
            3284.0,
            1591.0,
            3333.0
          ],
          "confidence": 0.999564528465271
        },
        {
          "text": "6.3",
          "bbox": [
            286.0,
            3359.0,
            353.0,
            3404.0
          ],
          "confidence": 0.9998762011528015
        },
        {
          "text": "Regulatory Milestones",
          "bbox": [
            591.0,
            3360.0,
            1053.0,
            3410.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "6.4",
          "bbox": [
            285.0,
            3434.0,
            357.0,
            3485.0
          ],
          "confidence": 0.9999008178710938
        },
        {
          "text": "Sales Milestones",
          "bbox": [
            591.0,
            3433.0,
            935.0,
            3483.0
          ],
          "confidence": 0.9999213218688965
        },
        {
          "text": "6.5",
          "bbox": [
            285.0,
            3510.0,
            357.0,
            3561.0
          ],
          "confidence": 0.9998565316200256
        },
        {
          "text": "Supply Payments",
          "bbox": [
            589.0,
            3512.0,
            945.0,
            3569.0
          ],
          "confidence": 0.9998472929000854
        },
        {
          "text": "Article 7. Payments, Books and Records",
          "bbox": [
            292.0,
            3594.0,
            1126.0,
            3636.0
          ],
          "confidence": 0.9927052855491638
        },
        {
          "text": "7.1",
          "bbox": [
            283.0,
            3664.0,
            357.0,
            3715.0
          ],
          "confidence": 0.9998772144317627
        },
        {
          "text": "Payment Method",
          "bbox": [
            589.0,
            3665.0,
            943.0,
            3719.0
          ],
          "confidence": 0.9999237060546875
        },
        {
          "text": "i",
          "bbox": [
            1642.0,
            3927.0,
            1675.0,
            3976.0
          ],
          "confidence": 0.6109925508499146
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ],
          "confidence": 0.9985166788101196
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1118.0,
            4477.0
          ],
          "confidence": 0.9932639598846436
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 1,
          "bbox": [
            281.0,
            4059.0,
            685.0,
            4090.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Zogenix will have the right, upon reasonable prior written notice and during Distributor's regular business hours, to audit Distributor's and its Affiliates' books and records by an independent certified public accounting firm of recognized international standing, and Distributor shall ensure that Zogenix has the right to audit its Sub-distributors' and subcontractors' books and records, to investigation potential violations of any of the representations, warranties or covenants in this Section 10.2, the FCPA or other Applicable Laws or Distributor's compliance policies.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Inspections conducted under this Section 7.5 shall be at the expense of Zogenix, unless a variation or error producing an underpayment in amounts payable exceeding [***] of the amount paid for a period covered by the inspection is established, in which case all reasonable costs relating to the inspection for such period shall be paid by Distributor.",
      "page_number": 6,
      "words": [
        {
          "text": "1.2 \"Alliance Manager' has the meaning set forth in Section 3.3.",
          "bbox": [
            448.0,
            685.0,
            1836.0,
            736.0
          ],
          "confidence": 0.9859306216239929
        },
        {
          "text": "1.3 \"Annual Report' has the meaning set forth in Section 6.5(c)",
          "bbox": [
            446.0,
            809.0,
            1823.0,
            861.0
          ],
          "confidence": 0.9771308302879333
        },
        {
          "text": "1.4 \"Applicable Laws\" means the applicable provisions of any and all national, supranational, regional, state and local",
          "bbox": [
            448.0,
            936.0,
            3027.0,
            985.0
          ],
          "confidence": 0.985500156879425
        },
        {
          "text": "laws, treaties, statutes, rules, regulations, administrative codes, industry codes, guidance, ordinances, judgments, decrees,.",
          "bbox": [
            277.0,
            1001.0,
            3025.0,
            1053.0
          ],
          "confidence": 0.9961791634559631
        },
        {
          "text": "directives, injunctions, orders or permits (including Regulatory Approvals) of or from any court, arbitrator, Regulatory Authority or",
          "bbox": [
            279.0,
            1067.0,
            3027.0,
            1118.0
          ],
          "confidence": 0.9920154213905334
        },
        {
          "text": "governmental agency or authority having jurisdiction over or related to the subject item, including the FCPA, export control,",
          "bbox": [
            277.0,
            1133.0,
            3025.0,
            1188.0
          ],
          "confidence": 0.9949026703834534
        },
        {
          "text": "embargo, trade sanction and data privacy laws, regulations, rules and licenses, and other laws and regulations pertaining to",
          "bbox": [
            277.0,
            1201.0,
            3025.0,
            1254.0
          ],
          "confidence": 0.993232011795044
        },
        {
          "text": "domestic or international corruption, commercial bribery, fraud, embezzlement or money laundering.",
          "bbox": [
            275.0,
            1259.0,
            2365.0,
            1325.0
          ],
          "confidence": 0.9901788830757141
        },
        {
          "text": "1.5 \"Business Day\"' means a day other than a Saturday, Sunday, any public holiday, or any bank holiday in the United",
          "bbox": [
            444.0,
            1389.0,
            3027.0,
            1440.0
          ],
          "confidence": 0.9882254004478455
        },
        {
          "text": "States or Japan.",
          "bbox": [
            279.0,
            1458.0,
            613.0,
            1508.0
          ],
          "confidence": 0.9998754262924194
        },
        {
          "text": "1.6 \"Change of Control' means any (a) direct or indirect acquisition of assets of a Party (i) equal to fifty percent (50%)",
          "bbox": [
            448.0,
            1581.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9898536801338196
        },
        {
          "text": "or more of the fair market value of a Party's consolidated assets, or (ii) to which fifty percent (50%) or more of a Party's net",
          "bbox": [
            281.0,
            1650.0,
            3029.0,
            1694.0
          ],
          "confidence": 0.9935340881347656
        },
        {
          "text": "revenues or net income on a consolidated basis are attributable, or (iii) representing substantially all of the properties or assets",
          "bbox": [
            277.0,
            1718.0,
            3027.0,
            1762.0
          ],
          "confidence": 0.9949082136154175
        },
        {
          "text": "related to a Party's obligations under this Agreement, (b) direct or indirect acquisition by a Person, or group of Persons acting in.",
          "bbox": [
            275.0,
            1780.0,
            3027.0,
            1831.0
          ],
          "confidence": 0.9926859736442566
        },
        {
          "text": "concert, of fifty percent (50%) or more of the voting equity interests of a Party, (c) tender offer or exchange offer that if",
          "bbox": [
            277.0,
            1846.0,
            3031.0,
            1899.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "consummated would result in any Person, or group of Persons acting in concert, beneficially owning fifty percent (50%) or more of.",
          "bbox": [
            277.0,
            1915.0,
            3032.0,
            1964.0
          ],
          "confidence": 0.9912351369857788
        },
        {
          "text": "the voting equity interests of a Party, (d) merger, consolidation, other business combination or similar transaction involving a Party,.",
          "bbox": [
            277.0,
            1979.0,
            3025.0,
            2032.0
          ],
          "confidence": 0.9915239810943604
        },
        {
          "text": "pursuant to which any Person would own fifty percent (50%) or more of the consolidated assets, net revenues or net income of a",
          "bbox": [
            275.0,
            2045.0,
            3029.0,
            2098.0
          ],
          "confidence": 0.9893941283226013
        },
        {
          "text": "Party, taken as a whole, or which results in the holders of the voting equity interests of a Party immediately prior to such merger.",
          "bbox": [
            277.0,
            2109.0,
            3023.0,
            2167.0
          ],
          "confidence": 0.9963723421096802
        },
        {
          "text": "consolidation, business combination or similar transaction ceasing to hold fifty percent (50%) or more of the combined voting",
          "bbox": [
            277.0,
            2178.0,
            3027.0,
            2231.0
          ],
          "confidence": 0.997050404548645
        },
        {
          "text": "power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, business combination or.",
          "bbox": [
            277.0,
            2246.0,
            3031.0,
            2297.0
          ],
          "confidence": 0.9887821078300476
        },
        {
          "text": "similar transaction, (e) liquidation or dissolution (or the adoption of a plan of liquidation or dissolution) of a Party, or (f) declaration",
          "bbox": [
            281.0,
            2317.0,
            3025.0,
            2361.0
          ],
          "confidence": 0.9977426528930664
        },
        {
          "text": "or payment of an extraordinary dividend (whether in cash or other property) by a Party, where the amount of the dividend or the in.",
          "bbox": [
            277.0,
            2379.0,
            3029.0,
            2434.0
          ],
          "confidence": 0.9966531991958618
        },
        {
          "text": "specie property which is the subject of the dividend would otherwise come within the application of any of clauses (a)-(e) above,.",
          "bbox": [
            277.0,
            2443.0,
            3027.0,
            2500.0
          ],
          "confidence": 0.9955662488937378
        },
        {
          "text": "in all cases where such transaction is to be entered into with any Person other than the other Party.",
          "bbox": [
            275.0,
            2509.0,
            2336.0,
            2564.0
          ],
          "confidence": 0.994972288608551
        },
        {
          "text": "1.7 \"CMC' means chemistry, manufacturing and controls.",
          "bbox": [
            446.0,
            2633.0,
            1649.0,
            2686.0
          ],
          "confidence": 0.9895760416984558
        },
        {
          "text": "1.8 \"Commercialization\"' means all activities directed to marketing, promoting, advertising, exhibiting, distributing",
          "bbox": [
            444.0,
            2756.0,
            3025.0,
            2810.0
          ],
          "confidence": 0.9943382143974304
        },
        {
          "text": "(including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise",
          "bbox": [
            285.0,
            2829.0,
            3025.0,
            2873.0
          ],
          "confidence": 0.9882383942604065
        },
        {
          "text": "commercially exploiting the Product in the Field in the Territory.",
          "bbox": [
            275.0,
            2887.0,
            1606.0,
            2946.0
          ],
          "confidence": 0.9925694465637207
        },
        {
          "text": "1.9 \"Commercialization Plan' has the meaning set forth in Section 5.1(b)",
          "bbox": [
            448.0,
            3013.0,
            2046.0,
            3061.0
          ],
          "confidence": 0.9942542314529419
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3223.0,
            1668.0,
            3262.0
          ],
          "confidence": 0.9846658706665039
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ],
          "confidence": 0.9990366697311401
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9950901865959167
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 6,
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Inspections conducted under this Section 7.5 shall be at the expense of Zogenix, unless a variation or error producing an underpayment in amounts payable exceeding [***] of the amount paid for a period covered by the inspection is established, in which case all reasonable costs relating to the inspection for such period shall be paid by Distributor.",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable prior written notice, Distributor shall permit an independent, certified public accountant selected by Zogenix and reasonably acceptable to Distributor, which acceptance will not be unreasonably withheld or delayed, to audit or inspect those books or records of Distributor and its Affiliates and Sub-distributors that relate to Net Sales for the sole purpose of verifying: (a) the payments due hereunder and payments due under the Supply Agreement; (b) the withholding taxes, if any, required by Applicable Laws to be withheld; and (c) Distributor's compliance with Sections 10.1 and 10.2. Such accountant will disclose to Zogenix only the amount and accuracy of payments reported and actually paid or otherwise payable under this Agreement or the Supply Agreement, and will send a copy of the report to Distributor at the same time it is sent to Zogenix. Prompt adjustments (including",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Upon reasonable prior written notice, Distributor shall permit an independent, certified public accountant selected by Zogenix and reasonably acceptable to Distributor, which acceptance will not be unreasonably withheld or delayed, to audit or inspect those books or records of Distributor and its Affiliates and Sub-distributors that relate to Net Sales for the sole purpose of verifying: (a) the payments due hereunder and payments due under the Supply Agreement; (b) the withholding taxes, if any, required by Applicable Laws to be withheld; and (c) Distributor's compliance with Sections 10.1 and 10.2. Such accountant will disclose to Zogenix only the amount and accuracy of payments reported and actually paid or otherwise payable under this Agreement or the Supply Agreement, and will send a copy of the report to Distributor at the same time it is sent to Zogenix. Prompt adjustments (including",
      "page_number": 6,
      "words": [
        {
          "text": "1.2 \"Alliance Manager' has the meaning set forth in Section 3.3.",
          "bbox": [
            448.0,
            685.0,
            1836.0,
            736.0
          ],
          "confidence": 0.9859306216239929
        },
        {
          "text": "1.3 \"Annual Report' has the meaning set forth in Section 6.5(c)",
          "bbox": [
            446.0,
            809.0,
            1823.0,
            861.0
          ],
          "confidence": 0.9771308302879333
        },
        {
          "text": "1.4 \"Applicable Laws\" means the applicable provisions of any and all national, supranational, regional, state and local",
          "bbox": [
            448.0,
            936.0,
            3027.0,
            985.0
          ],
          "confidence": 0.985500156879425
        },
        {
          "text": "laws, treaties, statutes, rules, regulations, administrative codes, industry codes, guidance, ordinances, judgments, decrees,.",
          "bbox": [
            277.0,
            1001.0,
            3025.0,
            1053.0
          ],
          "confidence": 0.9961791634559631
        },
        {
          "text": "directives, injunctions, orders or permits (including Regulatory Approvals) of or from any court, arbitrator, Regulatory Authority or",
          "bbox": [
            279.0,
            1067.0,
            3027.0,
            1118.0
          ],
          "confidence": 0.9920154213905334
        },
        {
          "text": "governmental agency or authority having jurisdiction over or related to the subject item, including the FCPA, export control,",
          "bbox": [
            277.0,
            1133.0,
            3025.0,
            1188.0
          ],
          "confidence": 0.9949026703834534
        },
        {
          "text": "embargo, trade sanction and data privacy laws, regulations, rules and licenses, and other laws and regulations pertaining to",
          "bbox": [
            277.0,
            1201.0,
            3025.0,
            1254.0
          ],
          "confidence": 0.993232011795044
        },
        {
          "text": "domestic or international corruption, commercial bribery, fraud, embezzlement or money laundering.",
          "bbox": [
            275.0,
            1259.0,
            2365.0,
            1325.0
          ],
          "confidence": 0.9901788830757141
        },
        {
          "text": "1.5 \"Business Day\"' means a day other than a Saturday, Sunday, any public holiday, or any bank holiday in the United",
          "bbox": [
            444.0,
            1389.0,
            3027.0,
            1440.0
          ],
          "confidence": 0.9882254004478455
        },
        {
          "text": "States or Japan.",
          "bbox": [
            279.0,
            1458.0,
            613.0,
            1508.0
          ],
          "confidence": 0.9998754262924194
        },
        {
          "text": "1.6 \"Change of Control' means any (a) direct or indirect acquisition of assets of a Party (i) equal to fifty percent (50%)",
          "bbox": [
            448.0,
            1581.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9898536801338196
        },
        {
          "text": "or more of the fair market value of a Party's consolidated assets, or (ii) to which fifty percent (50%) or more of a Party's net",
          "bbox": [
            281.0,
            1650.0,
            3029.0,
            1694.0
          ],
          "confidence": 0.9935340881347656
        },
        {
          "text": "revenues or net income on a consolidated basis are attributable, or (iii) representing substantially all of the properties or assets",
          "bbox": [
            277.0,
            1718.0,
            3027.0,
            1762.0
          ],
          "confidence": 0.9949082136154175
        },
        {
          "text": "related to a Party's obligations under this Agreement, (b) direct or indirect acquisition by a Person, or group of Persons acting in.",
          "bbox": [
            275.0,
            1780.0,
            3027.0,
            1831.0
          ],
          "confidence": 0.9926859736442566
        },
        {
          "text": "concert, of fifty percent (50%) or more of the voting equity interests of a Party, (c) tender offer or exchange offer that if",
          "bbox": [
            277.0,
            1846.0,
            3031.0,
            1899.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "consummated would result in any Person, or group of Persons acting in concert, beneficially owning fifty percent (50%) or more of.",
          "bbox": [
            277.0,
            1915.0,
            3032.0,
            1964.0
          ],
          "confidence": 0.9912351369857788
        },
        {
          "text": "the voting equity interests of a Party, (d) merger, consolidation, other business combination or similar transaction involving a Party,.",
          "bbox": [
            277.0,
            1979.0,
            3025.0,
            2032.0
          ],
          "confidence": 0.9915239810943604
        },
        {
          "text": "pursuant to which any Person would own fifty percent (50%) or more of the consolidated assets, net revenues or net income of a",
          "bbox": [
            275.0,
            2045.0,
            3029.0,
            2098.0
          ],
          "confidence": 0.9893941283226013
        },
        {
          "text": "Party, taken as a whole, or which results in the holders of the voting equity interests of a Party immediately prior to such merger.",
          "bbox": [
            277.0,
            2109.0,
            3023.0,
            2167.0
          ],
          "confidence": 0.9963723421096802
        },
        {
          "text": "consolidation, business combination or similar transaction ceasing to hold fifty percent (50%) or more of the combined voting",
          "bbox": [
            277.0,
            2178.0,
            3027.0,
            2231.0
          ],
          "confidence": 0.997050404548645
        },
        {
          "text": "power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, business combination or.",
          "bbox": [
            277.0,
            2246.0,
            3031.0,
            2297.0
          ],
          "confidence": 0.9887821078300476
        },
        {
          "text": "similar transaction, (e) liquidation or dissolution (or the adoption of a plan of liquidation or dissolution) of a Party, or (f) declaration",
          "bbox": [
            281.0,
            2317.0,
            3025.0,
            2361.0
          ],
          "confidence": 0.9977426528930664
        },
        {
          "text": "or payment of an extraordinary dividend (whether in cash or other property) by a Party, where the amount of the dividend or the in.",
          "bbox": [
            277.0,
            2379.0,
            3029.0,
            2434.0
          ],
          "confidence": 0.9966531991958618
        },
        {
          "text": "specie property which is the subject of the dividend would otherwise come within the application of any of clauses (a)-(e) above,.",
          "bbox": [
            277.0,
            2443.0,
            3027.0,
            2500.0
          ],
          "confidence": 0.9955662488937378
        },
        {
          "text": "in all cases where such transaction is to be entered into with any Person other than the other Party.",
          "bbox": [
            275.0,
            2509.0,
            2336.0,
            2564.0
          ],
          "confidence": 0.994972288608551
        },
        {
          "text": "1.7 \"CMC' means chemistry, manufacturing and controls.",
          "bbox": [
            446.0,
            2633.0,
            1649.0,
            2686.0
          ],
          "confidence": 0.9895760416984558
        },
        {
          "text": "1.8 \"Commercialization\"' means all activities directed to marketing, promoting, advertising, exhibiting, distributing",
          "bbox": [
            444.0,
            2756.0,
            3025.0,
            2810.0
          ],
          "confidence": 0.9943382143974304
        },
        {
          "text": "(including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise",
          "bbox": [
            285.0,
            2829.0,
            3025.0,
            2873.0
          ],
          "confidence": 0.9882383942604065
        },
        {
          "text": "commercially exploiting the Product in the Field in the Territory.",
          "bbox": [
            275.0,
            2887.0,
            1606.0,
            2946.0
          ],
          "confidence": 0.9925694465637207
        },
        {
          "text": "1.9 \"Commercialization Plan' has the meaning set forth in Section 5.1(b)",
          "bbox": [
            448.0,
            3013.0,
            2046.0,
            3061.0
          ],
          "confidence": 0.9942542314529419
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3223.0,
            1668.0,
            3262.0
          ],
          "confidence": 0.9846658706665039
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ],
          "confidence": 0.9990366697311401
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9950901865959167
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 6,
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_5",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Such records shall be subject to inspection in accordance with Section 7.5.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Not more than once per Fiscal Year or as otherwise agreed by the Parties, and subject to the terms of the applicable agreement between Zogenix and its Third Party manufacturers, Zogenix shall, at Distributor's request, conduct GMP audits of the Third Party manufacturers and, if applicable, exercise such other audit rights that Zogenix may have under such agreements, and shall disclose to Distributor the results of such audits.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Not more than once per Fiscal Year or as otherwise agreed by the Parties, and subject to the terms of the applicable agreement between Zogenix and its Third Party manufacturers, Zogenix shall, at Distributor's request, conduct GMP audits of the Third Party manufacturers and, if applicable, exercise such other audit rights that Zogenix may have under such agreements, and shall disclose to Distributor the results of such audits.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Such inspections may be made no more than once each Fiscal Year (unless an audit or inspection reveals a material inaccuracy in reports made under this Agreement, in which case it may be repeated within such Fiscal Year), and during normal business hours, with reasonable efforts to minimize disruption of Distributor's normal business activities.",
      "page_number": 6,
      "words": [
        {
          "text": "1.2 \"Alliance Manager' has the meaning set forth in Section 3.3.",
          "bbox": [
            448.0,
            685.0,
            1836.0,
            736.0
          ],
          "confidence": 0.9859306216239929
        },
        {
          "text": "1.3 \"Annual Report' has the meaning set forth in Section 6.5(c)",
          "bbox": [
            446.0,
            809.0,
            1823.0,
            861.0
          ],
          "confidence": 0.9771308302879333
        },
        {
          "text": "1.4 \"Applicable Laws\" means the applicable provisions of any and all national, supranational, regional, state and local",
          "bbox": [
            448.0,
            936.0,
            3027.0,
            985.0
          ],
          "confidence": 0.985500156879425
        },
        {
          "text": "laws, treaties, statutes, rules, regulations, administrative codes, industry codes, guidance, ordinances, judgments, decrees,.",
          "bbox": [
            277.0,
            1001.0,
            3025.0,
            1053.0
          ],
          "confidence": 0.9961791634559631
        },
        {
          "text": "directives, injunctions, orders or permits (including Regulatory Approvals) of or from any court, arbitrator, Regulatory Authority or",
          "bbox": [
            279.0,
            1067.0,
            3027.0,
            1118.0
          ],
          "confidence": 0.9920154213905334
        },
        {
          "text": "governmental agency or authority having jurisdiction over or related to the subject item, including the FCPA, export control,",
          "bbox": [
            277.0,
            1133.0,
            3025.0,
            1188.0
          ],
          "confidence": 0.9949026703834534
        },
        {
          "text": "embargo, trade sanction and data privacy laws, regulations, rules and licenses, and other laws and regulations pertaining to",
          "bbox": [
            277.0,
            1201.0,
            3025.0,
            1254.0
          ],
          "confidence": 0.993232011795044
        },
        {
          "text": "domestic or international corruption, commercial bribery, fraud, embezzlement or money laundering.",
          "bbox": [
            275.0,
            1259.0,
            2365.0,
            1325.0
          ],
          "confidence": 0.9901788830757141
        },
        {
          "text": "1.5 \"Business Day\"' means a day other than a Saturday, Sunday, any public holiday, or any bank holiday in the United",
          "bbox": [
            444.0,
            1389.0,
            3027.0,
            1440.0
          ],
          "confidence": 0.9882254004478455
        },
        {
          "text": "States or Japan.",
          "bbox": [
            279.0,
            1458.0,
            613.0,
            1508.0
          ],
          "confidence": 0.9998754262924194
        },
        {
          "text": "1.6 \"Change of Control' means any (a) direct or indirect acquisition of assets of a Party (i) equal to fifty percent (50%)",
          "bbox": [
            448.0,
            1581.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9898536801338196
        },
        {
          "text": "or more of the fair market value of a Party's consolidated assets, or (ii) to which fifty percent (50%) or more of a Party's net",
          "bbox": [
            281.0,
            1650.0,
            3029.0,
            1694.0
          ],
          "confidence": 0.9935340881347656
        },
        {
          "text": "revenues or net income on a consolidated basis are attributable, or (iii) representing substantially all of the properties or assets",
          "bbox": [
            277.0,
            1718.0,
            3027.0,
            1762.0
          ],
          "confidence": 0.9949082136154175
        },
        {
          "text": "related to a Party's obligations under this Agreement, (b) direct or indirect acquisition by a Person, or group of Persons acting in.",
          "bbox": [
            275.0,
            1780.0,
            3027.0,
            1831.0
          ],
          "confidence": 0.9926859736442566
        },
        {
          "text": "concert, of fifty percent (50%) or more of the voting equity interests of a Party, (c) tender offer or exchange offer that if",
          "bbox": [
            277.0,
            1846.0,
            3031.0,
            1899.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "consummated would result in any Person, or group of Persons acting in concert, beneficially owning fifty percent (50%) or more of.",
          "bbox": [
            277.0,
            1915.0,
            3032.0,
            1964.0
          ],
          "confidence": 0.9912351369857788
        },
        {
          "text": "the voting equity interests of a Party, (d) merger, consolidation, other business combination or similar transaction involving a Party,.",
          "bbox": [
            277.0,
            1979.0,
            3025.0,
            2032.0
          ],
          "confidence": 0.9915239810943604
        },
        {
          "text": "pursuant to which any Person would own fifty percent (50%) or more of the consolidated assets, net revenues or net income of a",
          "bbox": [
            275.0,
            2045.0,
            3029.0,
            2098.0
          ],
          "confidence": 0.9893941283226013
        },
        {
          "text": "Party, taken as a whole, or which results in the holders of the voting equity interests of a Party immediately prior to such merger.",
          "bbox": [
            277.0,
            2109.0,
            3023.0,
            2167.0
          ],
          "confidence": 0.9963723421096802
        },
        {
          "text": "consolidation, business combination or similar transaction ceasing to hold fifty percent (50%) or more of the combined voting",
          "bbox": [
            277.0,
            2178.0,
            3027.0,
            2231.0
          ],
          "confidence": 0.997050404548645
        },
        {
          "text": "power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, business combination or.",
          "bbox": [
            277.0,
            2246.0,
            3031.0,
            2297.0
          ],
          "confidence": 0.9887821078300476
        },
        {
          "text": "similar transaction, (e) liquidation or dissolution (or the adoption of a plan of liquidation or dissolution) of a Party, or (f) declaration",
          "bbox": [
            281.0,
            2317.0,
            3025.0,
            2361.0
          ],
          "confidence": 0.9977426528930664
        },
        {
          "text": "or payment of an extraordinary dividend (whether in cash or other property) by a Party, where the amount of the dividend or the in.",
          "bbox": [
            277.0,
            2379.0,
            3029.0,
            2434.0
          ],
          "confidence": 0.9966531991958618
        },
        {
          "text": "specie property which is the subject of the dividend would otherwise come within the application of any of clauses (a)-(e) above,.",
          "bbox": [
            277.0,
            2443.0,
            3027.0,
            2500.0
          ],
          "confidence": 0.9955662488937378
        },
        {
          "text": "in all cases where such transaction is to be entered into with any Person other than the other Party.",
          "bbox": [
            275.0,
            2509.0,
            2336.0,
            2564.0
          ],
          "confidence": 0.994972288608551
        },
        {
          "text": "1.7 \"CMC' means chemistry, manufacturing and controls.",
          "bbox": [
            446.0,
            2633.0,
            1649.0,
            2686.0
          ],
          "confidence": 0.9895760416984558
        },
        {
          "text": "1.8 \"Commercialization\"' means all activities directed to marketing, promoting, advertising, exhibiting, distributing",
          "bbox": [
            444.0,
            2756.0,
            3025.0,
            2810.0
          ],
          "confidence": 0.9943382143974304
        },
        {
          "text": "(including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise",
          "bbox": [
            285.0,
            2829.0,
            3025.0,
            2873.0
          ],
          "confidence": 0.9882383942604065
        },
        {
          "text": "commercially exploiting the Product in the Field in the Territory.",
          "bbox": [
            275.0,
            2887.0,
            1606.0,
            2946.0
          ],
          "confidence": 0.9925694465637207
        },
        {
          "text": "1.9 \"Commercialization Plan' has the meaning set forth in Section 5.1(b)",
          "bbox": [
            448.0,
            3013.0,
            2046.0,
            3061.0
          ],
          "confidence": 0.9942542314529419
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3223.0,
            1668.0,
            3262.0
          ],
          "confidence": 0.9846658706665039
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ],
          "confidence": 0.9990366697311401
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9950901865959167
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 6,
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_7_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "Such inspections may be made no more than once each Fiscal Year (unless an audit or inspection reveals a material inaccuracy in reports made under this Agreement, in which case it may be repeated within such Fiscal Year), and during normal business hours, with reasonable efforts to minimize disruption of Distributor's normal business activities.",
      "page_number": 7,
      "words": [
        {
          "text": "1.10 \"Commercially Reasonable Efforts\" means, with respect to a Party's specific obligations under this Agreement.",
          "bbox": [
            448.0,
            687.0,
            3020.0,
            740.0
          ],
          "confidence": 0.9909249544143677
        },
        {
          "text": "that level of efforts and resources, [***]. Commercially Reasonable Efforts requires that the applicable Party: (i) [***], (ii) [***]",
          "bbox": [
            276.0,
            749.0,
            3021.0,
            811.0
          ],
          "confidence": 0.9880976676940918
        },
        {
          "text": "and (iii) [***]",
          "bbox": [
            281.0,
            822.0,
            576.0,
            873.0
          ],
          "confidence": 0.9970481991767883
        },
        {
          "text": "1.11\"Confidential Information\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            943.0,
            2041.0,
            994.0
          ],
          "confidence": 0.9926530122756958
        },
        {
          "text": "1.12 \"Confidentiality Agreement' means that certain Mutual Confidential Disclosure Agreement, dated June 21, 2018,.",
          "bbox": [
            448.0,
            1069.0,
            3023.0,
            1118.0
          ],
          "confidence": 0.9926425218582153
        },
        {
          "text": "between Zogenix and Distributor.",
          "bbox": [
            279.0,
            1137.0,
            975.0,
            1179.0
          ],
          "confidence": 0.9874060153961182
        },
        {
          "text": "1.13 \"Control' (including any variations such as \"Controlled\"' and \"Controlling') means, with respect to any Information,",
          "bbox": [
            446.0,
            1255.0,
            3027.0,
            1308.0
          ],
          "confidence": 0.9865282773971558
        },
        {
          "text": "other than pursuant to this Agreement) to grant to the other Party the applicable access or other right under this Agreement without",
          "bbox": [
            283.0,
            1394.0,
            3027.0,
            1438.0
          ],
          "confidence": 0.9939649105072021
        },
        {
          "text": "violating the terms of an agreement with a Third Party.",
          "bbox": [
            277.0,
            1453.0,
            1408.0,
            1511.0
          ],
          "confidence": 0.9684579372406006
        },
        {
          "text": "1.14 \"Data' means any and all scientific, technical or test data pertaining to the Product in the Field that is generated by or",
          "bbox": [
            446.0,
            1577.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9855688214302063
        },
        {
          "text": "under the authority of Distributor or its Affiliates, Sub-distributors or other subcontractors or by or under the authority of Zogenix",
          "bbox": [
            281.0,
            1646.0,
            3023.0,
            1694.0
          ],
          "confidence": 0.9938080906867981
        },
        {
          "text": "or Zogenix ex-Territory Distributors before or during the Term, including research data, clinical pharmacology data, CMC data",
          "bbox": [
            283.0,
            1718.0,
            3023.0,
            1762.0
          ],
          "confidence": 0.9969605803489685
        },
        {
          "text": "(including analytical and quality control data and stability data), preclinical data, clinical data and all submissions made in",
          "bbox": [
            279.0,
            1778.0,
            3025.0,
            1829.0
          ],
          "confidence": 0.9950602054595947
        },
        {
          "text": "association with an IND or MAA filed in or outside the Territory with respect to the Product in the Field, in each case to the extent",
          "bbox": [
            281.0,
            1849.0,
            3027.0,
            1893.0
          ],
          "confidence": 0.987460732460022
        },
        {
          "text": "such data either (a) is Controlled by Zogenix on the Effective Date or (b) comes within a Party's Control during the Term.",
          "bbox": [
            283.0,
            1917.0,
            2820.0,
            1961.0
          ],
          "confidence": 0.993439793586731
        },
        {
          "text": "1.15 \"Development' means all activities directed to research, non-clinical and preclinical studies and trials, CMC Data.",
          "bbox": [
            446.0,
            2034.0,
            3027.0,
            2085.0
          ],
          "confidence": 0.9875854253768921
        },
        {
          "text": "collection, clinical studies and trials, Investigator Initiated Studies, toxicology studies, publication and presentation of study results.",
          "bbox": [
            283.0,
            2107.0,
            3021.0,
            2151.0
          ],
          "confidence": 0.995169997215271
        },
        {
          "text": "preparation and submission to Regulatory Authorities of an MAA concerning the Product, interacting with Regulatory Authorities",
          "bbox": [
            275.0,
            2165.0,
            3029.0,
            2226.0
          ],
          "confidence": 0.9990032315254211
        },
        {
          "text": "prior to and following Regulatory Approval of the Product, and Product pricing negotiations and decisions concerning the Product.",
          "bbox": [
            275.0,
            2235.0,
            3018.0,
            2288.0
          ],
          "confidence": 0.9938952922821045
        },
        {
          "text": "1.16 \"Disclosing Party\"' has the meaning set forth in Section 8.1.",
          "bbox": [
            446.0,
            2355.0,
            1838.0,
            2410.0
          ],
          "confidence": 0.9761294722557068
        },
        {
          "text": "1.17 \"Distribution Term' means the period commencing on the first Regulatory Approval of the Product in the Territory.",
          "bbox": [
            444.0,
            2480.0,
            3021.0,
            2531.0
          ],
          "confidence": 0.9935619831085205
        },
        {
          "text": "and continuing until [***1, or if this Agreement is terminated earlier pursuant to Article 12, the effective date of such termination..",
          "bbox": [
            283.0,
            2549.0,
            2960.0,
            2598.0
          ],
          "confidence": 0.9789053201675415
        },
        {
          "text": "1.18 \"Distributor Invention' has the meaning set forth in Section 9.1(b)(i).",
          "bbox": [
            446.0,
            2668.0,
            2059.0,
            2721.0
          ],
          "confidence": 0.9846929311752319
        },
        {
          "text": "1.19 \"Executives'' has the meaning set forth in Section 3.1(d)",
          "bbox": [
            446.0,
            2790.0,
            1756.0,
            2842.0
          ],
          "confidence": 0.9630396962165833
        },
        {
          "text": "1.20 \"FCPA\" means the U.S. Foreign Corrupt Practices Act (15 U.S.C.  78dd-1 et seq.), as amended.",
          "bbox": [
            444.0,
            2911.0,
            2672.0,
            2968.0
          ],
          "confidence": 0.9867299795150757
        },
        {
          "text": "1.21 \"FDA\" means the Food and Drug Administration, or any successor agency thereto",
          "bbox": [
            446.0,
            3035.0,
            2302.0,
            3090.0
          ],
          "confidence": 0.99086993932724
        },
        {
          "text": "3",
          "bbox": [
            1637.0,
            3245.0,
            1666.0,
            3287.0
          ],
          "confidence": 0.9986329674720764
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ],
          "confidence": 0.9976620674133301
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9953268766403198
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 7,
          "bbox": [
            281.0,
            3448.0,
            685.0,
            3479.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Audit Rights_5",
      "question": "Highlight the parts (if any) of this contract related to \"Audit Rights\" that should be reviewed by a lawyer. Details: Does a party have the right to  audit the books, records, or physical locations of the counterparty to ensure compliance with the contract?",
      "answer_text": "interest under Section 7.6 for underpaid amounts) shall be made by the Parties to reflect the results of such audit.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Uncapped Liability_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party’s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT; provided however, that this Section 10.5 shall not be construed to limit (a) either Party's right to special, incidental or consequential damages for the other Party's breach of Article 8 or (b) either Party's indemnification rights or obligations under Article 11.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Uncapped Liability_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Uncapped Liability\" that should be reviewed by a lawyer. Details: Is a party’s liability uncapped upon the breach of its obligation in the contract? This also includes uncap liability for a particular type of breach such as IP infringement or breach of confidentiality obligation.",
      "answer_text": "NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT; provided however, that this Section 10.5 shall not be construed to limit (a) either Party's right to special, incidental or consequential damages for the other Party's breach of Article 8 or (b) either Party's indemnification rights or obligations under Article 11.",
      "page_number": 3,
      "words": [
        {
          "text": "Article 13. Dispute Resolution.",
          "bbox": [
            292.0,
            700.0,
            903.0,
            744.0
          ],
          "confidence": 0.9863702058792114
        },
        {
          "text": "13.1",
          "bbox": [
            285.0,
            771.0,
            379.0,
            820.0
          ],
          "confidence": 0.9999197721481323
        },
        {
          "text": "Objective",
          "bbox": [
            587.0,
            771.0,
            789.0,
            826.0
          ],
          "confidence": 0.999786913394928
        },
        {
          "text": "13.2",
          "bbox": [
            285.0,
            848.0,
            381.0,
            897.0
          ],
          "confidence": 0.9999430179595947
        },
        {
          "text": "Resolution by Executives",
          "bbox": [
            591.0,
            855.0,
            1104.0,
            899.0
          ],
          "confidence": 0.9999337196350098
        },
        {
          "text": "13.3",
          "bbox": [
            285.0,
            926.0,
            379.0,
            976.0
          ],
          "confidence": 0.9999669194221497
        },
        {
          "text": "Arbitration",
          "bbox": [
            593.0,
            930.0,
            812.0,
            974.0
          ],
          "confidence": 0.999957799911499
        },
        {
          "text": "Article 14. General Provisions.",
          "bbox": [
            288.0,
            1005.0,
            905.0,
            1051.0
          ],
          "confidence": 0.9819156527519226
        },
        {
          "text": "14.1",
          "bbox": [
            285.0,
            1080.0,
            377.0,
            1129.0
          ],
          "confidence": 0.9999156594276428
        },
        {
          "text": "Governing Law",
          "bbox": [
            587.0,
            1080.0,
            906.0,
            1135.0
          ],
          "confidence": 0.9998216032981873
        },
        {
          "text": "14.2",
          "bbox": [
            285.0,
            1157.0,
            379.0,
            1206.0
          ],
          "confidence": 0.9999524354934692
        },
        {
          "text": "Force Majeure",
          "bbox": [
            589.0,
            1160.0,
            895.0,
            1210.0
          ],
          "confidence": 0.9948508143424988
        },
        {
          "text": "14.3",
          "bbox": [
            285.0,
            1235.0,
            379.0,
            1283.0
          ],
          "confidence": 0.9999619722366333
        },
        {
          "text": "Assignment",
          "bbox": [
            589.0,
            1237.0,
            837.0,
            1288.0
          ],
          "confidence": 0.9998873472213745
        },
        {
          "text": "14.4",
          "bbox": [
            285.0,
            1312.0,
            382.0,
            1361.0
          ],
          "confidence": 0.9999409914016724
        },
        {
          "text": "Severability",
          "bbox": [
            589.0,
            1314.0,
            826.0,
            1365.0
          ],
          "confidence": 0.9629895091056824
        },
        {
          "text": "14.5",
          "bbox": [
            285.0,
            1389.0,
            379.0,
            1438.0
          ],
          "confidence": 0.9999606609344482
        },
        {
          "text": "Notices",
          "bbox": [
            581.0,
            1387.0,
            753.0,
            1442.0
          ],
          "confidence": 0.9998845458030701
        },
        {
          "text": "14.6",
          "bbox": [
            285.0,
            1467.0,
            381.0,
            1515.0
          ],
          "confidence": 0.9999539256095886
        },
        {
          "text": "Entire Agreement; Amendments.",
          "bbox": [
            591.0,
            1469.0,
            1258.0,
            1515.0
          ],
          "confidence": 0.9874879121780396
        },
        {
          "text": "14.7",
          "bbox": [
            285.0,
            1544.0,
            379.0,
            1593.0
          ],
          "confidence": 0.9740194082260132
        },
        {
          "text": "Headings",
          "bbox": [
            583.0,
            1540.0,
            784.0,
            1600.0
          ],
          "confidence": 0.9998876452445984
        },
        {
          "text": "14.8",
          "bbox": [
            285.0,
            1621.0,
            381.0,
            1670.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "Independent Contractors",
          "bbox": [
            591.0,
            1626.0,
            1098.0,
            1668.0
          ],
          "confidence": 0.9999529123306274
        },
        {
          "text": "14.9",
          "bbox": [
            286.0,
            1698.0,
            379.0,
            1747.0
          ],
          "confidence": 0.9999675750732422
        },
        {
          "text": "Waiver",
          "bbox": [
            585.0,
            1695.0,
            744.0,
            1751.0
          ],
          "confidence": 0.999850332736969
        },
        {
          "text": "14.1",
          "bbox": [
            285.0,
            1774.0,
            377.0,
            1824.0
          ],
          "confidence": 0.9999295473098755
        },
        {
          "text": "Cumulative Remedies",
          "bbox": [
            591.0,
            1776.0,
            1037.0,
            1822.0
          ],
          "confidence": 0.9752135872840881
        },
        {
          "text": "14.11",
          "bbox": [
            286.0,
            1853.0,
            399.0,
            1900.0
          ],
          "confidence": 0.9998602867126465
        },
        {
          "text": "Waiver of Rule of Construction",
          "bbox": [
            593.0,
            1858.0,
            1227.0,
            1895.0
          ],
          "confidence": 0.995116651058197
        },
        {
          "text": "14.12",
          "bbox": [
            286.0,
            1930.0,
            404.0,
            1977.0
          ],
          "confidence": 0.9999540448188782
        },
        {
          "text": "Interpretation",
          "bbox": [
            585.0,
            1929.0,
            867.0,
            1983.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "14.13",
          "bbox": [
            286.0,
            2006.0,
            402.0,
            2054.0
          ],
          "confidence": 0.999951183795929
        },
        {
          "text": "No Third Party Beneficiaries.",
          "bbox": [
            589.0,
            2012.0,
            1185.0,
            2056.0
          ],
          "confidence": 0.9892049431800842
        },
        {
          "text": "14.14",
          "bbox": [
            286.0,
            2085.0,
            404.0,
            2133.0
          ],
          "confidence": 0.9999547004699707
        },
        {
          "text": "English Language",
          "bbox": [
            589.0,
            2085.0,
            956.0,
            2142.0
          ],
          "confidence": 0.9997346997261047
        },
        {
          "text": "14.15",
          "bbox": [
            286.0,
            2162.0,
            404.0,
            2209.0
          ],
          "confidence": 0.9999393224716187
        },
        {
          "text": "Counterparts",
          "bbox": [
            587.0,
            2163.0,
            858.0,
            2213.0
          ],
          "confidence": 0.9999754428863525
        },
        {
          "text": "14.16",
          "bbox": [
            286.0,
            2238.0,
            404.0,
            2286.0
          ],
          "confidence": 0.9999632835388184
        },
        {
          "text": "Further Actions",
          "bbox": [
            589.0,
            2238.0,
            912.0,
            2286.0
          ],
          "confidence": 0.988930881023407
        },
        {
          "text": "i1",
          "bbox": [
            1635.0,
            2706.0,
            1673.0,
            2756.0
          ],
          "confidence": 0.62410569190979
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2911.0,
            687.0,
            2942.0
          ],
          "confidence": 0.9991046786308289
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9972134232521057
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 3,
          "bbox": [
            279.0,
            2911.0,
            687.0,
            2942.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Cap On Liability_2_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT; provided however, that this Section 10.5 shall not be construed to limit (a) either Party's right to special, incidental or consequential damages for the other Party's breach of Article 8 or (b) either Party's indemnification rights or obligations under Article 11.",
      "page_number": 2,
      "words": [
        {
          "text": "7.2",
          "bbox": [
            283.0,
            694.0,
            357.0,
            746.0
          ],
          "confidence": 0.9998911023139954
        },
        {
          "text": "Currency Conversion",
          "bbox": [
            593.0,
            700.0,
            1026.0,
            744.0
          ],
          "confidence": 0.9997856616973877
        },
        {
          "text": "7.3",
          "bbox": [
            283.0,
            771.0,
            355.0,
            822.0
          ],
          "confidence": 0.9999483227729797
        },
        {
          "text": "Taxes",
          "bbox": [
            581.0,
            769.0,
            718.0,
            826.0
          ],
          "confidence": 0.9998666644096375
        },
        {
          "text": "7.4",
          "bbox": [
            283.0,
            848.0,
            357.0,
            899.0
          ],
          "confidence": 0.9999235272407532
        },
        {
          "text": "Records",
          "bbox": [
            585.0,
            852.0,
            759.0,
            897.0
          ],
          "confidence": 0.999837338924408
        },
        {
          "text": "7.5",
          "bbox": [
            283.0,
            925.0,
            355.0,
            976.0
          ],
          "confidence": 0.9999225735664368
        },
        {
          "text": "Audits",
          "bbox": [
            589.0,
            925.0,
            727.0,
            978.0
          ],
          "confidence": 0.9998431205749512
        },
        {
          "text": "7.6",
          "bbox": [
            283.0,
            1001.0,
            357.0,
            1053.0
          ],
          "confidence": 0.9999238848686218
        },
        {
          "text": "Late Payments",
          "bbox": [
            587.0,
            1009.0,
            903.0,
            1053.0
          ],
          "confidence": 0.9999462366104126
        },
        {
          "text": "Article 8. Confidentiality.",
          "bbox": [
            286.0,
            1076.0,
            787.0,
            1133.0
          ],
          "confidence": 0.9470240473747253
        },
        {
          "text": "8.1",
          "bbox": [
            283.0,
            1155.0,
            355.0,
            1206.0
          ],
          "confidence": 0.9998834133148193
        },
        {
          "text": "Confidential Information",
          "bbox": [
            593.0,
            1162.0,
            1084.0,
            1202.0
          ],
          "confidence": 0.9998041987419128
        },
        {
          "text": "8.2",
          "bbox": [
            283.0,
            1233.0,
            357.0,
            1285.0
          ],
          "confidence": 0.9999167323112488
        },
        {
          "text": "Exceptions",
          "bbox": [
            587.0,
            1235.0,
            816.0,
            1290.0
          ],
          "confidence": 0.9999329447746277
        },
        {
          "text": "8.3",
          "bbox": [
            285.0,
            1314.0,
            355.0,
            1361.0
          ],
          "confidence": 0.9999248385429382
        },
        {
          "text": "Permitted Disclosures",
          "bbox": [
            589.0,
            1314.0,
            1040.0,
            1360.0
          ],
          "confidence": 0.9991523027420044
        },
        {
          "text": "8.4",
          "bbox": [
            283.0,
            1389.0,
            357.0,
            1440.0
          ],
          "confidence": 0.9999470710754395
        },
        {
          "text": "Confidentiality of this Agreement and its Terms",
          "bbox": [
            593.0,
            1394.0,
            1561.0,
            1438.0
          ],
          "confidence": 0.9983221292495728
        },
        {
          "text": "8.5",
          "bbox": [
            283.0,
            1466.0,
            357.0,
            1517.0
          ],
          "confidence": 0.9999310374259949
        },
        {
          "text": "Public Announcements",
          "bbox": [
            591.0,
            1471.0,
            1062.0,
            1513.0
          ],
          "confidence": 0.9999222755432129
        },
        {
          "text": "8.6",
          "bbox": [
            283.0,
            1542.0,
            359.0,
            1593.0
          ],
          "confidence": 0.9998968243598938
        },
        {
          "text": "Publication",
          "bbox": [
            585.0,
            1544.0,
            814.0,
            1594.0
          ],
          "confidence": 0.9998170733451843
        },
        {
          "text": "8.7",
          "bbox": [
            283.0,
            1621.0,
            357.0,
            1670.0
          ],
          "confidence": 0.9999094009399414
        },
        {
          "text": "Prior Non-Disclosure Agreements",
          "bbox": [
            589.0,
            1623.0,
            1292.0,
            1668.0
          ],
          "confidence": 0.9828970432281494
        },
        {
          "text": "8.8",
          "bbox": [
            283.0,
            1698.0,
            357.0,
            1749.0
          ],
          "confidence": 0.9999458193778992
        },
        {
          "text": "Equitable Relief",
          "bbox": [
            591.0,
            1703.0,
            923.0,
            1747.0
          ],
          "confidence": 0.9970293045043945
        },
        {
          "text": "Article 9. Intellectual Property Ownership and Enforcement",
          "bbox": [
            292.0,
            1780.0,
            1521.0,
            1824.0
          ],
          "confidence": 0.9913383722305298
        },
        {
          "text": "9.1",
          "bbox": [
            280.0,
            1847.0,
            356.0,
            1904.0
          ],
          "confidence": 0.9999046325683594
        },
        {
          "text": "Ownership of Intellectual Property",
          "bbox": [
            589.0,
            1855.0,
            1298.0,
            1904.0
          ],
          "confidence": 0.9852703213691711
        },
        {
          "text": "9.2",
          "bbox": [
            283.0,
            1928.0,
            357.0,
            1979.0
          ],
          "confidence": 0.9999018311500549
        },
        {
          "text": "Zogenix Patent Prosecution and Maintenance",
          "bbox": [
            591.0,
            1935.0,
            1528.0,
            1979.0
          ],
          "confidence": 0.9999276995658875
        },
        {
          "text": "9.3",
          "bbox": [
            283.0,
            2006.0,
            355.0,
            2058.0
          ],
          "confidence": 0.9999368786811829
        },
        {
          "text": "Infringement by Third Parties",
          "bbox": [
            593.0,
            2012.0,
            1196.0,
            2056.0
          ],
          "confidence": 0.9958657622337341
        },
        {
          "text": "9.4",
          "bbox": [
            283.0,
            2083.0,
            357.0,
            2133.0
          ],
          "confidence": 0.9999353885650635
        },
        {
          "text": "Third Party Intellectual Property Rights",
          "bbox": [
            589.0,
            2087.0,
            1397.0,
            2136.0
          ],
          "confidence": 0.9975267648696899
        },
        {
          "text": "9.5",
          "bbox": [
            283.0,
            2160.0,
            357.0,
            2211.0
          ],
          "confidence": 0.9999289512634277
        },
        {
          "text": "Patent Term Restoration",
          "bbox": [
            591.0,
            2165.0,
            1093.0,
            2206.0
          ],
          "confidence": 0.9915556907653809
        },
        {
          "text": "9.6",
          "bbox": [
            283.0,
            2237.0,
            357.0,
            2288.0
          ],
          "confidence": 0.9999411702156067
        },
        {
          "text": "Patent Marking",
          "bbox": [
            587.0,
            2234.0,
            910.0,
            2292.0
          ],
          "confidence": 0.9983199834823608
        },
        {
          "text": "9.7",
          "bbox": [
            283.0,
            2313.0,
            357.0,
            2365.0
          ],
          "confidence": 0.9998450875282288
        },
        {
          "text": "Zogenix Trademarks",
          "bbox": [
            593.0,
            2321.0,
            1013.0,
            2365.0
          ],
          "confidence": 0.9998643398284912
        },
        {
          "text": "9.8",
          "bbox": [
            283.0,
            2390.0,
            357.0,
            2441.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Product Trademarks",
          "bbox": [
            589.0,
            2394.0,
            1011.0,
            2440.0
          ],
          "confidence": 0.9998607635498047
        },
        {
          "text": "Article 10. Representations, Warranties and Covenants; Limitation of Liability",
          "bbox": [
            290.0,
            2474.0,
            1874.0,
            2518.0
          ],
          "confidence": 0.9939117431640625
        },
        {
          "text": "10.1",
          "bbox": [
            280.0,
            2539.0,
            381.0,
            2599.0
          ],
          "confidence": 0.9998412728309631
        },
        {
          "text": "Mutual Representations, Warranties and Covenants",
          "bbox": [
            591.0,
            2551.0,
            1646.0,
            2595.0
          ],
          "confidence": 0.9918951988220215
        },
        {
          "text": "10.2",
          "bbox": [
            285.0,
            2624.0,
            381.0,
            2673.0
          ],
          "confidence": 0.9998495578765869
        },
        {
          "text": "Representations, Warranties and Covenants of Distributor",
          "bbox": [
            589.0,
            2628.0,
            1773.0,
            2672.0
          ],
          "confidence": 0.999252438545227
        },
        {
          "text": "10.3",
          "bbox": [
            286.0,
            2701.0,
            379.0,
            2750.0
          ],
          "confidence": 0.9998793601989746
        },
        {
          "text": "Representations and Warranties of Zogenix",
          "bbox": [
            591.0,
            2706.0,
            1477.0,
            2750.0
          ],
          "confidence": 0.9997750520706177
        },
        {
          "text": "10.4",
          "bbox": [
            286.0,
            2778.0,
            382.0,
            2827.0
          ],
          "confidence": 0.9998469948768616
        },
        {
          "text": "Disclaimer",
          "bbox": [
            585.0,
            2777.0,
            814.0,
            2827.0
          ],
          "confidence": 0.9999192953109741
        },
        {
          "text": "10.5",
          "bbox": [
            286.0,
            2854.0,
            379.0,
            2904.0
          ],
          "confidence": 0.9998223185539246
        },
        {
          "text": "Limitation of Liability",
          "bbox": [
            587.0,
            2852.0,
            1021.0,
            2908.0
          ],
          "confidence": 0.9875666499137878
        },
        {
          "text": "Article 11. Indemnification",
          "bbox": [
            290.0,
            2937.0,
            832.0,
            2979.0
          ],
          "confidence": 0.9832529425621033
        },
        {
          "text": "11.1",
          "bbox": [
            282.0,
            3003.0,
            376.0,
            3060.0
          ],
          "confidence": 0.9997841715812683
        },
        {
          "text": "Indemnification of Zogenix",
          "bbox": [
            589.0,
            3009.0,
            1138.0,
            3059.0
          ],
          "confidence": 0.999589204788208
        },
        {
          "text": "11.2",
          "bbox": [
            285.0,
            3086.0,
            375.0,
            3136.0
          ],
          "confidence": 0.9980589151382446
        },
        {
          "text": "Indemnification of Distributor",
          "bbox": [
            587.0,
            3088.0,
            1193.0,
            3134.0
          ],
          "confidence": 0.9997336864471436
        },
        {
          "text": "11.3",
          "bbox": [
            285.0,
            3163.0,
            375.0,
            3212.0
          ],
          "confidence": 0.9998749494552612
        },
        {
          "text": "Procedure",
          "bbox": [
            585.0,
            3163.0,
            803.0,
            3213.0
          ],
          "confidence": 0.99989914894104
        },
        {
          "text": "11.4",
          "bbox": [
            285.0,
            3240.0,
            377.0,
            3289.0
          ],
          "confidence": 0.9998754858970642
        },
        {
          "text": "Insurance",
          "bbox": [
            585.0,
            3241.0,
            796.0,
            3291.0
          ],
          "confidence": 0.9998952150344849
        },
        {
          "text": "Article 12. Term and Termination",
          "bbox": [
            290.0,
            3322.0,
            968.0,
            3364.0
          ],
          "confidence": 0.988312840461731
        },
        {
          "text": "12.1",
          "bbox": [
            283.0,
            3392.0,
            381.0,
            3446.0
          ],
          "confidence": 0.999920666217804
        },
        {
          "text": "Term",
          "bbox": [
            584.0,
            3393.0,
            703.0,
            3446.0
          ],
          "confidence": 0.9998182654380798
        },
        {
          "text": "12.2",
          "bbox": [
            285.0,
            3472.0,
            381.0,
            3521.0
          ],
          "confidence": 0.999936580657959
        },
        {
          "text": "Termination",
          "bbox": [
            587.0,
            3476.0,
            832.0,
            3519.0
          ],
          "confidence": 0.9999456405639648
        },
        {
          "text": "12.3",
          "bbox": [
            285.0,
            3549.0,
            379.0,
            3598.0
          ],
          "confidence": 0.9999634027481079
        },
        {
          "text": "Rights on Termination.",
          "bbox": [
            593.0,
            3554.0,
            1037.0,
            3598.0
          ],
          "confidence": 0.9866342544555664
        },
        {
          "text": "12.4",
          "bbox": [
            280.0,
            3621.0,
            383.0,
            3681.0
          ],
          "confidence": 0.9999217391014099
        },
        {
          "text": "Exercise of Right to Terminate",
          "bbox": [
            591.0,
            3633.0,
            1218.0,
            3675.0
          ],
          "confidence": 0.984305202960968
        },
        {
          "text": "12.5",
          "bbox": [
            285.0,
            3704.0,
            379.0,
            3753.0
          ],
          "confidence": 0.9999560117721558
        },
        {
          "text": "Damages; Relief",
          "bbox": [
            587.0,
            3704.0,
            946.0,
            3759.0
          ],
          "confidence": 0.9997478127479553
        },
        {
          "text": "12.6",
          "bbox": [
            285.0,
            3781.0,
            381.0,
            3830.0
          ],
          "confidence": 0.9999510645866394
        },
        {
          "text": "Accrued Obligations; Survival",
          "bbox": [
            593.0,
            3786.0,
            1204.0,
            3830.0
          ],
          "confidence": 0.9839729070663452
        },
        {
          "text": ":F",
          "bbox": [
            1640.0,
            4042.0,
            1668.0,
            4086.0
          ],
          "confidence": 0.6659884452819824
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ],
          "confidence": 0.9985311627388
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9941036105155945
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 2,
          "bbox": [
            279.0,
            4243.0,
            687.0,
            4274.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Cap On Liability_3_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "NEITHER PARTY SHALL BE ENTITLED TO RECOVER FROM THE OTHER PARTY ANY SPECIAL, INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES IN CONNECTION WITH THIS AGREEMENT; provided however, that this Section 10.5 shall not be construed to limit (a) either Party's right to special, incidental or consequential damages for the other Party's breach of Article 8 or (b) either Party's indemnification rights or obligations under Article 11.",
      "page_number": 3,
      "words": [
        {
          "text": "Article 13. Dispute Resolution.",
          "bbox": [
            292.0,
            700.0,
            903.0,
            744.0
          ],
          "confidence": 0.9863702058792114
        },
        {
          "text": "13.1",
          "bbox": [
            285.0,
            771.0,
            379.0,
            820.0
          ],
          "confidence": 0.9999197721481323
        },
        {
          "text": "Objective",
          "bbox": [
            587.0,
            771.0,
            789.0,
            826.0
          ],
          "confidence": 0.999786913394928
        },
        {
          "text": "13.2",
          "bbox": [
            285.0,
            848.0,
            381.0,
            897.0
          ],
          "confidence": 0.9999430179595947
        },
        {
          "text": "Resolution by Executives",
          "bbox": [
            591.0,
            855.0,
            1104.0,
            899.0
          ],
          "confidence": 0.9999337196350098
        },
        {
          "text": "13.3",
          "bbox": [
            285.0,
            926.0,
            379.0,
            976.0
          ],
          "confidence": 0.9999669194221497
        },
        {
          "text": "Arbitration",
          "bbox": [
            593.0,
            930.0,
            812.0,
            974.0
          ],
          "confidence": 0.999957799911499
        },
        {
          "text": "Article 14. General Provisions.",
          "bbox": [
            288.0,
            1005.0,
            905.0,
            1051.0
          ],
          "confidence": 0.9819156527519226
        },
        {
          "text": "14.1",
          "bbox": [
            285.0,
            1080.0,
            377.0,
            1129.0
          ],
          "confidence": 0.9999156594276428
        },
        {
          "text": "Governing Law",
          "bbox": [
            587.0,
            1080.0,
            906.0,
            1135.0
          ],
          "confidence": 0.9998216032981873
        },
        {
          "text": "14.2",
          "bbox": [
            285.0,
            1157.0,
            379.0,
            1206.0
          ],
          "confidence": 0.9999524354934692
        },
        {
          "text": "Force Majeure",
          "bbox": [
            589.0,
            1160.0,
            895.0,
            1210.0
          ],
          "confidence": 0.9948508143424988
        },
        {
          "text": "14.3",
          "bbox": [
            285.0,
            1235.0,
            379.0,
            1283.0
          ],
          "confidence": 0.9999619722366333
        },
        {
          "text": "Assignment",
          "bbox": [
            589.0,
            1237.0,
            837.0,
            1288.0
          ],
          "confidence": 0.9998873472213745
        },
        {
          "text": "14.4",
          "bbox": [
            285.0,
            1312.0,
            382.0,
            1361.0
          ],
          "confidence": 0.9999409914016724
        },
        {
          "text": "Severability",
          "bbox": [
            589.0,
            1314.0,
            826.0,
            1365.0
          ],
          "confidence": 0.9629895091056824
        },
        {
          "text": "14.5",
          "bbox": [
            285.0,
            1389.0,
            379.0,
            1438.0
          ],
          "confidence": 0.9999606609344482
        },
        {
          "text": "Notices",
          "bbox": [
            581.0,
            1387.0,
            753.0,
            1442.0
          ],
          "confidence": 0.9998845458030701
        },
        {
          "text": "14.6",
          "bbox": [
            285.0,
            1467.0,
            381.0,
            1515.0
          ],
          "confidence": 0.9999539256095886
        },
        {
          "text": "Entire Agreement; Amendments.",
          "bbox": [
            591.0,
            1469.0,
            1258.0,
            1515.0
          ],
          "confidence": 0.9874879121780396
        },
        {
          "text": "14.7",
          "bbox": [
            285.0,
            1544.0,
            379.0,
            1593.0
          ],
          "confidence": 0.9740194082260132
        },
        {
          "text": "Headings",
          "bbox": [
            583.0,
            1540.0,
            784.0,
            1600.0
          ],
          "confidence": 0.9998876452445984
        },
        {
          "text": "14.8",
          "bbox": [
            285.0,
            1621.0,
            381.0,
            1670.0
          ],
          "confidence": 0.9999672174453735
        },
        {
          "text": "Independent Contractors",
          "bbox": [
            591.0,
            1626.0,
            1098.0,
            1668.0
          ],
          "confidence": 0.9999529123306274
        },
        {
          "text": "14.9",
          "bbox": [
            286.0,
            1698.0,
            379.0,
            1747.0
          ],
          "confidence": 0.9999675750732422
        },
        {
          "text": "Waiver",
          "bbox": [
            585.0,
            1695.0,
            744.0,
            1751.0
          ],
          "confidence": 0.999850332736969
        },
        {
          "text": "14.1",
          "bbox": [
            285.0,
            1774.0,
            377.0,
            1824.0
          ],
          "confidence": 0.9999295473098755
        },
        {
          "text": "Cumulative Remedies",
          "bbox": [
            591.0,
            1776.0,
            1037.0,
            1822.0
          ],
          "confidence": 0.9752135872840881
        },
        {
          "text": "14.11",
          "bbox": [
            286.0,
            1853.0,
            399.0,
            1900.0
          ],
          "confidence": 0.9998602867126465
        },
        {
          "text": "Waiver of Rule of Construction",
          "bbox": [
            593.0,
            1858.0,
            1227.0,
            1895.0
          ],
          "confidence": 0.995116651058197
        },
        {
          "text": "14.12",
          "bbox": [
            286.0,
            1930.0,
            404.0,
            1977.0
          ],
          "confidence": 0.9999540448188782
        },
        {
          "text": "Interpretation",
          "bbox": [
            585.0,
            1929.0,
            867.0,
            1983.0
          ],
          "confidence": 0.999941349029541
        },
        {
          "text": "14.13",
          "bbox": [
            286.0,
            2006.0,
            402.0,
            2054.0
          ],
          "confidence": 0.999951183795929
        },
        {
          "text": "No Third Party Beneficiaries.",
          "bbox": [
            589.0,
            2012.0,
            1185.0,
            2056.0
          ],
          "confidence": 0.9892049431800842
        },
        {
          "text": "14.14",
          "bbox": [
            286.0,
            2085.0,
            404.0,
            2133.0
          ],
          "confidence": 0.9999547004699707
        },
        {
          "text": "English Language",
          "bbox": [
            589.0,
            2085.0,
            956.0,
            2142.0
          ],
          "confidence": 0.9997346997261047
        },
        {
          "text": "14.15",
          "bbox": [
            286.0,
            2162.0,
            404.0,
            2209.0
          ],
          "confidence": 0.9999393224716187
        },
        {
          "text": "Counterparts",
          "bbox": [
            587.0,
            2163.0,
            858.0,
            2213.0
          ],
          "confidence": 0.9999754428863525
        },
        {
          "text": "14.16",
          "bbox": [
            286.0,
            2238.0,
            404.0,
            2286.0
          ],
          "confidence": 0.9999632835388184
        },
        {
          "text": "Further Actions",
          "bbox": [
            589.0,
            2238.0,
            912.0,
            2286.0
          ],
          "confidence": 0.988930881023407
        },
        {
          "text": "i1",
          "bbox": [
            1635.0,
            2706.0,
            1673.0,
            2756.0
          ],
          "confidence": 0.62410569190979
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2911.0,
            687.0,
            2942.0
          ],
          "confidence": 0.9991046786308289
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9972134232521057
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 3,
          "bbox": [
            279.0,
            2911.0,
            687.0,
            2942.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Cap On Liability_5",
      "question": "Highlight the parts (if any) of this contract related to \"Cap On Liability\" that should be reviewed by a lawyer. Details: Does the contract include a cap on liability upon the breach of a party’s obligation? This includes time limitation for the counterparty to bring claims or maximum amount for recovery.",
      "answer_text": "Neither Party will be liable to the other for Indirect Losses in connection with any recall or withdrawal pursuant to this Section.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Insurance_10",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party, at its own expense, shall maintain product liability and other appropriate insurance (or self- insure) in an amount consistent with industry standards during the Term.",
      "page_number": 10,
      "words": [
        {
          "text": "Sales of a Product for use in conducting clinical trials of the Product in the Territory in order to obtain Regulatory Approval",
          "bbox": [
            446.0,
            687.0,
            3025.0,
            740.0
          ],
          "confidence": 0.9933760166168213
        },
        {
          "text": "of the Product in the Territory shall be excluded from Net Sales calculations for all purposes..",
          "bbox": [
            279.0,
            753.0,
            2215.0,
            806.0
          ],
          "confidence": 0.9936053156852722
        },
        {
          "text": "Upon any sale or other disposition of the Product for any consideration other than exclusively monetary consideration on",
          "bbox": [
            450.0,
            879.0,
            3029.0,
            928.0
          ],
          "confidence": 0.9955773949623108
        },
        {
          "text": "bona fide arm's-length terms, for purposes of calculating Net Sales under this Agreement, the Product shall be deemed to be sold",
          "bbox": [
            277.0,
            943.0,
            3027.0,
            996.0
          ],
          "confidence": 0.9938769340515137
        },
        {
          "text": "exclusively for money at the average sales price during the applicable reporting period generally achieved for the Product in the.",
          "bbox": [
            277.0,
            1009.0,
            3029.0,
            1065.0
          ],
          "confidence": 0.9977632761001587
        },
        {
          "text": "Field in the Territory when the Product is sold alone and not with other products..",
          "bbox": [
            279.0,
            1078.0,
            1974.0,
            1126.0
          ],
          "confidence": 0.9936575889587402
        },
        {
          "text": "Distributor and its Affiliates and Sub-distributors shall not sell the Product in combination with or as part of a bundle with",
          "bbox": [
            446.0,
            1201.0,
            3025.0,
            1250.0
          ],
          "confidence": 0.9868108630180359
        },
        {
          "text": "other products, or offer packaged arrangements to customers that include the Product, in such a manner as to disproportionately",
          "bbox": [
            283.0,
            1272.0,
            3021.0,
            1316.0
          ],
          "confidence": 0.9923547506332397
        },
        {
          "text": "discount the selling price of the Product as compared with the weighted-average discount applied to the other products, as a.",
          "bbox": [
            277.0,
            1334.0,
            3029.0,
            1385.0
          ],
          "confidence": 0.9869493246078491
        },
        {
          "text": "percent of the respective list prices (or if not available, a good faith estimate thereof) of such products and the Product prior to",
          "bbox": [
            277.0,
            1402.0,
            3025.0,
            1453.0
          ],
          "confidence": 0.9896950125694275
        },
        {
          "text": "applying the discount.",
          "bbox": [
            281.0,
            1465.0,
            734.0,
            1521.0
          ],
          "confidence": 0.9828034043312073
        },
        {
          "text": "1.44 \"NHr' means the Japanese national health insurance system, or its successor system..",
          "bbox": [
            448.0,
            1590.0,
            2333.0,
            1637.0
          ],
          "confidence": 0.9817475080490112
        },
        {
          "text": "1.45 \"NHI Price\" means the reimbursement price of the maximum daily dose of Product for purposes of the NHI..",
          "bbox": [
            446.0,
            1710.0,
            2855.0,
            1762.0
          ],
          "confidence": 0.976787269115448
        },
        {
          "text": "1.46 \"NHI Price Listing\"' means the listing of the NHI Price by Central Social Insurance Medical Council (Chuikyo) of.",
          "bbox": [
            446.0,
            1833.0,
            3031.0,
            1884.0
          ],
          "confidence": 0.9809008240699768
        },
        {
          "text": "the MHLW.",
          "bbox": [
            279.0,
            1902.0,
            529.0,
            1946.0
          ],
          "confidence": 0.9985179901123047
        },
        {
          "text": "1.47 \"Out-of-Pocket Costs and Expenses\"' means the costs and expenses incurred by one or both Parties (as.",
          "bbox": [
            444.0,
            2023.0,
            3025.0,
            2074.0
          ],
          "confidence": 0.9863541126251221
        },
        {
          "text": "applicable) that are directly attributable to and reasonably allocated to a specified project, program or task. Out-of-Pocket Costs.",
          "bbox": [
            281.0,
            2094.0,
            3027.0,
            2143.0
          ],
          "confidence": 0.9894804358482361
        },
        {
          "text": "and Expenses shall include payments made to third parties such as contract research organizations and investigators and the fully",
          "bbox": [
            277.0,
            2156.0,
            3025.0,
            2209.0
          ],
          "confidence": 0.9907313585281372
        },
        {
          "text": "burdened cost of drug product. Out-of-Pocket Costs and Expenses shall not include a Party's employee costs..",
          "bbox": [
            279.0,
            2226.0,
            2610.0,
            2275.0
          ],
          "confidence": 0.9961137175559998
        },
        {
          "text": "1.48 \"Patent' means (a) any patent, certificate of invention, application for certificate of invention, priority patent filing and",
          "bbox": [
            444.0,
            2344.0,
            3027.0,
            2401.0
          ],
          "confidence": 0.9821420311927795
        },
        {
          "text": "patent application, and (b) any renewal, division, continuation (in whole or in part) or request for continued examination of any of.",
          "bbox": [
            277.0,
            2414.0,
            3031.0,
            2467.0
          ],
          "confidence": 0.988559365272522
        },
        {
          "text": "such patent, certificate of invention and patent application, and any patent or certificate of invention issuing thereon, and any",
          "bbox": [
            277.0,
            2482.0,
            3025.0,
            2533.0
          ],
          "confidence": 0.990950345993042
        },
        {
          "text": "reissue, reexamination, extension, restoration by any existing or future extension or restoration mechanism, division, renewal,",
          "bbox": [
            279.0,
            2553.0,
            3023.0,
            2597.0
          ],
          "confidence": 0.9931027889251709
        },
        {
          "text": "substitution, confirmation, registration, revalidation, revision and addition of or to any of the foregoing.",
          "bbox": [
            277.0,
            2609.0,
            2402.0,
            2670.0
          ],
          "confidence": 0.993749737739563
        },
        {
          "text": "1.49 \"Person\"' means any individual, corporation, partnership, limited liability company, trust or other entity..",
          "bbox": [
            446.0,
            2736.0,
            2699.0,
            2787.0
          ],
          "confidence": 0.9838226437568665
        },
        {
          "text": "1.50 \"Pharmacovigilance Agreement' has the meaning set forth in Section 4.5.",
          "bbox": [
            448.0,
            2860.0,
            2162.0,
            2909.0
          ],
          "confidence": 0.9933353066444397
        },
        {
          "text": "6",
          "bbox": [
            1638.0,
            3070.0,
            1669.0,
            3110.0
          ],
          "confidence": 0.9856734275817871
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            277.0,
            3264.0,
            687.0,
            3302.0
          ],
          "confidence": 0.9991859197616577
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9954123497009277
        }
      ],
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 10,
          "bbox": [
            277.0,
            3264.0,
            687.0,
            3302.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Insurance_10",
      "question": "Highlight the parts (if any) of this contract related to \"Insurance\" that should be reviewed by a lawyer. Details: Is there a requirement for insurance that must be maintained by one party for the benefit of the counterparty?",
      "answer_text": "Each Party shall provide a certificate of insurance (or evidence of self-insurance) evidencing such coverage to the other Party upon written request.",
      "page_number": 10,
      "words": [
        {
          "text": "Sales of a Product for use in conducting clinical trials of the Product in the Territory in order to obtain Regulatory Approval",
          "bbox": [
            446.0,
            687.0,
            3025.0,
            740.0
          ],
          "confidence": 0.9933760166168213
        },
        {
          "text": "of the Product in the Territory shall be excluded from Net Sales calculations for all purposes..",
          "bbox": [
            279.0,
            753.0,
            2215.0,
            806.0
          ],
          "confidence": 0.9936053156852722
        },
        {
          "text": "Upon any sale or other disposition of the Product for any consideration other than exclusively monetary consideration on",
          "bbox": [
            450.0,
            879.0,
            3029.0,
            928.0
          ],
          "confidence": 0.9955773949623108
        },
        {
          "text": "bona fide arm's-length terms, for purposes of calculating Net Sales under this Agreement, the Product shall be deemed to be sold",
          "bbox": [
            277.0,
            943.0,
            3027.0,
            996.0
          ],
          "confidence": 0.9938769340515137
        },
        {
          "text": "exclusively for money at the average sales price during the applicable reporting period generally achieved for the Product in the.",
          "bbox": [
            277.0,
            1009.0,
            3029.0,
            1065.0
          ],
          "confidence": 0.9977632761001587
        },
        {
          "text": "Field in the Territory when the Product is sold alone and not with other products..",
          "bbox": [
            279.0,
            1078.0,
            1974.0,
            1126.0
          ],
          "confidence": 0.9936575889587402
        },
        {
          "text": "Distributor and its Affiliates and Sub-distributors shall not sell the Product in combination with or as part of a bundle with",
          "bbox": [
            446.0,
            1201.0,
            3025.0,
            1250.0
          ],
          "confidence": 0.9868108630180359
        },
        {
          "text": "other products, or offer packaged arrangements to customers that include the Product, in such a manner as to disproportionately",
          "bbox": [
            283.0,
            1272.0,
            3021.0,
            1316.0
          ],
          "confidence": 0.9923547506332397
        },
        {
          "text": "discount the selling price of the Product as compared with the weighted-average discount applied to the other products, as a.",
          "bbox": [
            277.0,
            1334.0,
            3029.0,
            1385.0
          ],
          "confidence": 0.9869493246078491
        },
        {
          "text": "percent of the respective list prices (or if not available, a good faith estimate thereof) of such products and the Product prior to",
          "bbox": [
            277.0,
            1402.0,
            3025.0,
            1453.0
          ],
          "confidence": 0.9896950125694275
        },
        {
          "text": "applying the discount.",
          "bbox": [
            281.0,
            1465.0,
            734.0,
            1521.0
          ],
          "confidence": 0.9828034043312073
        },
        {
          "text": "1.44 \"NHr' means the Japanese national health insurance system, or its successor system..",
          "bbox": [
            448.0,
            1590.0,
            2333.0,
            1637.0
          ],
          "confidence": 0.9817475080490112
        },
        {
          "text": "1.45 \"NHI Price\" means the reimbursement price of the maximum daily dose of Product for purposes of the NHI..",
          "bbox": [
            446.0,
            1710.0,
            2855.0,
            1762.0
          ],
          "confidence": 0.976787269115448
        },
        {
          "text": "1.46 \"NHI Price Listing\"' means the listing of the NHI Price by Central Social Insurance Medical Council (Chuikyo) of.",
          "bbox": [
            446.0,
            1833.0,
            3031.0,
            1884.0
          ],
          "confidence": 0.9809008240699768
        },
        {
          "text": "the MHLW.",
          "bbox": [
            279.0,
            1902.0,
            529.0,
            1946.0
          ],
          "confidence": 0.9985179901123047
        },
        {
          "text": "1.47 \"Out-of-Pocket Costs and Expenses\"' means the costs and expenses incurred by one or both Parties (as.",
          "bbox": [
            444.0,
            2023.0,
            3025.0,
            2074.0
          ],
          "confidence": 0.9863541126251221
        },
        {
          "text": "applicable) that are directly attributable to and reasonably allocated to a specified project, program or task. Out-of-Pocket Costs.",
          "bbox": [
            281.0,
            2094.0,
            3027.0,
            2143.0
          ],
          "confidence": 0.9894804358482361
        },
        {
          "text": "and Expenses shall include payments made to third parties such as contract research organizations and investigators and the fully",
          "bbox": [
            277.0,
            2156.0,
            3025.0,
            2209.0
          ],
          "confidence": 0.9907313585281372
        },
        {
          "text": "burdened cost of drug product. Out-of-Pocket Costs and Expenses shall not include a Party's employee costs..",
          "bbox": [
            279.0,
            2226.0,
            2610.0,
            2275.0
          ],
          "confidence": 0.9961137175559998
        },
        {
          "text": "1.48 \"Patent' means (a) any patent, certificate of invention, application for certificate of invention, priority patent filing and",
          "bbox": [
            444.0,
            2344.0,
            3027.0,
            2401.0
          ],
          "confidence": 0.9821420311927795
        },
        {
          "text": "patent application, and (b) any renewal, division, continuation (in whole or in part) or request for continued examination of any of.",
          "bbox": [
            277.0,
            2414.0,
            3031.0,
            2467.0
          ],
          "confidence": 0.988559365272522
        },
        {
          "text": "such patent, certificate of invention and patent application, and any patent or certificate of invention issuing thereon, and any",
          "bbox": [
            277.0,
            2482.0,
            3025.0,
            2533.0
          ],
          "confidence": 0.990950345993042
        },
        {
          "text": "reissue, reexamination, extension, restoration by any existing or future extension or restoration mechanism, division, renewal,",
          "bbox": [
            279.0,
            2553.0,
            3023.0,
            2597.0
          ],
          "confidence": 0.9931027889251709
        },
        {
          "text": "substitution, confirmation, registration, revalidation, revision and addition of or to any of the foregoing.",
          "bbox": [
            277.0,
            2609.0,
            2402.0,
            2670.0
          ],
          "confidence": 0.993749737739563
        },
        {
          "text": "1.49 \"Person\"' means any individual, corporation, partnership, limited liability company, trust or other entity..",
          "bbox": [
            446.0,
            2736.0,
            2699.0,
            2787.0
          ],
          "confidence": 0.9838226437568665
        },
        {
          "text": "1.50 \"Pharmacovigilance Agreement' has the meaning set forth in Section 4.5.",
          "bbox": [
            448.0,
            2860.0,
            2162.0,
            2909.0
          ],
          "confidence": 0.9933353066444397
        },
        {
          "text": "6",
          "bbox": [
            1638.0,
            3070.0,
            1669.0,
            3110.0
          ],
          "confidence": 0.9856734275817871
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            277.0,
            3264.0,
            687.0,
            3302.0
          ],
          "confidence": 0.9991859197616577
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9954123497009277
        }
      ],
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 10,
          "bbox": [
            277.0,
            3264.0,
            687.0,
            3302.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Distributor shall not, and shall cause its Affiliates not to, (i) use, seek to register, or otherwise claim rights in any Trademark that is confusingly similar to, misleading or deceptive with respect to, or that materially dilutes, any of the Zogenix Trademarks, or (ii) knowingly do, cause to be done, or knowingly omit to do any act, the doing, causing or omitting of which endangers, undermines, impairs, destroys or similarly affects, in any material respect, the validity or strength of any of the Zogenix Trademarks (including any registration or pending registration application relating thereto) or the value of the goodwill pertaining to any of the Zogenix Trademarks.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_6_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Distributor shall not, and shall cause its Affiliates not to, (i) use, seek to register, or otherwise claim rights in any Trademark that is confusingly similar to, misleading or deceptive with respect to, or that materially dilutes, any of the Zogenix Trademarks, or (ii) knowingly do, cause to be done, or knowingly omit to do any act, the doing, causing or omitting of which endangers, undermines, impairs, destroys or similarly affects, in any material respect, the validity or strength of any of the Zogenix Trademarks (including any registration or pending registration application relating thereto) or the value of the goodwill pertaining to any of the Zogenix Trademarks.",
      "page_number": 6,
      "words": [
        {
          "text": "1.2 \"Alliance Manager' has the meaning set forth in Section 3.3.",
          "bbox": [
            448.0,
            685.0,
            1836.0,
            736.0
          ],
          "confidence": 0.9859306216239929
        },
        {
          "text": "1.3 \"Annual Report' has the meaning set forth in Section 6.5(c)",
          "bbox": [
            446.0,
            809.0,
            1823.0,
            861.0
          ],
          "confidence": 0.9771308302879333
        },
        {
          "text": "1.4 \"Applicable Laws\" means the applicable provisions of any and all national, supranational, regional, state and local",
          "bbox": [
            448.0,
            936.0,
            3027.0,
            985.0
          ],
          "confidence": 0.985500156879425
        },
        {
          "text": "laws, treaties, statutes, rules, regulations, administrative codes, industry codes, guidance, ordinances, judgments, decrees,.",
          "bbox": [
            277.0,
            1001.0,
            3025.0,
            1053.0
          ],
          "confidence": 0.9961791634559631
        },
        {
          "text": "directives, injunctions, orders or permits (including Regulatory Approvals) of or from any court, arbitrator, Regulatory Authority or",
          "bbox": [
            279.0,
            1067.0,
            3027.0,
            1118.0
          ],
          "confidence": 0.9920154213905334
        },
        {
          "text": "governmental agency or authority having jurisdiction over or related to the subject item, including the FCPA, export control,",
          "bbox": [
            277.0,
            1133.0,
            3025.0,
            1188.0
          ],
          "confidence": 0.9949026703834534
        },
        {
          "text": "embargo, trade sanction and data privacy laws, regulations, rules and licenses, and other laws and regulations pertaining to",
          "bbox": [
            277.0,
            1201.0,
            3025.0,
            1254.0
          ],
          "confidence": 0.993232011795044
        },
        {
          "text": "domestic or international corruption, commercial bribery, fraud, embezzlement or money laundering.",
          "bbox": [
            275.0,
            1259.0,
            2365.0,
            1325.0
          ],
          "confidence": 0.9901788830757141
        },
        {
          "text": "1.5 \"Business Day\"' means a day other than a Saturday, Sunday, any public holiday, or any bank holiday in the United",
          "bbox": [
            444.0,
            1389.0,
            3027.0,
            1440.0
          ],
          "confidence": 0.9882254004478455
        },
        {
          "text": "States or Japan.",
          "bbox": [
            279.0,
            1458.0,
            613.0,
            1508.0
          ],
          "confidence": 0.9998754262924194
        },
        {
          "text": "1.6 \"Change of Control' means any (a) direct or indirect acquisition of assets of a Party (i) equal to fifty percent (50%)",
          "bbox": [
            448.0,
            1581.0,
            3025.0,
            1630.0
          ],
          "confidence": 0.9898536801338196
        },
        {
          "text": "or more of the fair market value of a Party's consolidated assets, or (ii) to which fifty percent (50%) or more of a Party's net",
          "bbox": [
            281.0,
            1650.0,
            3029.0,
            1694.0
          ],
          "confidence": 0.9935340881347656
        },
        {
          "text": "revenues or net income on a consolidated basis are attributable, or (iii) representing substantially all of the properties or assets",
          "bbox": [
            277.0,
            1718.0,
            3027.0,
            1762.0
          ],
          "confidence": 0.9949082136154175
        },
        {
          "text": "related to a Party's obligations under this Agreement, (b) direct or indirect acquisition by a Person, or group of Persons acting in.",
          "bbox": [
            275.0,
            1780.0,
            3027.0,
            1831.0
          ],
          "confidence": 0.9926859736442566
        },
        {
          "text": "concert, of fifty percent (50%) or more of the voting equity interests of a Party, (c) tender offer or exchange offer that if",
          "bbox": [
            277.0,
            1846.0,
            3031.0,
            1899.0
          ],
          "confidence": 0.990446150302887
        },
        {
          "text": "consummated would result in any Person, or group of Persons acting in concert, beneficially owning fifty percent (50%) or more of.",
          "bbox": [
            277.0,
            1915.0,
            3032.0,
            1964.0
          ],
          "confidence": 0.9912351369857788
        },
        {
          "text": "the voting equity interests of a Party, (d) merger, consolidation, other business combination or similar transaction involving a Party,.",
          "bbox": [
            277.0,
            1979.0,
            3025.0,
            2032.0
          ],
          "confidence": 0.9915239810943604
        },
        {
          "text": "pursuant to which any Person would own fifty percent (50%) or more of the consolidated assets, net revenues or net income of a",
          "bbox": [
            275.0,
            2045.0,
            3029.0,
            2098.0
          ],
          "confidence": 0.9893941283226013
        },
        {
          "text": "Party, taken as a whole, or which results in the holders of the voting equity interests of a Party immediately prior to such merger.",
          "bbox": [
            277.0,
            2109.0,
            3023.0,
            2167.0
          ],
          "confidence": 0.9963723421096802
        },
        {
          "text": "consolidation, business combination or similar transaction ceasing to hold fifty percent (50%) or more of the combined voting",
          "bbox": [
            277.0,
            2178.0,
            3027.0,
            2231.0
          ],
          "confidence": 0.997050404548645
        },
        {
          "text": "power of the surviving, purchasing or continuing entity immediately after such merger, consolidation, business combination or.",
          "bbox": [
            277.0,
            2246.0,
            3031.0,
            2297.0
          ],
          "confidence": 0.9887821078300476
        },
        {
          "text": "similar transaction, (e) liquidation or dissolution (or the adoption of a plan of liquidation or dissolution) of a Party, or (f) declaration",
          "bbox": [
            281.0,
            2317.0,
            3025.0,
            2361.0
          ],
          "confidence": 0.9977426528930664
        },
        {
          "text": "or payment of an extraordinary dividend (whether in cash or other property) by a Party, where the amount of the dividend or the in.",
          "bbox": [
            277.0,
            2379.0,
            3029.0,
            2434.0
          ],
          "confidence": 0.9966531991958618
        },
        {
          "text": "specie property which is the subject of the dividend would otherwise come within the application of any of clauses (a)-(e) above,.",
          "bbox": [
            277.0,
            2443.0,
            3027.0,
            2500.0
          ],
          "confidence": 0.9955662488937378
        },
        {
          "text": "in all cases where such transaction is to be entered into with any Person other than the other Party.",
          "bbox": [
            275.0,
            2509.0,
            2336.0,
            2564.0
          ],
          "confidence": 0.994972288608551
        },
        {
          "text": "1.7 \"CMC' means chemistry, manufacturing and controls.",
          "bbox": [
            446.0,
            2633.0,
            1649.0,
            2686.0
          ],
          "confidence": 0.9895760416984558
        },
        {
          "text": "1.8 \"Commercialization\"' means all activities directed to marketing, promoting, advertising, exhibiting, distributing",
          "bbox": [
            444.0,
            2756.0,
            3025.0,
            2810.0
          ],
          "confidence": 0.9943382143974304
        },
        {
          "text": "(including storage for distribution or inventory), detailing, selling, (and offering for sale or contracting to sell), or otherwise",
          "bbox": [
            285.0,
            2829.0,
            3025.0,
            2873.0
          ],
          "confidence": 0.9882383942604065
        },
        {
          "text": "commercially exploiting the Product in the Field in the Territory.",
          "bbox": [
            275.0,
            2887.0,
            1606.0,
            2946.0
          ],
          "confidence": 0.9925694465637207
        },
        {
          "text": "1.9 \"Commercialization Plan' has the meaning set forth in Section 5.1(b)",
          "bbox": [
            448.0,
            3013.0,
            2046.0,
            3061.0
          ],
          "confidence": 0.9942542314529419
        },
        {
          "text": "2",
          "bbox": [
            1637.0,
            3223.0,
            1668.0,
            3262.0
          ],
          "confidence": 0.9846658706665039
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ],
          "confidence": 0.9990366697311401
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9950901865959167
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 6,
          "bbox": [
            281.0,
            3423.0,
            687.0,
            3454.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Distributor shall not, and shall cause its Affiliates not to, (i) use, seek to register, or otherwise claim rights in the Territory in any Trademark that is confusingly similar to, misleading or deceptive with respect to, or that materially dilutes, any of the Product Trademarks, or (ii) knowingly do, cause to be done, or knowingly omit to do any act, the doing, causing or omitting of which endangers, undermines, impairs, destroys or similarly affects, in any material respect, the validity or strength of any of the Product Trademarks (including any registration or pending registration application relating thereto) or the value of the goodwill pertaining to any of the Product Trademarks.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Distributor shall not, and shall cause its Affiliates not to, (i) use, seek to register, or otherwise claim rights in the Territory in any Trademark that is confusingly similar to, misleading or deceptive with respect to, or that materially dilutes, any of the Product Trademarks, or (ii) knowingly do, cause to be done, or knowingly omit to do any act, the doing, causing or omitting of which endangers, undermines, impairs, destroys or similarly affects, in any material respect, the validity or strength of any of the Product Trademarks (including any registration or pending registration application relating thereto) or the value of the goodwill pertaining to any of the Product Trademarks.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_5",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Distributor acknowledges Zogenix's exclusive ownership of the Product Trademarks and agrees not to take any action inconsistent with such ownership.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_5",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Distributor acknowledges Zogenix's exclusive ownership of the Zogenix Trademarks and agrees not to take any action inconsistent with such ownership.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_4_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Zogenix shall have the right to terminate this Agreement immediately upon written notice to Distributor (i) if Distributor or any of its Affiliates or Sub-distributors, directly or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Zogenix Patent (or any related Patent owned or controlled by Zogenix outside the Territory); (ii) if Zogenix determines that Distributor or its Affiliates or Sub- distributors are, or have caused or shall cause any Zogenix Indemnitee to be, in violation of the FCPA or any other Applicable Laws; or (iii) if Zogenix decides to withdraw the Product from the market in the Territory or otherwise believes that the promotion of the Product in the Field in the Territory presents a substantial risk of harm or injury to consumers which risk is unacceptable according to established principles of medical ethics.",
      "page_number": 4,
      "words": [
        {
          "text": "List of Exhibits",
          "bbox": [
            1479.0,
            693.0,
            1829.0,
            731.0
          ],
          "confidence": 0.9999566078186035
        },
        {
          "text": "Exhibit 1.70 Unlabeled Drug Product",
          "bbox": [
            281.0,
            811.0,
            1062.0,
            857.0
          ],
          "confidence": 0.9997545480728149
        },
        {
          "text": "Exhibit 1.74 Zogenix ZX008 Patents as of the Effective Date",
          "bbox": [
            281.0,
            881.0,
            1555.0,
            925.0
          ],
          "confidence": 0.9936935901641846
        },
        {
          "text": "Exhibit 2.3 Material Terms of Supply Agreement.",
          "bbox": [
            277.0,
            943.0,
            1305.0,
            996.0
          ],
          "confidence": 0.9846095442771912
        },
        {
          "text": "Exhibit 4.2(a) The initial version of the Regulatory Plan.",
          "bbox": [
            281.0,
            1011.0,
            1423.0,
            1060.0
          ],
          "confidence": 0.9895549416542053
        },
        {
          "text": "Exhibit 8.5(a) Press Release",
          "bbox": [
            281.0,
            1082.0,
            875.0,
            1126.0
          ],
          "confidence": 0.9996809363365173
        },
        {
          "text": "Exhibit 9.7 Zogenix Trademarks",
          "bbox": [
            277.0,
            1144.0,
            955.0,
            1195.0
          ],
          "confidence": 0.9909662008285522
        },
        {
          "text": "Exhibit 9.8 Product Trademarks",
          "bbox": [
            279.0,
            1211.0,
            953.0,
            1257.0
          ],
          "confidence": 0.9970877766609192
        },
        {
          "text": "Exhibit 10.2(b) Form of Compliance Certification.",
          "bbox": [
            281.0,
            1279.0,
            1314.0,
            1323.0
          ],
          "confidence": 0.981337308883667
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ],
          "confidence": 0.999293327331543
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            332.0,
            4437.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9932283759117126
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "US-DOCS\\105216871.19",
          "page": 4,
          "bbox": [
            279.0,
            2388.0,
            685.0,
            2419.0
          ]
        }
      ]
    },
    {
      "id": "ZogenixInc_20190509_10-Q_EX-10.2_11663313_EX-10.2_Distributor Agreement__Covenant Not To Sue_5_multi",
      "question": "Highlight the parts (if any) of this contract related to \"Covenant Not To Sue\" that should be reviewed by a lawyer. Details: Is a party restricted from contesting the validity of the counterparty’s ownership of intellectual property or otherwise bringing a claim against the counterparty for matters unrelated to the contract?",
      "answer_text": "Zogenix shall have the right to terminate this Agreement immediately upon written notice to Distributor (i) if Distributor or any of its Affiliates or Sub-distributors, directly or indirectly through any Third Party, commences any interference or opposition proceeding with respect to, challenges the validity or enforceability of, or opposes any extension of or the grant of a supplementary protection certificate with respect to, any Zogenix Patent (or any related Patent owned or controlled by Zogenix outside the Territory); (ii) if Zogenix determines that Distributor or its Affiliates or Sub- distributors are, or have caused or shall cause any Zogenix Indemnitee to be, in violation of the FCPA or any other Applicable Laws; or (iii) if Zogenix decides to withdraw the Product from the market in the Territory or otherwise believes that the promotion of the Product in the Field in the Territory presents a substantial risk of harm or injury to consumers which risk is unacceptable according to established principles of medical ethics.",
      "page_number": 5,
      "words": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ],
          "confidence": 0.9838802218437195
        },
        {
          "text": "This DISTRIBUTORSHIP AGREEMENT (\"Agreement') is entered into as of March 18, 2019 (the \"Effective",
          "bbox": [
            446.0,
            810.0,
            3025.0,
            861.0
          ],
          "confidence": 0.9915458559989929
        },
        {
          "text": "Date') by and between ZOGENIX, INC., having a place of business at 5959 Horton Street, Suite 500, Emeryville, California",
          "bbox": [
            275.0,
            875.0,
            3027.0,
            932.0
          ],
          "confidence": 0.9927026629447937
        },
        {
          "text": "94608( \"Zogenix') and Nippon Shinyaku Company, Ltd., having a place of business at 14, Nishinosho-Monguchi-cho, Kisshoin,",
          "bbox": [
            281.0,
            947.0,
            3025.0,
            996.0
          ],
          "confidence": 0.9760836362838745
        },
        {
          "text": "Minami-ku, Kyoto 601-8550, Japan (\"Distributor'). Zogenix and Distributor may be referred to individually as a \"Party\"' and",
          "bbox": [
            277.0,
            1011.0,
            3027.0,
            1062.0
          ],
          "confidence": 0.9831045866012573
        },
        {
          "text": "collectively as the \"Parties\"'",
          "bbox": [
            283.0,
            1082.0,
            877.0,
            1124.0
          ],
          "confidence": 0.9640311002731323
        },
        {
          "text": "RECITALS",
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ],
          "confidence": 0.9994953274726868
        },
        {
          "text": "WHEREAS, Zogenix is developing its proprietary fenfluramine product, known as Fintepla..",
          "bbox": [
            446.0,
            1317.0,
            2412.0,
            1376.0
          ],
          "confidence": 0.9937957525253296
        },
        {
          "text": "WHEREAS, Zogenix wishes to commercialize such product through a distributor that will promote, market, sell and",
          "bbox": [
            451.0,
            1449.0,
            3025.0,
            1493.0
          ],
          "confidence": 0.9903298616409302
        },
        {
          "text": "distribute such product within the Territory;.",
          "bbox": [
            279.0,
            1507.0,
            1180.0,
            1566.0
          ],
          "confidence": 0.9769384264945984
        },
        {
          "text": "WHEREAS, Distributor has the ability to promote, market, sell and distribute such product within the Territory for the",
          "bbox": [
            446.0,
            1634.0,
            3025.0,
            1685.0
          ],
          "confidence": 0.9918984770774841
        },
        {
          "text": "treatment of Dravet syndrome and Lennox-Gastaut syndrome and any additional indications approved in the Territory, and wishes",
          "bbox": [
            281.0,
            1707.0,
            3023.0,
            1751.0
          ],
          "confidence": 0.9928691387176514
        },
        {
          "text": "to be Zogenix's exclusive distributor of such product for such indications within the Territory, and Zogenix is willing to grant to",
          "bbox": [
            277.0,
            1769.0,
            3025.0,
            1820.0
          ],
          "confidence": 0.9943161606788635
        },
        {
          "text": "Distributor such exclusive distribution rights on the terms and conditions set forth in this Agreement; and",
          "bbox": [
            277.0,
            1833.0,
            2452.0,
            1886.0
          ],
          "confidence": 0.9882798790931702
        },
        {
          "text": "WHEREAS, Zogenix agrees to manufacture (or have manufactured) and sell to Distributor such product for such",
          "bbox": [
            444.0,
            1955.0,
            3027.0,
            2012.0
          ],
          "confidence": 0.9973936080932617
        },
        {
          "text": "commercialization activities in the Territory, on the terms and conditions set forth in this Agreement and in a separate supply",
          "bbox": [
            277.0,
            2023.0,
            3023.0,
            2078.0
          ],
          "confidence": 0.9925696849822998
        },
        {
          "text": "agreement to be entered into by the Parties..",
          "bbox": [
            279.0,
            2092.0,
            1191.0,
            2144.0
          ],
          "confidence": 0.9872881770133972
        },
        {
          "text": "NOw, THEREFORE, in consideration of the foregoing premises and the mutual covenants herein contained, and for",
          "bbox": [
            446.0,
            2215.0,
            3025.0,
            2264.0
          ],
          "confidence": 0.9911332726478577
        },
        {
          "text": "other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Zogenix and Distributor",
          "bbox": [
            283.0,
            2286.0,
            3025.0,
            2330.0
          ],
          "confidence": 0.9953808784484863
        },
        {
          "text": "hereby agree as follows:.",
          "bbox": [
            281.0,
            2352.0,
            783.0,
            2396.0
          ],
          "confidence": 0.9865036606788635
        },
        {
          "text": "ARTICLE 1.",
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ],
          "confidence": 0.9921110272407532
        },
        {
          "text": "DEFINITIONS",
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ],
          "confidence": 0.9983474612236023
        },
        {
          "text": "1.1 \"Affiliate\"' of a Party means any entity that, directly or indirectly, through one or more intermediaries, controls, is",
          "bbox": [
            446.0,
            2655.0,
            3027.0,
            2714.0
          ],
          "confidence": 0.9874007105827332
        },
        {
          "text": "controlled by, or is under common control with such Party, as the case may be, but for only so long as such control exists. As used",
          "bbox": [
            285.0,
            2730.0,
            3025.0,
            2774.0
          ],
          "confidence": 0.990530252456665
        },
        {
          "text": "in this Section 1.1, \"control' means (a) to possess, directly or indirectly, the power to direct the management or policies of an",
          "bbox": [
            277.0,
            2792.0,
            3025.0,
            2843.0
          ],
          "confidence": 0.9828458428382874
        },
        {
          "text": "entity, whether through ownership of voting securities, or by contract relating to voting rights or corporate governance; or (b) direct",
          "bbox": [
            277.0,
            2860.0,
            3027.0,
            2911.0
          ],
          "confidence": 0.9897759556770325
        },
        {
          "text": "or indirect beneficial ownership of more than fifty percent (50%) (or such lesser percentage which is the maximum allowed to be",
          "bbox": [
            277.0,
            2924.0,
            3027.0,
            2980.0
          ],
          "confidence": 0.9950239658355713
        },
        {
          "text": "owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity",
          "bbox": [
            283.0,
            2997.0,
            2824.0,
            3041.0
          ],
          "confidence": 0.9847685098648071
        },
        {
          "text": "US-DOCS\\105216871.19",
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ],
          "confidence": 0.998196005821228
        },
        {
          "text": "Source: ZOGENIX, INC., 10-Q, 5/9/2019",
          "bbox": [
            330.0,
            4435.0,
            1120.0,
            4479.0
          ],
          "confidence": 0.9943553805351257
        }
      ],
      "multi_page": true,
      "part_of": 2,
      "nearby_headers": [
        {
          "text": "DISTRIBUTORSHIP AGREEMENT",
          "page": 5,
          "bbox": [
            1216.0,
            693.0,
            2093.0,
            729.0
          ]
        },
        {
          "text": "RECITALS",
          "page": 5,
          "bbox": [
            1517.0,
            1201.0,
            1789.0,
            1244.0
          ]
        },
        {
          "text": "ARTICLE 1.",
          "page": 5,
          "bbox": [
            1508.0,
            2471.0,
            1803.0,
            2514.0
          ]
        },
        {
          "text": "DEFINITIONS",
          "page": 5,
          "bbox": [
            1474.0,
            2540.0,
            1832.0,
            2578.0
          ]
        },
        {
          "text": "US-DOCS\\105216871.19",
          "page": 5,
          "bbox": [
            279.0,
            3401.0,
            687.0,
            3432.0
          ]
        }
      ]
    }
  ]
}